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Abstract 
 
 
Elucidating protein structures, dynamics, and interactions is critical for understanding 
their roles in health and disease. In the biopharmaceutical industry, bioanalytical science allows, 
e.g., insights into how these complex molecules interact, and enables their characterization to 
assure safety and consistency of biotherapeutic manufacturing. Mass spectrometry (MS)-based 
methods, such as hydrogen/deuterium exchange (HDX) MS, are powerful tools for structural 
proteomics. This dissertation presents analytical strategies for incorporating gas-phase 
fragmentation for improved structural resolution in HDX MS workflows in both positive and 
negative ion mode, and for improving host cell protein characterization in biopharmaceuticals. 
HDX is typically performed in positive ion mode. In Chapter 2, the feasibility of several 
negative ion mode tandem mass spectrometry (MS/MS) techniques for HDX coupling is 
explored. Regio-selectively deuterated peptide anions were fragmented by negative-ion collision 
induced dissociation (nCID), negative-ion free radical initiated peptide sequencing (nFRIPS), 
electron detachment dissociation (EDD), and negative-ion electron capture dissociation (niECD) 
to determine the extent of H/D scrambling in each MS/MS technique. nCID induces extensive 
H/D scrambling involving histidine C-2 and Cβ-hydrogen atoms for histidine-containing peptides. 
nFRIPS proceeds with complete hydrogen scrambling but without histidine participation, 
whereas EDD and niECD demonstrate moderate scrambling with slightly lower levels in niECD. 
However, improved ionization efficiency, ion transmission, and fragmentation efficiency under 
HDX quenching conditions are needed for routine application of niECD in HDX MS workflows. 
Due to the acidic HDX quenching conditions, the acid protease pepsin is employed for 
protein digestion. However, resulting peptic peptides may not contain basic residues and 
xxi 
 
therefore carry less average charge than typical tryptic peptides. In Chapter 3, supercharging 
strategies are explored for combination with electron capture/transfer dissociation 
(ECD/ETD)-based HDX MS/MS in positive ion mode. These MS/MS techniques require 
analytes to carry at least two positive charges. The supercharging reagent m-NBA was found to 
enhance the average charge state for a variety of pepsin-derived peptides, thus increasing 
ECD/ETD fragmentation efficiency and peptide sequence coverage in bottom-up HDX liquid 
chromatography (LC)/MS workflows. Retention time shifts in the presence of m-NBA were 
avoided by injecting m-NBA through a mixing tee following the analytical column. 
During these experiments, b-type ions were observed in ECD spectra of supercharged 
peptides. Such fragment ions are atypical in ECD but have been found at increased levels for 
peptides containing few or no basic residues. In Chapter 4, we find that such peptides also show 
abundant hydrogen atom loss from the charge-reduced radical species. We show that, upon ECD 
of supercharged peptides, the number and abundance of b ions increases with increasing charge 
state; b ions are prevalent in ECD spectra when the number of protons is higher than the number 
of basic sites. Under the same conditions, significantly less abundant b ions were seen in ETD 
than ECD. The observed difference between ECD and ETD is likely due to different internal 
energy prior to dissociation. We propose that b ions should be considered in ExD database 
searches for supercharged peptides in HDX MS/MS, and that ETD may be superior to ECD for 
minimizing deuterium scrambling in such experiments. 
In Chapter 5, an offline hydrophilic interaction chromatography (HILIC) sample 
preparation method for improving detection of residual host cell proteins (HCPs) in 
biotherapeutic proteins by LC MS/MS is described. This method enriches HCPs while depleting 
high abundance biotherapeutic proteins, enabling detection of previously unobserved HCPs in 
drug substances. 
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Chapter 1 
 
 
Introduction 
 
 
1.1 Mass Spectrometry-Based Protein Structural Analysis 
Proteins are an important group of large biological molecules that represent the functional 
aspect of gene activities in living cells. The term proteome, first introduced by Wilkins et al. [1] 
in 1995, denotes the total number of proteins expressed by a genome at any given time while the 
term proteomics typically refers to global identification and quantification of proteins. In order to 
perform their biological functions, one or more amino-acid chains fold into specific spatial 
conformations to form protein higher-order structure (i.e., secondary, tertiary, and quaternary), 
driven by a number of intramolecular non-covalent interactions. Intermolecular interactions 
between proteins (or between proteins and other biomolecules) are also prevalent, as proteins 
rarely act alone and their functions are regulated. This type of interaction between proteins is 
referred to as protein-protein interaction (PPI).  
1.1.1 Biotherapeutic Proteins 
Protein therapy, based on the protective properties of passive immunization, has become 
an increasingly important mode of medical treatment. Recombinant DNA technology enables the 
development of protein therapy by allowing mass production of homogenous proteins of interest 
from living cells following well-defined bioprocesses. Such biotherapeutic proteins are 
employed to treat a variety of diseases [2, 3]. 
A large number of biotherapeutic proteins are monoclonal antibodies (mAb) or 
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mAb-based modalities, such as antibody-drug conjugates (ADCs), bispecific antibodies, or 
domain antibodies [2]. Antibodies are immune system-related proteins, known as 
immunoglobulins. An antibody consists of four polypeptides, including two identical heavy 
chains (H) and two identical light chains (L). Heavy and light chains are joined by non-covalent 
interactions and covalent interchain disulfide bonds to form a “Y” shaped molecule. mAbs 
function therapeutically via several mechanisms, including by inducing apoptosis in cells that 
express the target (antigen), by blocking protein ligand binding to its receptor, and/or by 
modulating signaling pathways [3]. 
Fusion proteins are another type of biotherapeutic proteins. They are generated through 
the fusing of two or more genes, which originally code for separate proteins. One kind of fusion 
protein is produced by adding a half-life extension protein (e.g., albumin, transferrin, antibody Fc 
region) to small recombinant peptides/proteins (< 60 kDa), for increasing the half-life of these 
relatively small biotherapeutics [4]. Other kinds of fusion proteins aim to enable the targeting of 
a specific cell surface component for improved biological activity at the target site (e.g., 
antibody-cytokine fusion proteins) [5], to promote binding to the target (e.g., bivalent Fc fusion 
proteins) [6], or to confer bispecific functions. 
Compared with small molecule drugs, biotherapeutic proteins are not only larger in 
molecular size but also show much more complex higher-order structure. The vast majority of 
biotherapeutic proteins are produced from prokaryotic- or eukaryotic-based expression systems 
[7]. One key factor for selecting an appropriate expression system is the post-translational 
modification (PTM) requirements for optimal extraction, stability, and drug activities. However, 
biotherapeutic proteins usually exist as complex heterogeneous mixtures containing variants with 
different PTMs and aggregation states, and are susceptible to further modifications. Undesirable 
PTMs may cause potential problems, e.g., reduced drug efficacy and unwanted toxicity [8, 9]. 
Elucidating PTM structure for biotherapeutic proteins aids protein engineering for improved 
therapeutic properties. It is also crucial to characterize the higher-order structure of 
biotherapeutic proteins to understand their stability, conformation, and functional activities. 
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1.1.2 Mass Spectrometry-Based Structural Biology Tools 
Elucidating protein structures as well as PPIs is an essential prerequisite for 
understanding their roles in health and disease. X-ray crystallography [10, 11], cryo-electron 
microscopy (cryo-EM) [12, 13], and nuclear magnetic resonance (NMR) spectroscopy [14] are 
valuable techniques for protein structural studies and have been routinely applied. In addition, 
recent developments in modern mass spectrometry (MS) have resulted in structural proteomics 
techniques. Although each technique has its own strengths and limitations, mass spectrometry 
has unique advantages, including high throughput and high sensitivity [15-17] for studies of 
protein systems of varying levels of complexity; exceptional detection limits, down to 
zeptomoles [18],  and localization of post-translational modifications (PTMs) via multi-stage 
MS (MS
n
) [19-21], while elucidating protein/peptide structures down to the single amino acid 
residue level [22]. Overall, MS performs not only as a qualitative but also a quantitative tool for 
large scale proteomics studies [23, 24]. 
MS-based structural biology tools have also been developed and applied to studies of 
biomolecular conformations, dynamics, and molecular interactions [25, 26]. Solution-phase 
labeling methods, such as hydrogen/deuterium exchange (HDX) [27], covalent labeling [28], and 
hydroxyl radical labeling [29], modify the analyte mass based on its three-dimensional structure 
in solution, thus reflecting structural information by mass shift of the molecular ion. Covalent 
cross-linking [30] reveals the distances between intramolecular and/or intermolecular pairs of 
functional groups, which can serve as characteristic features of protein conformational change. 
Limited proteolysis [31] detects the outermost regions of protein surfaces exposed to the active 
sites of proteolytic enzymes. The protein charge state distribution [32-34] generated by 
electrospray ionization (ESI) [35] can also be used to probe structural changes. Other MS 
approaches that can provide protein structural information include native ESI-MS [36] and ion 
mobility MS [37]. A combination of different types of structural MS techniques can yield 
complementary information.  
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1.1.3 Characterization of Host Cell Proteins in Biopharmaceuticals 
A large portion of the biopharmaceuticals today are produced by recombinant DNA 
technology using a well-selected host cell system [38]. Besides the recombinant protein drug, 
host cells express a large number of their own proteins related to normal cell functions. Even 
after orthogonal purification steps, low levels (ranging from <1 to a few hundred ppm) of host 
cell proteins (HCPs) may still exist in the final drug product. These protein impurities may 
significantly affect drug efficacy and cause immunogenicity. Therefore, detection and 
quantification of residual HCPs as potential process-related impurities is important for 
biopharmaceutical companies to meet regulatory requirements [39]. 
The enzyme-linked immunosorbent assay (ELISA) [40], as a common form of 
immunoassay, is frequently used in the biopharmaceutical industry for HCP measurement due to 
its high sensitivity and high throughput. In principle, anti-HCP antibodies can be produced by 
injecting HCP mixtures into animals to induce immune response and develop a multi-analyte 
ELISA kit. However, there are a few limitations associated with this technique, such as 
less-than-ideal coverage, dilutional nonlinearity, signal biased by proteins of high 
abundance/immunogenicity. Other separation and visualization methods such as 1D/2D sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [41], 2D differential in-gel 
electrophoresis (DIGE) [42], western blot (WB) [43], etc., remain useful tools as well. However, 
in general, current analytical methods suffer from long method development times, require prior 
knowledge of contaminant proteins, and lack the capability of detecting a wide range of protein 
concentrations. LC/MS-based proteomics provides a powerful alternative method for HCP 
characterization, a supplement to affinity-based techniques, and has become a routine approach 
in the pharmaceutical industry. However, HCP LC/MS analysis is a challenging workflow 
because a dynamic range up to 6 orders of magnitude is required to be able to detect low ppm 
concentrations of residual HCPs in the presence of biotherapeutic proteins, which is out of range 
of current mass spectrometers. 
A couple of analytical strategies have been developed based on conventional bottom-up 
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LC/MS workflows aiming to overcome this dynamic range limitation. In addition, to be widely 
adopted by the biopharmaceutical industry, the analytical solution has to be highly robust and 
relatively fast. Monoclonal antibody (mAb) samples spiked with low abundance standard 
proteins in a series of concentrations is frequently used as a model to test assay sensitivity and 
dynamic range [44]. One approach to improve LC separation is to increase gradient length and/or 
column length. Waters Corporation (Milford, MA) introduced an online high-pH/low-pH RP/RP 
2D-LC system for comprehensive peptide separations and HCP analysis for mAbs [45]. Ion 
mobility can also be integrated in this workflow as an additional separation dimension to 
separate targeted peptide precursors from other co-eluting precursors [46]. However, 2D LC 
generally suffers from low throughput (e.g., 1-2 samples/day) and detection of <10 ppm HCPs is 
still challenging. HCP enrichment/mAb depletion during sample preparation is another strategy 
for improving HCP detection. Recently, Eli Lilly (Indianapolis, IN) reported a simple and robust 
method to characterize HCPs in mAbs by adopting trypsin digestion under native conditions, 
followed by precipitation of undigested mAb with heat treatment [44]. Following this procedure, 
residual HCPs are mostly digested in solution while the antibody is minimally digested and can 
be removed through filtration prior to proteomics analysis, whereas heat-labile HCPs and HCPs 
co-precipitating with the mAb are also lost. In terms of data acquisition, DDA is widely used to 
sample peptide precursors for MS/MS sequencing analysis, e.g., “top ten” method. Currently, 
applications of DIA for HCP detection are mostly in the form of MS
E
 or UDMS
E
 coupled with 
2D-LC developed by Waters [45, 46]. In accordance with LC/MS instrument type and data 
format, several software packages have been adopted for identification and quantification of 
HCPs, for example, PLGS (Protein Lynx Global Server; Waters), Proteome Discoverer (Thermo 
Scientific), Byonic and Byologic (Protein Metrics), etc. However, due to the sample complexity 
and low abundance, as well as the MS dynamic range limitation, HCP characterization in 
biotherapeutic protein preparations utilizing LC/MS strategies is still facing the issue of limited 
sensitivity.  
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1.2 Techniques and Strategies in Modern Proteomics 
1.2.1 Bottom-up vs. Top-down Proteomic Strategies 
Bottom-up, top-down, and middle-down are three main approaches for proteomic 
experiments with mass spectrometry [47-49]. In a bottom-up experiment, proteolytic digestion is 
involved to cleave intact proteins into peptide segments (< 3 kDa) and the resulting peptides are 
usually separated by reversed-phase liquid chromatography (RP LC) prior to mass analysis to 
improve detection sensitivity. The bottom-up approach is commonly used for peptide mass 
fingerprinting and tandem mass spectrometry (MS/MS) identification combined with database 
searching [50]. To improve digestion efficiency, more than one protease [47] may be used. In 
addition, reduction and alkylation are often performed before proteolysis to break disulfide 
bonds between cysteine residues and prevent reformation of these linkages. To date, bottom-up 
proteomics is routinely applied to identify thousands of proteins present in one sample, even 
though the method may provide ambiguous results if only few peptides are detected from a 
particular protein. Another drawback for bottom-up analysis is that protein digestion inevitably 
increases the complexity of the analyte pool, making 100% protein sequence coverage and 
accurate assignment of proteoforms [49] containing various PTMs difficult to achieve.  
The top-down strategy [51, 52], a term first introduced by McLafferty and coworkers [53], 
addresses the aforementioned issues by bypassing the proteolysis step and instead performing 
fragmentation on intact proteins in the gas phase. The intact mass and fragment masses are then 
compared to a sequence database. This approach can provide information about PTMs as 
PTM-retainable MS/MS techniques are utilized, such as electron capture dissociation (ECD) [54] 
and electron transfer dissociation (ETD) [55]. Top-down proteomics is mostly performed with 
Fourier transform MS [49] that enables high resolution and high mass accuracy, yet is still 
limited by MS/MS fragmentation efficiency and sequence coverage and thus most applicable to 
small-to-medium size proteins (< 40 kDa) [51, 56]. Recently, the use of native ESI MS has 
shown promise for the characterization of intact protein complexes in the 100 kDa to 1 MDa 
regime [52]. 
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The third approach, middle-down proteomics [51, 57], combines the advantages of the 
bottom-up and top-down strategies and has recently been adopted for characterization of large 
proteins, such as antibodies, and protein complexes. With the middle-down strategy, the analyte 
is less complex compared with the bottom-up method, while the strength of the top-down 
method, such as localization of proteoform-specific PTMs [58], can be maintained. 
1.2.2 Liquid Chromatography Mass Spectrometry (LC/MS) 
High performance liquid chromatography (HPLC; or high-pressure liquid 
chromatography) [59] is a powerful separation technique applicable to a variety of analytes. The 
principle of separation is based on the distribution of the components in a liquid between two 
immiscible phases, i.e., stationary and mobile phases, when the mobile phase containing the 
analytes permeates through the stationary phase bed in a given direction under high pressure. 
Five common types of liquid chromatography include adsorption chromatography, partition 
chromatography, ion-exchange chromatography, size-exclusion chromatography, and affinity 
chromatography. Among these, the most widely used kind for peptide separation in proteomics is 
the reverse-phase (RP) mode of the partition chromatography, which utilizes a non-polar 
(hydrophobic) stationary phase covalently bonded with octadecyl (C18), octyl (C8), or phenyl 
(C4) groups, and a polar mobile phase [60-62]. As a result, hydrophobic molecules in the polar 
mobile phase adsorb more strongly to the hydrophobic stationary phase and hydrophilic 
molecules will pass through the column to be eluted first. Hydrophobic molecules can be eluted 
from the column by decreasing the polarity of the mobile phase using organic solvent. A solvent 
gradient, commencing at low organic concentration and increasing to high organic concentration, 
can effectively improve the separation of analytes. On the contrary, for hydrophilic interaction 
chromatography (HILIC) [63, 64], a variant of normal-phase liquid chromatography, the 
stationary phase is highly polar (e.g., silica, amide, diol, cyano, etc. [65]) and the mobile phase is 
composed of mostly non-polar organic solution with a minor portion of water. Adding a polar 
phase (water in this case) to a polar surface will result in the formation of a water layer. Polar 
analytes partition into and out of this adsorbed water layer. The water content of the mobile 
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phase increases with the decrease of the organic portion, resulting in retention and then elution of 
polar analytes such as amino acids, peptides, metabolites, saccharides, etc. [66]. 
LC/MS combines the physical separation capabilities of LC with the mass analysis 
capability of MS. This tandem technique has been widely used to analyze biochemical, organic, 
and inorganic compounds in complex samples [67-73]. Currently, the most common LC/MS 
interfaces are ESI, atmospheric pressure chemical ionization (APCI), and atmospheric pressure 
photo-ionization (APPI) [69]. These ion sources enable online transition of analytes from 
solution phase to the gas phase. Recent development in LC techniques has led to higher 
separation efficiency and lower detection limits by use of columns with smaller inner diameter 
and stationary particle size [74]; higher pressure resistance is therefore required for current LC 
systems. Ultrahigh performance liquid chromatography (UPLC or UHPLC) [75] and nanoflow 
LC (nLC) [76-78] were developed to accommodate these demands. Also, with the improvement 
of robust MS instrumentation and computational tools, LC/MS-based proteomics [79] has 
witnessed rapid advancements and growing applications in recent years. 
1.2.3 Fourier Transform Mass Spectrometry (FT MS) 
Mass spectrometry (MS) measures the mass-to-charge ratio (m/z) of charged molecules. 
Basic components of a mass spectrometer include an inlet for sample introduction (usually LC or 
direct infusion), an ion source, a mass analyzer, an ion detector and a data system to process the 
output data and generate a spectrum. Different types of mass analyzers vary in resolution, 
transmission, and mass limit. A high mass resolution is desired for high selectivity, i.e., ability to 
distinguish between two species of small mass difference.  
In LC/MS proteomics experiments, high resolution MS enables accurate peptide ion 
and/or fragment ion annotation and PTM assignment, allowing for rapid identification of 
proteins via peptide mass fingerprinting and high quality MS/MS identification. Top-down 
proteomics is also based on high resolution tandem MS and is mostly performed with Fourier 
transform MS (FT MS) [49]. FT MS has received considerable attention for its ability to achieve 
both high resolution and high mass accuracy [80]. The next two sections will focus on two kinds 
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of well-known FT-based high resolution mass spectrometers: Fourier transform-ion cyclotron 
resonance (FT-ICR) mass spectrometers and Orbitrap mass spectrometers. These two types of 
MS systems were used to complete this dissertation. 
FT-ICR mass spectrometers [81, 82] feature unprecedented resolution and mass accuracy 
compared with other types of mass analyzers such as time-of-flight (TOF), quadrupole (Q), or 
ion trap mass analyzers, as well as the capability of implementing various MS/MS fragmentation 
techniques. The theory of ion cyclotron resonance was developed by Lawrence in the 1930s [83]. 
However, it was not until 1978 that Comisarow and Marshall built the first FT-ICR MS 
instrument [84, 85]. A main component in FT-ICR MS is a superconducting magnet featuring 
high field strength. The resolution of the instrument improves as the magnetic field strength 
increases. Therefore, design of instruments with stronger fields is a current trend and recently a 
21-Tesla magnetic field has been successfully applied to FT-ICR MS to achieve baseline isotopic 
resolution for antibodies [86, 87]. The ICR analyzer cell is another critical component, in which 
ions are trapped, mass analyzed, and detected. The “Infinity Cell” [88] design improves ion 
trapping although the more recent dynamically harmonized FT-ICR cell designed by Nikolaev et 
al. [89] further improves FT-ICR resolving power. In addition, ultra-high vacuum is required 
(10
-9–10-10 Torr) when ions are detected to achieve high resolution. 
Ion cyclotron motion is the basis for ICR mass analyzer. As indicated in Equation 1.1 and 
Figure 1.1, a moving ion experiences a Lorentz force in the presence of a magnetic field, 
resulting in periodic cyclotron motion whose frequency (fc) is determined by the charge of the 
ion, q, the magnetic field strength, B, and the mass of the ion, m, while independent of the ion 
kinetic energy. fc typically falls in the range of tens of kilohertz (kHz) to megahertz (MHz) [80]. 
B is held constant and the m/z of an ion (m/q) is consequently determined by measuring its 
cyclotron frequency. In reality, a combination of three types of motion, i.e., cyclotron motion, 
trapping motion, and magnetron motion, complicates the actual trajectories of ion movement in 
the ICR cell [90]. In the FT-ICR MS system used in the Hakansson Lab (Figure 1.2), the ions to 
be analyzed undergo dipolar excitation [91] as a sinusoidal voltage is applied to a pair of 
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excitation plates in the ICR cell. Ions that are in resonance with the excitation frequency spiral 
outwards from the center of the cell into a larger cyclotron orbit. All ions with the same m/z are 
excited coherently and undergo cyclotron motion as a packet. A rapid frequency sweep [92], or 
r.f. chirp, is applied during the excitation event to achieve broadband detection. The ion package 
passes the detection plates and induces a sinusoidal image current whose frequency is almost 
equal to the frequency of the ion cyclotron motion. This image current can be amplified, 
digitized, and stored as a time domain transient, which is then converted to a mass spectrum by 
performing a Fourier transform. Mass resolution improves in correlation with the length of the 
transient [80]. 
Equation 1.1      
  
   
 
 
Figure 1.1 Cyclotron motion of a positively charged ion in the plane perpendicular to the 
magnetic field lines.  
The FT-ICR instrumentation platform in the Hakansson Lab (Figure 1.2) is equipped with 
an Apollo II ESI source, a dual ion funnel/skimmer, a chemical ionization source, a quadrupole 
mass filter, a hexapole collision cell, an ICR Infinity Cell, a hollow dispenser cathode, and a CO2 
IR laser. It allows ion-neutral, ion-electron, ion-ion, and ion-photon activation, including 
collision-induced dissociation (CID), electron capture/transfer dissociation (ECD/ETD), and 
infrared multiphoton dissociation (IRMPD). The unique capability of performing not only 
positive but also negative ion mode ion-electron fragmentation, such as electron detachment 
dissociation (EDD) and negative ion electron capture dissociation (niECD), makes the FT-ICR a 
superior tool for fundamental studies of gaseous radical chemistry. However, completion of a 
high-resolution mass spectrum scan (no lower than 512k data points) typically takes 0.5-1.0 s on 
our FT-ICR mass spectrometer, which results in fewer peptides being detected in typical LC/MS 
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workflows and, consequently, lower sequence coverage for proteomics experiments compared to 
Orbitrap or TOF MS.  
 
Figure 1.2 Schematic diagram of a 7-T SolariX quadrupole-FT-ICR mass spectrometer (Bruker 
Daltonics). 
The Orbitrap mass analyzer, developed from the work of Makarov [93], is a new member 
of the FT MS family [94-96]. The first commercial implementation was in 2005 in a hybrid 
instrument, LTQ Orbitrap, featuring a linear ion trap front-end [97]. Orbitrap mass spectrometers 
combine the principle of image current detection and the use of ion trapping in precisely defined 
electrode structures, while eliminating the necessity for a superconducting magnet as in FT-ICR. 
In both Orbitrap and FT-ICR MS, ions are trapped in ultrahigh vacuum to ensure very long mean 
free paths (tens to hundreds of kilometers) [80]. In addition, ions are detected based on their 
image current followed by FT processing. The digitized image current in the time domain is 
Fourier-transformed into the frequency domain in the same way as FT-ICR. However, in an 
Orbitrap instrument, the use of electric fields only for ion trapping makes it possible to 
implement on a bench top [98]. High-mass resolution can routinely be achieved with the 
Orbitrap MS in a relatively small amount of time (<1 s) that is compatible with UPLC. Thus, the 
Orbitrap type of mass spectrometers is widely used for current routine proteomics analysis [77, 
98]. 
Figures 1.3 and 1.4 show two Orbitrap MS systems, LTQ Orbitrap XL and Orbitrap 
(Hexapole) 
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Fusion Lumos. The LTQ Orbitrap features a linear ion trap enabling mass detection in front of 
the C-trap (a C-shaped rf-only quadrupole) and an octapole collision cell (HCD cell) following 
the C-trap [97]. As an ion storage device, the C-trap enables pulsed ion injection into Orbitrap, 
the second mass analyzer on the instrument that typically provides much higher mass resolution 
than the front-end ion trap. The Orbitrap Fusion Lumos is the state-of-the-art model in the 
Orbitrap family nowadays featuring a tribrid architecture including a front-end segmented 
quadrupole, a back-end dual-pressure ion trap, and an ultrahigh field Orbitrap mass analyzer. 
 
Figure 1.3 Schematic diagram of an LTQ Orbitrap XL hybrid FT mass spectrometer (Thermo 
Fisher Scientific). 
API Ion Source LTQ XL Linear Ion Trap 
Orbitrap Mass Analyzer 
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Figure 1.4 Schematic diagram of an Orbitrap Fusion Lumos tribrid mass spectrometer (Thermo 
Fisher Scientific). 
1.2.4 Tandem Mass Spectrometry (MS/MS) 
The development of multi-stage and multi-functional hybrid instruments has enabled 
versatility of MS
n
 (n≥2) experiments with FT MS instrumentation. MS/MS for peptide 
fragmentation and sequencing is crucial for MS-based proteomics. In typical bottom-up 
proteomics experiments, ESI-generated co-eluting peptide ions in one MS
1
 spectrum are a 
mixture of various peptide species and charge states. Ion species with a specific m/z value are 
typically mass filtered through a front-end quadrupole or ion trap using an isolation width of 1-5 
m/z. Isolated peptide ions (also called precursor ions or parent ions) then undergo inelastic 
collisions with neutral inert gas molecules such as helium or argon; the most common MS/MS 
technique referred to as collision-induced dissociation (CID) [99, 100], for peptide backbone 
fragmentation. All generated fragment ions (also called product ions or daughter ions) as well as 
undissociated precursor ions are then mass analyzed. Data-dependent acquisition (DDA) and 
data-independent acquisition (DIA) are two modes of data collection in MS/MS [101]. For DDA, 
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a fixed number of precursor ions whose m/z values are recorded in an MS
1
 survey scan are 
selected sequentially and subjected to a second-stage MS/MS analysis [102]. DIA attempts to 
remedy the drawback of the DDA method that only a fixed number of ion species are subjected 
to fragmentation from one survey scan, potentially causing significant information loss in highly 
complex samples. For DIA, all ions within a selected m/z range are fragmented at one time and 
analyzed by second-stage MS/MS [103]; high resolution MS is thus essential to effectively 
resolve fragment ions generated from different peptide ions. SWATH [104] and MS
E
 [105] are 
two commercial methods to reduce the complexity of DIA MS/MS spectra. In top-down 
experiments, a series of protein ions with multiple charge states is usually present together with 
other charged species such as contaminants, adducts, fragments, etc. Mass filtration is necessary 
to clean up the spectrum prior to fragmentation of certain species, given that dissociation of 
multiply charged protein ions typically generates overlapped MS/MS spectra consisting of 
fragment ions of multiple charge states. Fragmentation of proteins containing labile PTMs result 
in further complexity due to retention/loss of the modified functional groups.  
ESI can be operated in both positive and negative ion modes. Based on the polarity of 
precursor ions, the combination of mass analyzers, and the incorporation of neutral gas 
molecules/radical ions/electrons/photons, different types of fragmentation techniques can be 
applied to proteins/peptides. The nomenclature of common types of peptide backbone fragment 
ions (or “sequence ions”) observed upon different fragmentation techniques is illustrated in 
Figure 1.5, as proposed by Roepstorff and Fohlman in 1984 [106] and later modified by 
Biemann [107]. 
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Figure 1.5 Nomenclature for peptide fragment ions in MS/MS. Adapted from Roepstorff and 
Fohlman [106] and Biemann [107]. 
1.2.4.1 Slow-Heating Fragmentation 
The aforementioned CID technique involves slow heating [108], where positively or 
negatively charged protein/peptide ions are activated under low-energy collision conditions. 
Slow activation methods rely on multiple discrete activation events such as multiple collisions 
(e.g., CID) or multiple photon absorption (e.g., IRMPD) [108, 109]. The time scale for the 
multiple activation events can be long, on the order of ms or longer. The energy obtained by 
collisions is distributed through the peptide/protein ion via intramolecular vibrational energy 
redistribution (IVR) [110]. Dissociation of the weakest bonds in the molecule occurs once the 
internal energy of the vibrationally activated ion is raised above threshold and the lowest energy 
pathways will be followed. CID of protonated peptide ions mainly result in b- and y-type 
backbone fragment ions, while CID of deprotonated peptide ions typically result in y- and c-type 
fragment ions [111, 112]. In both cases, neutral losses from side chains such as water and 
phosphoric acid are also frequently observed.  
Currently, the widely acknowledged framework to describe how protonated peptides 
dissociate upon collisional activation is termed the “mobile proton” model [113-116]. This model 
assumes that, for protonated peptide ions formed by soft ionization methods such as ESI, protons 
are initially localized on the most basic sites in the molecule, including the N-terminus and the 
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side chains of basic amino acid residues. During ion activation, these protons migrate to less 
basic sites provided that they are not sequestered by strongly basic amino acid side chains [117, 
118]. It is known from the results of molecular orbital calculations that protonation of the amide 
nitrogen leads to considerable weakening of the amide bond [119], thus triggering 
charge-directed mechanisms [119-122] that provide mainly b- and y-ions, the two types of 
complementary fragment ions resulting from cleavage of the -CO-NH- peptide bond. 
CID of deprotonated peptides has received less attention in proteomics studies. However, 
the mass spectra of negatively charged peptides can provide an important supplement to positive 
ion spectra in sequencing peptides [112, 123]. Bowie and coworkers described the fundamental 
backbone cleavages and the characteristic side-chain fragmentations for deprotonated peptides 
[111, 124, 125]. They suggested that the fragmentation pathways are often dependent on the 
specific peptide sequence and the side-chain structure of some amino acids. 
1.2.4.2 Electron-Based Fragmentation 
As two commonly used electron-based fragmentation techniques, ECD [126] and ETD 
[127] can study non-covalent complexes [128] and preserve labile bonds to preclude the 
significant PTM losses typically observed in slow-heating methods [129-131]. Compared to CID, 
ECD and ETD often provide more peptide backbone cleavages and less side-chain losses. As 
indicated in Scheme 1.1(A), the principle of ECD is to react multiply protonated polypeptide 
cations with low-energy electrons. Capture of near-thermal free electrons results in 
charge-reduced radical intermediates that further fragment at the N-Cα bond of the peptide 
backbone to produce c’- and z•-ions. a•- and y-ions are also observed in ECD mass spectra at 
lower abundance. In addition, ECD results in  S-S bond cleavage [132]. The mechanism of 
N-Cα peptide backbone bond cleavage upon electron capture is not fully understood; different 
mechanisms are currently proposed [126, 133-137]. ETD (2004) was introduced several years 
later than ECD (1998) [127]. Electrons in ETD are delivered by radical anions (e.g., 
fluoranthene), unlike the free electrons employed in ECD (Scheme 1.1(B)). Subsequent peptide 
backbone N-Cα bond cleavage is assumed to proceed by the same mechanism as that in ECD 
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[134]. Unlike ECD, almost exclusively implemented on FT-ICR MS instruments, ETD can be 
implemented on relatively affordable, robust, and widespread ion trap mass spectrometers, which 
makes ETD more accessible than ECD, especially with instrumentation that deliver 
proteomics-grade performance such as high-resolution Orbitrap or TOF MS. Recently, the 
feasibility of performing ECD on benchtop MS instruments has also been explored [138]. 
(A)  [M + nH]n+ + e-(< 1 eV) → [M + nH]
(n-1)+•
 → Fragments 
(B)  [M + nH]n+ + A-• → [M + nH](n-1)+• → Fragments 
(C)  [M - nH]n- + e-(> 10 eV) → [M - nH]
(n-1)-•
 + 2e
-
 → Fragments 
(D)  [M - nH]n- + e-(~2.5 – 6.5 eV) → [M - nH]
(n+1)-•
 → Fragments 
Scheme 1.1 Fragmentation routes for (A) ECD, (B) ETD, (C) EDD, and (D) niECD. 
Interaction of more energetic electrons (~10 eV) with multiply protonated peptide cations 
leads to increased efficiency of secondary fragmentation, a process known as hot ECD (HECD) 
[139]. In electron ionization dissociation (EID), involvement of electrons with even higher 
energy (up to 20-100 eV) may induce further ionization accompanied by extensive backbone 
fragmentation [140, 141]. Peptide backbone N-Cα bond cleavage is also possible for negatively 
charged peptide anions following capture of a slightly more energetic (~2.5-6.5 eV) electron, a 
novel MS/MS technique termed negative ion electron capture dissociation (niECD) which was 
first discovered in the Hakansson Lab in 2011 [142, 143]. When multiply charged peptide anions 
interact with energetic electrons (>10 eV) in electron detachment dissociation (EDD), Cα–C 
backbone bond cleavage is a preferential fragmentation pathway to yield mainly a
•
- and x-ions 
for proteins and peptides [144, 145]. Both niECD and EDD are believed to proceed via 
radical-driven fragmentation mechanism and may find application in mass spectrometry for 
peptide sequencing and localization of labile PTMs, especially acidic ones that show improved 
ionization efficiency in negative ion mode, e.g., phosphorylation [142, 145, 146] and sulfation 
[143]. However, one drawback of niECD and EDD of polypeptides is their low fragmentation 
efficiency. Also, the use of highly energetic electrons in EDD may induce additional neutral 
losses and side-chain losses with less useful structural information, for example, the 
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characteristic CO2 loss [144]. In this sense, niECD may mitigate the issue by utilizing less 
energetic electrons. 
In addition to the aforementioned electron-based fragmentation methods, free radical 
initiated peptide sequencing (FRIPS) [147, 148] is an alternative radical-driven MS/MS 
technique. Different from the electron-mediated radical-driven mechanisms discussed above, 
radical initiation in FRIPS is accomplished through vibrational activation. A stable free radical 
initiator attached to free amines in protonated or deprotonated peptide ions undergo homolytic 
bond cleavage upon mild collisional activation to generate odd-electron species. The initiated 
radical is then propagated through the peptide ion to yield a variety of backbone fragments. 
FRIPS has shown potential to achieve localization of labile acidic modifications in negative ion 
mode [149]. 
1.2.5 Charging and Supercharging 
Mass spectrometers measure the m/z values of chemical species in gaseous form that 
carry a net charge. Thus, a key prerequisite is to ionize molecules of interest and transfer them 
into the gas phase. ESI [150] and matrix-assisted laser desorption/ionization (MALDI) [151] are 
by far the two most widely used “soft” ionization techniques for MS [152]. Both ESI and 
MALDI induce minor or no fragmentation. While MALDI typically forms singly charged ions, 
multiply charged ions are often formed via ESI, particularly for large analytes. ESI is thus the 
preferred method for coupling with mass analyzers of limited m/z range. In addition, ESI is a 
suitable ion source to couple LC with MS. 
1.2.5.1 Electrospray Ionization (ESI) 
The invention and application of ESI is a key milestone in the development of modern 
mass spectrometry [150]. ESI allows for biomolecules with varying sizes to be introduced into 
the gas phase carrying multiple charges. Under specific ESI conditions, proteins can be ionized 
without denaturation; thus non-covalent protein complexes can remain intact. ESI proceeds with 
the dispersal of a fine spray of charged droplets, from a Taylor cone formed at a small aperture 
capillary tip maintained at high voltage (e.g., 2.5-6.0 kV), followed by solvent evaporation, 
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droplet shrinkage, and ion formation from the highly charged nanodroplets [35, 153, 154]. The 
application of a nebulizing gas, e.g., nitrogen, which shears around the sample solution spray, 
assists rapid solvent evaporation and allows a higher sample flow rate, typically between one and 
several hundred μL min-1. With the aid of an elevated source temperature and/or another stream 
of nitrogen drying gas, the shrinking droplets build up their charge density, until surface tension 
and Coulomb repulsion are balanced, a critical point termed the Rayleigh limit [18]. The 
Rayleigh limit predicts the maximum number (zR) of elementary charges e possible for a 
spherical droplet of radius R: 
Equation 1.2      
        
 
 
where ε0 is the vacuum permittivity and γ is the surface tension of the liquid. Gaseous analyte 
ions generated from ESI follow a pressure gradient and a potential gradient towards the analyzer 
region of the mass spectrometer. 
Mechanisms for ESI are still under debate. Three major ion formation mechanisms are 
the ion evaporation model (IEM), charged residue model (CRM), and chain ejection model 
(CEM) [154, 155]. Low molecular weight species are believed to be ejected from droplet 
surfaces into the gas phase at the final stage of ESI, referred to as IEM. In CRM, nanodroplets 
that are close to Rayleigh limit and only contain one single analyte molecule evaporate to 
dryness. The nanodroplet transfers its charge to the analyte before it evaporates. It is widely 
accepted that large molecules with compact structures are released into the gas phase as 
described by CRM. Unfolded and hydrophobic proteins are believed to follow CEM ejected out 
of the droplet as a chain [156]. 
1.2.5.2 Supercharging Strategies 
Back in 2001, Williams and coworkers discovered that addition of glycerol or 
m-nitrobenzyl alcohol (m-NBA) into electrospray solutions dramatically increased both the 
maximum observed charge state and the abundances of the high protein and peptide charge states 
[157]. Later, a number of studies were conducted to explore the mechanism of this 
charge-enhancing effect [158-162] and expand the application of the strategy, termed 
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“supercharging”. In addition to m-NBA [157], a number of molecules have been found to 
promote protein/peptide charging when added to ESI solvents (or LC mobile phases) in relatively 
low concentration, such as sulfolane [162, 163], dimethyl sulfoxide (DMSO) [164], propylene 
carbonate [32, 165], 1,2-butylene carbonate [166], etc. These low-volatility additives are referred 
to as “supercharging reagents”. Some supercharging reagents, such as m-NBA, have been found 
to be effective for both native (aqueous) [167] and denaturing (aqueous/organic) [168] ESI spray 
solutions. Novel supercharging reagents continue to be developed, including trivalent metal 
cations [169, 170]. Also, the extent of ESI supercharging in both ion modes has been investigated 
[171]. It was found that the same supercharging agents did not induce the same significant 
increase of charging for protein ions in negative ion mode ESI as observed in positive ion mode. 
Over the past two decades, there have been discussions and debates over the mechanism 
of chemical supercharging. During evaporation, ESI droplets become enriched with the reagent 
due to its low volatility [158] and high boiling point (bp>180 ºC) [157] relative to typical solvent 
molecules. In denaturing conditions in which proteins are more unfolded, retention of these 
reagent molecules causes an increase of the droplet surface tension and thus a higher charge 
density needed to reach Rayleigh limit [157]. More highly charged ions can be formed from 
droplets with a higher charge density. However, this argument contradicts the solution-phase 
properties of m-NBA (γm-NBA<γwater) [162]. Results from experiments using thermal activation 
[167], HDX MS [164, 172], traveling wave ion mobility MS (TWIMS MS) [173], and chemical 
cross-linking [174] indicated that chemical and/or thermal denaturation of the analyte in the ESI 
droplet is the primary reason for aqueous solution supercharging of proteins and complexes. 
Circular dichroism spectroscopy (CD) monitored the transition of protein structure from folded 
to unfolded states as sulfolane was added to the solution [171], consistent with this hypothesis. 
However, this unfolding mechanism was questioned with differential mobility analyzer-mass 
spectrometry (DMA-MS) data [175] and TWIMS data [173] indicating that supercharging 
occurred without extensive unfolding. Other investigations considered supercharging 
reagent-protein interactions [163, 176], as well as the supercharging reagent Bronsted acid/base 
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chemistry [159]. Meanwhile, ESI models (IEM, CRM and CEM) [155] have been frequently 
used to describe the supercharging process. Recent molecular dynamics (MD) simulations 
revealed that supercharging may be caused by a charge trapping mechanism [160, 161] for 
proteins electrosprayed from aqueous solution and released via the CRM, while charge carriers 
are ejected from the surface via the IEM with droplet shrinkage. Extended protein ions were 
shown to be formed by the CEM in supercharging ESI [156]. 
Benefits of charge enhancement through supercharging and other strategies are obvious 
for the performance of FT-based mass analyzers [93, 177] and the efficiency of tandem mass 
spectrometric techniques that require multiply charged precursors, such as ECD and ETD. 
Several studies reported on reduced fragmentation efficiency and limited sequence coverage for 
doubly charged peptides in ETD [178, 179]. Our group has also looked into the charge state 
effect on ECD performance using a variety of proteolytic peptides and demonstrated that triply 
protonated peptides show improved fragmentation efficiency than their doubly protonated 
counterparts [180]. Since the ECD/ETD fragmentation efficiency is greatest for ≥3+ peptide ions 
[180-182], it presents a problem in bottom-up proteomics strategies where proteins are 
enzymatically digested into peptides with limited size. Doubly charged peptide ions are reported 
to be the most abundant ion species from trypsin-digested proteins [183]. The problem with 
reduced ECD/ETD fragmentation is even more pronounced in bottom-up HDX experiments 
because pepsin-derived peptides [184] do not necessarily carry basic amino acid residues 
(protonation sites) at their C-terminus as trypsin-derived peptides [185] do.  
McLuckey and coworkers have shown that elevated bath gas temperature can increase the 
overall sequence coverage for tryptic peptides containing more than seven residues [178]. Using 
proteases such as Lys-C or Asp-N is another approach to increase peptide ion charge states, since 
longer peptides (20-25 residues) are generated that tend to hold more charges (3-6) than tryptic 
peptides [127, 181]. Kjeldsen and coworkers found that by adding just 0.1% m-NBA to LC 
mobile phases in LC ETD MS/MS experiments, the average charge states for tryptic peptides 
were significantly increased, resulting in improved ETD fragmentation efficiency and, 
22 
 
consequently, improved peptide sequencing for regular peptides and phosphopeptides [168]. 
Furthermore, m-NBA has been adopted to promote charging for a variety of peptides derived 
from other proteases [186, 187]. In addition to chemical supercharging, electrothermal 
supercharging (ETS) [188, 189] was recently applied to native proteins by simply elevating the 
potential and the capillary temperature in a nanoESI source. It has been shown that protein 
denaturation occurring in ESI droplets is the primary mechanism for ETS [190]. 
1.3 Hydrogen/Deuterium Exchange Mass Spectrometry (HDX MS) 
Protein HDX MS has evolved into a powerful method for investigation of protein 
conformation, folding/unfolding, dynamics, and interactions [191-195]. The traditional method 
for HDX studies has been two-dimensional NMR spectroscopy [196, 197]; however, HDX 
experiments have shifted mostly towards MS lately. Attractive features of HDX MS include great 
sensitivity, straightforward measurement, ideally unlimited size range, and capability to detect 
complex systems such as membrane proteins [198-200]. 
The HDX technique was first developed in the early 1950s by Kaj Linderstrom-Lang and 
coworkers [201]. They used density gradient tubes to monitor the protein mass increase as a 
result of hydrogen substitution for deuterium. Later, Englander and coworkers employed liquid 
scintillation counting to measure hydrogen/tritium exchange [202] and used NMR to examine 
HDX [197]. HDX was coupled to MS in the early 1990s [203], soon after the introduction of soft 
ionization methods. Rapid advances in this technique have been occurring ever since. This 
section exclusively focuses on commonly employed solution-phase HDX MS. 
1.3.1 HDX Kinetics 
HDX MS relies on the fact that exposure of a protein to D2O or other deuterated solvents 
can induce rapid amide hydrogen to deuterium exchange in disordered regions that lack stable 
hydrogen bonding. Tightly folded regions are much more protected from HDX, resulting in 
slower isotope exchange behavior [191, 193, 194]. The technique takes advantage of the inherent 
and spontaneous exchange of labile hydrogen atoms in a protein to serve as reporters of its global 
or local conformational environment. A general exchange mechanism for native proteins is 
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described as: 
Equation 1.3            
   
         
   
         
   
           
where kop and kcl are rate constants for the opening and closing transitions, and kch is the intrinsic 
rate constant for N–H → N–D exchange determined for totally solvent-exposed amides, also 
referred to as the chemical rate constant. As indicated in Equation 1.3, HDX kinetics is strongly 
associated with the opening/closing (or unfolding/refolding) events of native proteins in solution. 
Isotopic labeling can only occur during short-lived transitions to an open state. The equilibrium 
between protein opening motion (kop) and closing motion (kcl) characterizes the populations of 
structurally open protein and structurally closed protein in solution. The overall (observed) HD 
exchange rate constant kHDX can be described by Equation 1.4 [204]: 
Equation 1.4        
      
       
 
The corresponding protection factor [205] is defined by: 
Equation 1.5     
   
    
 
The density of intramolecular hydrogen bonding and solvent access both contribute to protection 
of the amides [191]. If the unfolding/refolding event is much faster than the chemical exchange 
(       ), multiple openings and closings must take place before exchange occurs. kHDX can 
thus be described as: 
Equation 1.6        
      
   
 
This mechanism is termed EX2. If the protein refolds at a rate much slower than the chemical 
exchange (       ), amide labeling occurs during the very first opening event, following EX1 
behavior: 
Equation 1.7            
In nature, most proteins follow EX2 behavior [191], although some proteins can be induced to 
undergo deuterium exchange by the EX1 mechanism by exposing the protein to denaturants 
[206]. Intermediate cases that exhibit aspects of both mechanisms have been reported as well 
kc l  ko p D2O 
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[204]. Bimodal isotope distributions are a signature for HDX that follows EX1 [206, 207]. 
However, one has to be careful in identifying EX1 behavior, as sometimes sample carryover 
during LC can lead to false EX1 characteristics [208]. 
HDX can proceed via catalysis by acid, base, and water. The pD dependence of kch is 
given by: 
Equation 1.8           
        
      
in which kA, kB, and kW are the acid-, base-, and water-catalyzed intrinsic rate constants. Basic 
catalysis is the dominant mechanism in near-neutral solution [209]. The exchange becomes 
minimal at pD ~2.5 and kch decreases ~4 orders of magnitude if pD is lowered from 7 to 2.5. In 
addition to pD, HDX depends on temperature, although the HDX rate is less sensitive to 
temperature change than pD change. A 10-fold change in exchange rate can be obtained by a 
change of one pH unit or ~22 ºC in temperature [197]. Moreover, amide hydrogen exchange 
depends on the side chain structures of neighboring amino acid residues for unstructured 
polypeptides [209]. 
1.3.2 HDX MS approaches 
1.3.2.1 Bottom-up HDX MS 
A typical procedure for HDX comprises isotope labeling, quench, proteolytic digestion, 
desalting/separation, and mass analysis [194]. HDX is usually initiated by dilution of the protein 
in deuterated buffer for each of several periods of time (continuous labeling), e.g., 1 min, 10 min, 
1 h, etc. The dilution should be 10- to 20-fold to achieve at most 90-95% D labeling. The 
exchange is then quenched by lowering the solution pH to ~2.5 and the temperature to ~0 ºC 
followed by enzymatic digestion either in solution [210] or on-column with an immobilized acid 
protease [211]. Alternatively, the digestion step can be skipped for global HDX analysis [190] or 
top-down HDX of intact proteins [212, 213]. Following proteolysis, the protein digests are 
desalted and separated through fast and chilled LC and then analyzed by MS (Figure 1.6). 
Because side chain deuteriums back-exchange for hydrogen during the LC step, only deuteriums 
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at the backbone amides are retained and measured, with the exception of proline residues which 
do not have backbone amide hydrogens [193, 195]. Because deuterium is twice as heavy as 
hydrogen, the exchange can be detected and quantified by mass shift. Deuterium content is 
calculated by subtracting the average mass of the undeuterated peptide (no HDX control) from 
that of the deuterated one at each incubation period. Comparison of deuterium uptake profiles 
under two sets of conditions provides insight into the protein conformational dynamics [191, 193, 
214, 215]. 
 
Figure 1.6 Diagram of protein HDX MS and MS/MS workflows with the use of LC and/or 
gas-phase fragmentation techniques. Reprinted with permission from ref [230]. Copyright 2014 
American Chemical Society. 
In HDX MS experiments, conducting proteolytic digestion before LC/MS (bottom-up 
method) is helpful for monitoring conformational changes in small regions of a large protein. 
The acid protease commonly used in HDX is pepsin, which remains active under quenching 
conditions. In most cases, pepsin is added to a final level of 2:1 to 1:1 (w/w) protein:pepsin for 
in-solution digestion. Other acid-resistant proteases such as protease XIII and protease XVIII, 
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although less popular than pepsin, can yield complementary digestion patterns [184, 216, 217]. 
The use of more than one protease in HDX experiments [184] resulted in enhanced sequence 
resolution, as more overlapped peptide segments could be produced. However, due to the fairly 
non-selective cleavage pattern of pepsin and other acid proteases [216], tandem MS is usually 
suggested to confirm the identity of undeuterated peptides before HDX measurements. The use 
of denaturants (e.g., guanidine HCl or urea) [218] and/or disulfide bond reducing agents (e.g., 
tris(2-carboxyethyl)phosphine (TCEP)) [219] mixed with quenching solutions enables quenching 
of the HDX and simultaneous denaturing/reduction of the protein, thus improving digestion 
efficiency.  
In addition to continuous labeling, one can also apply pulsed labeling to monitor rapid 
conformational changes in proteins in the presence of perturbant, such as denaturing agents, pH 
and/or temperature change, etc. In pulsed HDX, the exchange is only performed for a brief time 
(e.g., 10 s) [220-222]. Even shorter exposure time (milliseconds to seconds) was achievable on a 
more sophisticated labeling apparatus, such as a stopped-flow setup [223] or a microfluidic 
device [224].  
 
Figure 1.7 Diagram of online pepsin digestion setup, modified from ref [194]. The pepsin 
column can be placed either inside or outside the cooling chamber. 
Enzymatic digestion can also be achieved on-column if the protease is immobilized on a 
stationary phase (e.g., POROS beads [225, 226], ethyl-bridged hybrid particles [75]) packed into 
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a conventional stainless steel column. Attractive features of online digestion include that the 
effective protease concentration on-column is much larger than that in-solution, leading to higher 
digestion efficiency; the protease is not injected onto the analytical column, so a cleaner 
chromatogram can be created; and the reproducibility of protein digestion is improved compared 
with manual sample handling. To achieve online digestion, an LC setup incorporating an 
auxiliary pump and a binary solvent pump has been designed to couple the immobilized pepsin 
column with a C18 analytical column, in which a trap column is placed between the enzymatic 
column and the analytical column [75, 211, 225]. A diagram of the online pepsin digestion setup 
is shown in Figure 1.7. The additional auxiliary pump (Pump C in Figure 1.7) is to drive the 
protein through the pepsin column with aqueous solvent (usually water containing 0.1% formic 
acid). The digested sample is then carried to the peptide trap located on a second switch valve 
(the first switch valve is an injection valve for rapid sample loading). Following a short desalting 
period, the switch valve is set so that solvent from the binary pump (Pump A and Pump B in 
Figure 1.7) elutes peptides from the trap, enabling their separation and analysis by LC/MS. 
Although the pepsin column is usually used at ambient temperature, all other parts of the system 
are immersed in an ice bath or placed in a refrigerator to minimize deuterium loss. Nevertheless, 
one needs to be careful about back-exchange and carryover issues associated with immobilized 
pepsin columns [225]. 
In addition to online digestion, a number of efforts have been made to improve 
proteolysis in HDX due to the time limitation [210] and temperature requirement under 
quenching conditions. Mysling et al. demonstrated that electrochemical reduction of disulfide 
bonds is efficient under quench conditions [227]. New proteolytic enzymes suitable for HDX 
experiments have been investigated too [217, 228]. 
Strategies to improve separation and mass spectrometry analysis in HDX experiments 
include the use of UPLC [229] or supercritical fluid chromatography (SFC) [210, 230] instead of 
HPLC which performs poorly at 0 ºC, a shorter yet efficient gradient compared to a conventional 
one [210], well-controlled refrigerated systems [231, 232], high resolution mass analyzers such 
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as FT-ICR [216, 233], appropriate tandem MS techniques [213], etc. The coupling of tandem MS 
to HDX is discussed in more detail in the following section.  
Automation is another major trend in HDX MS. Recent development in automation of 
HDX sample handling has greatly improved throughput, increased reproducibility, reduced 
back-exchange during sample freezing/thawing, and eliminated human error. Waters Corporation 
(Milford, MA) developed a complete HDX setup composed of nanoAcquity solvent managers 
linked to an HDX manager (with cooling system) and a Synapt G2-S mass spectrometer. They 
also collaborated with Leap Technologies (Carrboro, NC) to provide an automated sample 
handling solution with a Leap robot. Thermo Scientific (La Jolla, CA) also introduced their first 
HDX setup in 2012. In addition, the demand for managing the large amount of data generated 
from an HDX experiment has provoked the development of automated or semi-automated data 
processing platforms. Software tools, such as HX-Express [234], Hydra [235], The Deuterator 
[236], HD Desktop [237], HeXicon [238], HDXFinder [239], etc., provide a user-friendly 
interface to complete deuterium uptake calculation, data visualization and comparison. However, 
some of these packages require the file type(s) of MS raw data generated by a certain MS 
instrument manufacturer, thus are not universal solutions for all HDX practitioners. 
1.3.2.2 Top-down HDX MS 
One drawback of the bottom-up HDX method is that spatial resolution is limited by the 
size of each proteolytic peptide, typically 5-10 residues in length [240]. In addition, the 
enzymatic cleavage events inevitably cause loss of HDX information at the two terminal residues. 
Even the combination of different proteases and generation of highly overlapped peptide 
segments cannot ensure a resolution of deuterium uptake down to single amino acid residue level 
[241]. Also, the proteolysis and chromatographic separation in bottom-up experiments are 
usually associated with the issue of back exchange [225]. 
Top-down MS/MS attempts to overcome these limitations by directly infusing deuterated 
proteins into a mass spectrometer and applying gas-phase fragmentation to the intact protein ions 
to yield complementary N- and C-terminal ion pairs, as indicated by the dashed line in Figure 1.6. 
29 
 
Higher spatial resolution can be obtained in top-down experiments, ideally to the single-residue 
level, because gas-phase fragmentation may generate the fragment ions that differ by one amino 
acid and the difference in deuterium contents of such adjacent ions can yield HDX information at 
a single backbone amide [54, 193]. Top-down HDX MS may also allow protein dynamics 
characterization in a conformer-specific fashion [242, 243]. However, top-down HDX MS had 
not enjoyed significant popularity until recently mainly due to several problems. One practical 
limitation is inadequate sequence coverage for larger polypeptides and proteins, which frequently 
results from limited fragmentation efficiency and/or limited resolving power of mass 
spectrometers for highly overlapped peaks, and leads to inferior spatial resolution. Incorporation 
of peptide ion fragmentation in the workflow of the bottom-up HDX MS measurements (Figure 
1.6) attempts to overcome the size limitation of proteins studied associated with the top-down 
strategy and has shown potential for obtaining near-residue-level resolution in HDX MS/MS for 
proteins smaller than 30 kDa [187, 218, 240]. While incorrect determination of deuterium levels 
for fragment ions may result from fast LC/MS/MS and inadequate data acquisition time, a 
solution to address this problem is to enhance the quality of MS/MS of deuterated peptide ions 
by increasing the data acquisition window in high-resolution mass spectrometry (e.g., FT-ICR) 
while eliminating the LC step [244]. 
Another important fundamental problem that hinders widespread use of top-down HDX 
MS/MS and MS/MS coupled with bottom-up HDX workflows is the frequent occurrence of 
hydrogen/deuterium (H/D) scrambling upon protein and peptide ion activation prior to or during 
the dissociation event, further discussed in the following section. 
1.3.3 Hydrogen/Deuterium (H/D) Scrambling in HDX MS/MS 
H/D scrambling refers to multiple reversible proton/deuteron transfers among all the 
labile sites in a gaseous peptide, i.e., all N-, S-, and O-linked hydrogen/deuterium atoms. The 
resulting, undesired, randomization of hydrogens and deuteriums in the gas phase distorts the 
labeling pattern from that obtained in solution and extensive H/D scrambling completely erases 
the information imprinted on a protein/peptide in solution. Therefore, H/D scrambling in the 
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gaseous peptide or protein ion is the main issue that has to be addressed prior to wider 
acceptance of MS/MS techniques to increase the spatial resolution in HDX MS experiments. 
Comparison of the deuterium distribution patterns on a polypeptide/protein backbone 
obtained by HDX MS/MS and by NMR provides a straightforward manner to detect the 
occurrence and extent of H/D scrambling [190, 245, 246]. Another method is to use a 
polypeptide model system with well-characterized and selective deuterium labeling in solution; 
deviation from the expected, well-defined, exchange patterns of the series of fragment ions 
indicates the occurrence of H/D scrambling. These peptides can be prepared in a manner that 
ensures that the deuterium is exclusively or considerably retained at backbone amides of one half 
of the peptide prior to MS analysis [247-253]. Such regioselective deuterium labeling can be 
achieved either by higher-order structure effects [249, 251] or primary structure effects [250, 252, 
253]. This method can also quantitate the H/D scrambling level during an MS/MS experiment by 
comparing the measured H/D distribution to the known solution pattern (0% scrambling) and the 
totally randomized distribution (100% scrambling), as indicated in Figure 1.8. 
 
Figure 1.8 Principle of measuring H/D scrambling by gas-phase fragmentation of selectively 
labeled model peptides. The figure accounts for C-terminal y-type ions and thus the sequence is 
read from right to left. 
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Early studies on determinants of H/D scrambling in top-down HDX MS/MS utilizing 
CID for protein ions indicated that the occurrence of hydrogen scrambling is associated with 
both collision energy and protein ion structure in the gas phase [246, 254]. Low-energy CID is 
the most common fragmentation method for protein and peptide ions and is accessible on most 
commercial mass spectrometers. Unfortunately, several studies have demonstrated extensive H/D 
scrambling upon collisional activation of protonated peptides and proteins for both b- and y-ions 
[251, 252, 255, 256], consistent with the current theoretical framework developed to understand 
CID-type fragmentation of protonated peptides, known as the “mobile proton” model [113, 114]. 
In this charge-directed fragmentation mechanism, internal energy elevation through multiple 
energetic collisions (>μs) facilitates intramolecular proton transfer from a basic site to a less 
basic backbone amide, which weakens the peptide bond to yield complementary b- and y-ions 
[114]. Protonation of the backbone amide is reversible in nature, which well explains the 
migration of deuteriums among labile sites in deuterated peptide ions. Negative ion mode CID 
has also been shown to induce complete hydrogen scrambling in deprotonated peptides using a 
MALDI ion source [249]. Overall, it has become a consensus that CID should not be used as a 
gas phase fragmentation technique in HDX MS experiments due to extensive H/D scrambling.  
Electron-based fragmentation, on the other hand, may provide a solution to the 
scrambling problem. Based on an early suggestion that ECD proceeds in a nonergodic manner 
[126], it was hypothesized that ECD and ETD may induce minimal hydrogen scrambling [126, 
247]. It is evident that these fragmentation techniques are gentle enough to cause peptide 
backbone fragmentation while retaining labile PTMs [129, 130]. Over the past decade, ECD and 
ETD have both been demonstrated to proceed with negligible intramolecular H/D migration in 
peptides [250, 253] and small intact proteins [213] (although recent work by Hamuro et al. 
implies that ETD fragmentation is accompanied by regioselective scrambling [257, 258]), thus 
allowing localization of deuteriums down to the single residue level without deviation from 
solution-phase labeling patterns. However, great care must be taken when conducting 
ECD/ETD-based HDX MS experiments, because careful optimization of the ion source and ion 
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transfer parameters is of vital importance to minimize H/D scrambling by vibrational excitation 
prior to the MS/MS event [250, 253, 259]. It is noteworthy that suitable parameters for ion 
source and ion transfer optics should be determined for each instrument type in order to find a 
compromise between minimal H/D scrambling levels and acceptable ion transmission efficiency 
and signal abundance [250, 253, 260]. 
In terms of other gas-phase fragmentation techniques for analysis of deuterated peptides, 
a rather limited number of studies have been conducted. MALDI in-source decay (ISD) was 
reported to yield minimum hydrogen scrambling [248]. IRMPD of intact protein ions following 
gas-phase HDX in an ICR cell showed a distribution of deuterium uptake different from the 
complete scrambling pattern, but the degree of scrambling increased as the laser power increased 
[261]. Recently, top-down HDX analysis of protein structures using ultraviolet photodissociation 
(UVPD) was achieved in positive ion mode on an Orbitrap Fusion Lumos Tribrid mass 
spectrometer equipped with a 213 nm laser [245]. UVPD is a recently developed 
fast-fragmentation technique based on irradiation of gaseous protein/peptide ions with far-UV 
light at a wavelength absorbable by peptide bonds [262, 263]. Fast radical-based mechanisms 
have been raised for understanding the UVPD process [262]. In this work, the lack of scrambling 
in UVPD was confirmed by comparing obtained deuteration data with NMR and X-ray 
crystallography results. In other recent work, quantitation of H/D scrambling during UVPD using 
a selectively labeled peptide was completed on a high-resolution Q-TOF mass spectrometer 
[264]. These results also showed that UVPD at 213 nm can proceed with limited H/D scrambling 
(<10% scrambling for a/x fragment ions) at mild ion source conditions. These findings indicate 
that UVPD fragmentation can be a valuable addition to the HDX MS toolbox for both bottom-up 
and top-down applications.  
1.4 Dissertation Overview 
This dissertation focuses on analytical strategy development for combining gas-phase 
fragmentation with HDX MS for protein structural analysis, and for improving host cell protein 
characterization in complex biopharmaceuticals. In Chapter 2, the feasibility of several negative 
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ion mode MS/MS techniques for improving HDX spatial resolution is explored, including nCID, 
nFRIPS, EDD, and niECD. Specifically, H/D scrambling levels associated with these techniques 
were measured and compared by use of basic and acidic regioselectively deuterium labeled 
model peptides. In Chapter 3, a supercharging strategy is described to facilitate ECD/ETD-based 
peptic peptide fragmentation to address the issue of limited charging in bottom-up HDX MS. The 
ability of the supercharging agent m-NBA to enhance average charging for short peptides 
frequently generated upon pepsin digestion is demonstrated and, consequently, improved 
ECD/ETD fragmentation efficiency, sequence coverage, and deuterium spatial resolution are 
achieved. Chapter 4 examines unconventional fragmentation behavior for supercharged peptides 
upon ECD/ETD. Standard peptides with few or no basic amino acid residues, a longer peptide 
(melittin), and proteolytically derived peptides are used to investigate the occurrence of atypical 
b-type fragment ions upon ECD and ETD, respectively, under supercharging conditions, 
providing insight into the different energetics of these two fragmentation methods that are often 
considered equivalent. Chapter 5 describes work I performed during a co-op program at 
Bristol-Myers Squibb (Hopewell, NJ) in 2018. An offline HILIC sample preparation method was 
developed for improving host cell protein detection in mAb and non-mAb biotherapeutic 
proteins by LC/MS. Finally, Chapter 6 summarizes all results and discusses future directions. 
The work in Chapter 2 is currently in press for the Journal of the American Society for 
Mass Spectrometry. Chapters 3 through 5 are written in multiple manuscript format. 
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Chapter 2 
 
 
Gas-Phase Hydrogen/Deuterium Scrambling in Negative-Ion Mode Tandem Mass 
Spectrometry 
 
 
2.1 Introduction 
Hydrogen/deuterium exchange (HDX) coupled with mass spectrometry (MS) is a 
powerful method for examining protein conformation and dynamics [1–5].  In HDX, protein 
amide hydrogen atoms are exchanged for deuterium (or vice versa).  The location and rate of 
exchange depend on solvent accessibility and protection derived from hydrogen bonding and are 
thus indicative of protein three-dimensional structure and unfolding/refolding rate.  When such 
deuterated samples are analyzed by a mass spectrometer, a mass shift of ~one Dalton is observed 
for each exchanged hydrogen atom.  The structural resolution of this technique, however, is 
typically limited to the peptide level with pepsin being the proteolytic enzyme of choice due to 
quenching at low pH (where most enzymes are inactive) to minimize deuterium back exchange 
prior to and during MS analysis.  Peptic peptides with overlapping sequences are required to 
measure H/D exchange rates at individual amino acid residues [6–9].  
Alternatively, dissociation via tandem mass spectrometry (MS/MS) could potentially be 
used to improve structural resolution, either by fragmenting proteolytic peptide ions, or to enable 
top-down (intact) analysis of deuterated proteins.  However, the most common MS/MS 
activation technique, positive-ion mode collision-induced dissociation (CID), has been reported 
to cause intramolecular hydrogen/deuterium (H/D) scrambling due to the increased vibrational 
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energy of protonated peptide/protein ions prior to dissociation and the up to millisecond time 
scale of CID [10–14].  Gas-phase H/D scrambling rearranges the deuteration pattern indicative of 
solution-phase protein structure/dynamics and, thus, erases the desired information.  
Electron-based activation methods, e.g., electron-capture/transfer dissociation 
(ECD/ETD), have demonstrated the ability to induce peptide backbone dissociation with 
minimum levels of H/D scrambling at carefully tuned instrument settings [15, 16].  In addition to 
these electron-based techniques, ultraviolet photodissociation was recently reported to proceed 
with minimum H/D scrambling [17, 18].  ECD/ETD have seen increased utilization in HDX 
workflows [19–27], but are either incompatible or ineffective for low charge-state precursor ions 
such as the short peptides frequently generated upon  pepsin digestion [28].  Furthermore, 
intramolecular hydrogen/deuterium migration upon ETD has recently been proposed to follow 
regio-selective behavior rather than a simple randomization process [29], thus further 
complicating spectral interpretation. 
Negative-ion mode MS/MS is gaining interest for proteomic analysis due to the 
importance of acidic post-translational modifications [30–37].  While the use of HDX in this 
polarity has been limited, applications towards carbohydrates and MALDI-generated peptide 
anions have been reported [38, 39] with prevalent H/D scrambling observed in MALDI tandem 
time-of-flight CID of peptide anions [39].  However, intramolecular H/D scrambling behavior in 
electrospray-generated peptide anions has, to our knowledge, not been examined.  
Here, we measure the extent of H/D scrambling in several negative-ion mode MS/MS 
techniques, including negative-ion mode CID (nCID), electron detachment dissociation (EDD) 
[40, 41], negative-ion electron capture dissociation (niECD) [34], and negative-ion mode free 
radical induced peptide sequencing (nFRIPS) [35, 42, 43].  Observed scrambling behaviors lend 
insight into the energetics of these processes.  
2.2 Experimental 
2.2.1 Materials 
The model peptides P1 (HHHHHHIIKIIK) [44], P3 (DDDDDDIIEIIE), and P4 
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(DDDDDIIEII) were synthesized by GenicBio Limited (Shanghai, China).  D2O (99.9 atom % D) 
was purchased from Sigma-Aldrich (St. Louis, MO).  o-TEMPO-Bz-NHS was synthesized as 
described previously [35].  All other chemicals were obtained at HPLC grade from Thermo 
Fisher Scientific (Waltham, MA) and used without further purification. 
2.2.2 Peptide Derivatization 
Acetylation of P1 (here referred to as peptide P2) was achieved by mixing a 110 mM P1 
solution in 30 μL methanol with a 20 μL 25% solution of acetic anhydride in methanol.  
Following three hour incubation at room temperature solvents were removed under vacuum. 
o-TEMPO-Bz-NHS was dissolved in acetonitrile at a concentration of 22 mM.  The P1 
conjugation reaction was buffered with 100 mM triethylamine acetate (pH 8) and performed 
using a four-fold excess of label overnight at 37°C.  These selected conditions enabled targeted 
labeling of the N-terminus.  The reaction solution was 60% acetonitrile which, after completion, 
was evaporated using a vacuum centrifuge followed by redissolution in water.  The poor water 
solubility of o-TEMPO-Bz-NHS enabled crude extraction of the labeled peptide.  For control 
experiments this purified stock solution was diluted to 1-5 µM and directly infused into the 
instrument.  
2.2.3 Deuterium/hydrogen Exchange 
 Deuterated peptides were prepared by dissolving unmodified peptides or diluting (1:20) 
derivatized peptides in D2O for a minimum of 18 h at 4 ºC.  The peptide concentration was 1,000 
μM, 500 μM , 50 μM, 100 μM, and 200 μM for nCID, nFRIPS, ECD, EDD, and niECD 
experiments, respectively.  Deuterated peptides were diluted to 10-20 μM using cooled protiated 
ESI solvents: 49:49:2 methanol:water:formic acid for ETD and nFRIPS and 45:45:10:0.1 
water:methanol:isopropanol:formic acid for nCID and positive ion mode ECD, both solvents at 
approximately pH 2.5.  Peptides P3 and P4 were diluted into 100 mM NH4HCO3 in 50:50:0.3 
H2O:isopropanol:formic acid (pH 4.0), or 45:45:10:0.05 H2O:methanol:isopropanol,ammonium 
hydroxide (pH 7.5) for niECD and EDD, respectively.  These solutions were immediately 
transferred to a precooled syringe (Hamilton Co., Reno, NV) or to a Nanomate (Advion, Ithaca, 
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NY) cooled to 0 ºC.  For syringe infusion, the syringe was mounted on a pump and cooled with 
ice bags or dry ice.  The flow rate was 10 μL/h for the Nanomate and 2-5.0 μL/min for the 
syringe pump. 
2.2.4 Mass Spectrometry 
Negative-ion mode CID MS/MS spectra were recorded on an Orbitrap-XL mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA) equipped with a Nanomate nanoESI 
source.  Doubly deprotonated precursor ions were isolated with an 18 m/z window and 
fragmented at a normalized collision energy of 30%.  Fragment ions were acquired in profile 
mode with four microscans and mass-analyzed in the Orbitrap.  Maximum ion injection times 
were set to 200 ms for MS/MS.  The automatic gain control targets were set to 1x10
5
 for MS/MS 
in the Orbitrap.  MS/MS data were gathered from m/z 210-1,600 in negative-ion mode. 
ECD, niECD, and EDD MS/MS spectra were recorded on a 7 T SolariX Fourier 
transform ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker Daltonics, Billerica, MA) 
equipped with an Apollo II ESI source.  For ECD experiments, an accumulation time of 0.4-0.5 s 
was used to optimize ion abundance.  Mass spectra were acquired from m/z 200-2,000 with 32 
scans for an overall acquisition time of less than one minute. Instrument parameters, including 
drying gas temperature, capillary exit voltage, deflector plate voltage, funnel 1 voltage, skimmer 
1 voltage, and quadrupole isolation width, were carefully tuned in order to define regimes of low 
and high scrambling levels (Table 2.1). ECD of triply protonated P1 ions was performed with a 
bias voltage of - 1.0 V and an irradiation time of 0.15 to 0.40 s.  A lens electrode placed in front 
of the cathode was set at + 9-10 V.  For negative-ion mode experiments on the SolariX, the 
nebulizing gas, drying gas, and temperature were set to 1 bar, 4.0 L/min, and 50-200 ºC, 
respectively.  Ions were accumulated for 3 s prior to EDD experiments.  Doubly deprotonated P3 
ions were irradiated at a cathode bias voltage of - 19 V for 2 s while the lens electrode was held 
at - 10 V.  Mass spectra were acquired from m/z 200-2,000 with 32 averaged scans, accumulated 
over 2-3 minutes.  For niECD experiments, the singly deprotonated peptides P3 and P4 were 
irradiated at a cathode bias voltage of - 4.7 V for 2 s while the lens electrode was held 1.0-1.5 V 
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lower than the cathode bias voltage to maximize the abundance of the charge-increased radical 
anion. 
Table 2.1 Instrument parameters for ECD experiments: The SolariX Q-FT-ICR mass 
spectrometer was tuned to accomplish “harsh” (complete scrambling) and “soft” conditions 
(minimum scrambling) in ECD MS/MS experiments. 
 
Instrumental parameters "Harsh" conditions "Soft" conditions 
ESI source Drying gas temperature 200 °C 40 °C 
 
Drying gas flow 2.0 L/min 3.5 L/min 
 
Nebulizing gas flow 2.0 bar 1.1 bar 
 
Capillary voltage (inlet) -4.4 kV -2.0 kV 
 
Capillary exit voltage 280 V 50 V 
 
Deflector plate voltage 260 V 40 V 
 
Funnel 1 voltage 110 V 10 V 
 
Skimmer 1 voltage 12 V 3 V 
 
Funnel 2 voltage 6.0 V 5.5 V 
 
Skimmer 2 voltage 5.0 V 5.0 V 
    
Qh interface Quadrupole focus lens -82 V -60 V 
 
Quadrupole isolation width 6 Da 30 Da 
 
Collision focus lens -50 V -35 V 
 
Collision voltage -4.0 V -0.5 V 
 
Ion accumulation time 0.4 sec 0.5 sec 
    
ICR cell Sweep excitation power 23.0% 18.5% 
 
Focusing lens 1 -47 V -30 V 
 
Focusing lens 2 -8 V -7 V 
 
Focusing lens 3 -33 V -22 V 
 
DC Bias -33 V -18 V 
 
Negative-ion mode FRIPS and positive-ion mode ETD and CID spectra were acquired on 
a Thermo Scientific Orbitrap Fusion Lumos (Waltham, MA).  To minimize scrambling, positive 
ion mode ETD and CID experiments were collected under the “softest” settings that allowed for 
stable electrospray.  The spray voltage, sheath gas, auxiliary gas, and RF lens were set to 3,600 V, 
2.5 (Arb), 1.5, and 10 %, respectively.  The 3+ charge state was isolated with a 10 m/z window 
and either reacted for 17 ms or subjected to 26% CID.  In both experiments, the generated 
product ions were measured in the orbitrap.  For nFRIPS, spectra were acquired with 2,700 V 
spray voltage, 7 sheath gas, 2 Aux gas, 150 °C ion transfer tube temperature, and 30% RF lens.  
For nFRIPS fragmentation, an MS
3
 workflow was used: the precursor ion was first dissociated 
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with 17% HCD and the homolytically cleaved product was then isolated with a 10 m/z window 
and further activated at 25% HCD.  The resulting product ions were measured in the orbitrap.  
2.2.5 Data Analysis 
Raw precursor and product ion deuterium contents were calculated by subtracting the 
observed weighted average natural isotopic distribution from the observed weighted average of 
deuterated equivalents (to yield Δmexp).  Observed product ion raw deuterium contents, were then 
converted to deuteration levels using the following equation:  
Equation 2.1     Deuteration level = Δmexp/(m100 - m0) 
where m100 corresponds to the weighted average isotopic distribution of the deuterated intact 
precursor ion and m0 corresponds to the weighted average of its natural isotopic distribution, 
respectively.  D/H exchange rates and predicted deuterium content curves under no scrambling 
conditions were calculated with the HXPep software (Zhongqi Zhang, Amgen, Thousand Oaks, 
CA), see Table 2.2 for peptides P3 and P4, unique to this work.  Theoretical 100% scrambling 
product ion curves were calculated by multiplying equation (1) with the following factor: 
Equation 2.2     100% scrambling factor = (HFrag/HPre) 
where HFrag is the number of exchangeable hydrogen atoms in a given fragment ion and HPre is 
the total number of exchangeable hydrogen atoms in the precursor ion.  Note that precursor ion 
charge states and the mechanism by which fragment ions were generated were both taken into 
consideration when calculating theoretical deuterium contents under complete scrambling 
conditions [34, 41, 45–49].  All experimental data are shown as the average of triplicate 
measurements.  In cases where incomplete product ion series were observed, the level of H/D 
scrambling was calculated according to the following equation: 
Equation 2.3     Scrambling level = (Δmexp - Δm0%)/(Δm100% - Δm0%) x 100% 
where Δm100% and Δm0% are the theoretical mass increases of the corresponding species in the 
case of 100% scrambling and 0% scrambling, respectively. 
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Table 2.2 Predicted intrinsic amide exchange rates of peptides P3 and P4. 
P3 
Residues 
Amide HDX rate 
Amide HDX 
half-life 
Amide HDX rate 
Amide HDX 
half-life P4 
Residues 
Amide HDX rate 
Amide HDX 
half-life 
k(min
-1
) t1/2 (min) k(min
-1
) t1/2 (min) k(min
-1
) t1/2 (min) 
pH 7.5 pH 7.5 pH 4.0 pH 4.0 pH 4.0 pH 4.0 
D2 1628  0.0004  31  0.02  D2 31  0.02  
D3 63  0.01  0.7  0.9  D3 0.7  0.9  
D4 63  0.01  0.7  0.9  D4 0.7  0.9  
D5 63  0.01  0.7  0.9  D5 0.7  0.9  
D6 63  0.01  0.7  0.9  I6 0.04  19  
I7 23  0.03  0.04  19  I7 0.007  103  
I8 21  0.03  0.007  103  E8 0.06  12  
E9 34  0.02  0.06  12  I9 0.03  27  
I10 25  0.03  0.03  27  I10 0.007  103  
I11 21  0.03  0.007  103  
   
E12 34  0.02  0.06  12  
   
a
 HDX rates of peptides P3 (DDDDDDIIEIIE) and P4 (DDDDDIIEII) were calculated at 0 °C, 
pH 7.5 and 4.0, using the HXPep software, based on an algorithm derived from Bai et al [50]. 
2.3 Results and Discussion 
The exchange rate of backbone amide hydrogen atoms in unstructured peptides depends 
on pH, temperature, steric hindrance, and the inductive influence of neighboring side chains [15, 
44, 50].  Utilizing these attributes, Rand et. al. designed the peptide HHHHHHIIKIIK (P1) to 
investigate H/D scrambling [15, 16, 44].  The difference in intrinsic exchange rates of histidine 
and isoleucine residues promotes preferential retention of deuterium on C-terminal residues.  The 
degree by which deuteriums migrate to N-terminal residues prior to backbone dissociation 
determines the applicability of an MS/MS technique for accurately determining deuterium 
location within this peptide (Figure 2.1).  Implementing a similar approach, we investigated the 
prevalence of H/D scrambling in a series of negative-ion mode MS/MS techniques.  
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Figure 2.1 Illustration of a selectively deuterated peptide undergoing gas-phase dissociation with 
(left) and without (right) H/D scrambling.  Blue and orange curves illustrate theoretical 0 and 
100% scrambling levels, respectively, for a hypothetical series of y-type ions (y2-y11). 
Previous positive-ion mode work demonstrated that the ionization process itself as well 
as the ion transport conditions prior to MS/MS both have the potential to induce H/D scrambling 
[15].  That work also characterized the variables that must be adjusted to minimize these 
scrambling processes. Little is known about the conditions needed to minimize these processes in 
negative-ion mode; thus, on the utilized Bruker SolariX and Thermo Fusion Lumos instruments, 
settings were initially chosen that minimized scrambling in positive-ion mode as confirmed by 
ECD and ETD, respectively (Figures 2.2 and 2.3). These positive-ion mode settings were then 
ported to negative-ion mode and modified as necessary to achieve signal-to-noise ratios 
sufficient for analysis (Tables 2.3 and 2.4). The Orbitrap XL is not equipped with activation 
techniques capable of examining the extent of scrambling; thus, the energetics of its ion source 
and ion transport were minimized according to literature values [15; Table 2.5]. 
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Figure 2.2 Deuteration levels of ECD-derived c-type fragment ions after tuning the ion source 
for gentle transmission. Data were collected on a Bruker SolariX FT-ICR mass spectrometer. 
 
Figure 2.3 Deuteration levels of ETD-derived c-type fragment ions after gentle ion transfer and 
selection conditions. Data were collected on a Thermo Scientific Orbitrap Fusion Lumos mass 
spectrometer. 
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Table 2.3 Instrument parameters for EDD experiments: Instrumental parameters of the SolariX 
Q-FT-ICR mass spectrometer were altered to create the “harsh” and “soft” conditions used in 
EDD MS/MS experiments. 
 
Instrumental parameters "Harsh" conditions "Soft" conditions 
ESI source Drying gas temperature 200 °C 50 °C 
 
Drying gas flow 4.0 L/min 4.0 L/min 
 
Nebulizing gas flow 1.1 bar 1.1 bar 
 
Capillary voltage (inlet) +3.6 kV +3.6 kV 
 
Capillary exit voltage -260 V -190 V 
 
Deflector plate voltage -240 V -170 V 
 
Funnel 1 voltage -120 V -60 V 
 
Skimmer 1 voltage -11 V -6 V 
 
Funnel 2 voltage -6.0 V -6.0 V 
 
Skimmer 2 voltage -5.0 V -5.0 V 
    
Qh interface Quadrupole isolation width 8.0 Da 18.0 Da 
 
Collision voltage 4.0 V 2.5 V 
 
Table 2.4 Instrument parameters for niECD experiments: Instrumental parameters of the SolariX 
Q-FT-ICR mass spectrometer used in niECD MS/MS experiments. 
 
Instrumental parameters Values 
ESI source Drying gas temperature 60 °C 
 
Drying gas flow 4.0 L/min 
 
Nebulizing gas flow 1.1 bar 
 
Capillary voltage (inlet) +3.5 kV 
 
Capillary exit voltage -210 V 
 
Deflector plate voltage -195 V 
 
Funnel 1 voltage -110 V 
 
Skimmer 1 voltage -14 V 
 
Funnel 2 voltage -6.0 V 
 
Skimmer 2 voltage -5.0 V 
   
Qh interface Quadrupole isolation width 20.0 Da 
 
Collision voltage 3.0 V 
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Table 2.5 Instrument parameters for nCID experiments: Relevant instrumental parameters for 
negative ion mode CID experiments on the LTQ Orbitrap XL mass spectrometer equipped with a 
Nanomate ion source. 
  
Standard values Tuned ranges 
Nanomate (nanoESI) Gas Pressure* 0.40 psi 0.30 ~ 0.55 psi 
 
Voltage* 1.35 kV 1.25 ~ 1.50 kV 
 
Flow rate* 10 μL/min  5 ~ 20 μL/min  
    
LTQ Orbitrap Capillary temperature* 80 °C 50 ~ 200 °C 
 
Capillary voltage* -40 V -20 ~ -80 V 
 
Tube lens voltage* -100 V -50 ~ -200 V 
    
 
Normalized collision energy* 30 10 ~ 200 
 
Ion trap isolation window* 18.0 Da 1.0 ~ 20.0 Da 
    
 
Multipole 00 offset voltage 4.5 V 
 
 
Lens 0 Voltage 4.5 V 
 
 
Multipole 0 offset voltage 5.0 V 
 
 
Lens 1 voltage* 9.0 V 8.0 ~ 36.0 V 
 
Gate lens voltage* 58.0 V 34.0 ~ 78.0 V 
 
Multipole 1 offset voltage* 9.5 V 6.0 ~ 12.0 V 
 
Multipole RF Amplitude 400 Vp-p   
 
Front lens 5.5 V 
 
* Parameters which were altered during the course of this work. 
2.3.1 H/D Scrambling in Collision Induced Dissociation of Electrosprayed Deprotonated 
Peptides 
Upon nCID, the doubly deprotonated peptide P1 dissociated into a near complete series 
of y-type (y4-y11) and c-type fragment ions (c2-c10) (Figure 2.4).  When deuterated P1 was 
dissociated, a corresponding set of isotopically enriched product ions was formed.  Observed 
isotopic distributions for two representative fragment ions with and without deuterium 
incorporation are shown in Figures 2.5A (c3 fragment) and C (y9 fragment), respectively.  The 
weighted average m/z values for the natural isotopic distributions are indicated with green solid 
lines and the weighted average m/z values for the deuterated species are indicated with grey solid 
lines.  The dashed lines in Figures 2.5A and C represent the calculated weighted average m/z 
values under no scrambling (blue dashed line) and complete scrambling (orange dashed line) 
conditions, respectively.  The N-terminal c3 fragment ion is expected to show a low deuteration 
level in the absence of scrambling whereas the C-terminal y9 fragment ion is expected to show a 
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high deuteration level.  Near complete scrambling is evident for the c3 fragment ion whereas the 
y9 ion shows a deuteration level even lower than that expected for 100% scrambling.  Figure 
2.5B illustrates the deuteration level of all observed nCID-derived c-type ions (black line) as 
well as their expected deuteration levels in the absence (blue line for 0%) and presence (orange 
line for 100%) of scrambling.  Similar to c3, all c-type ions show deuterium contents indicative 
of high scrambling levels.  Unlike the c-type ions but similar to the y9 ion, the deuteration level 
curve for the y-type ion series (Figure 2.5D, black line) does not follow the expected trend for 
100% scrambling (Figure 2.5D, orange line).  Unexpectedly, all these ions contain significantly 
less deuterium than previously observed for positive ion mode CID [51].  This apparent 
deuterium loss suggests that significantly more hydrogen atoms are participating in scrambling 
reactions in nCID compared with positive ion mode CID.  Also, the slope differential between 
the experimental data and 100% scrambling curves in Figure 2.5D indicates deuterium 
enrichment onto the N-terminal side of the peptide rather than randomization of the deuterium 
content.  
 
Figure 2.4 nCID MS/MS spectrum of doubly deprotonated P1 (HHHHHHIIKIIK). * indicates 
internal fragments. 
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Figure 2.5 Observed isotopic distributions of c3 (A) and y9 (C) fragment ions from nCID of the 
natural and deuterated peptide P1 (HHHHHHIIKIIK).  The weighted average m/z value for each 
species is illustrated by a solid green (natural) or grey (deuterated) line.  Theoretical deuteration 
levels for 100 and 0% scrambling are denoted with dashed orange (100%) and blue (0%) lines, 
respectively.  Deuteration levels for all measured P1 nCID-derived c- (B) and y-type (D) 
fragment ions.  Blue and orange lines represent expected deuteration levels for 0 and 100% 
scrambling, respectively. 
To examine whether this aberrant scrambling behavior is mediated by the lysine residues, 
P1 was acetylated, resulting in modification of the N-terminus and both lysine residues.  
Deuterated doubly deprotonated *HHHHHHIIK*IIK* (P2) was then subjected to nCID, yielding 
a near complete sequence of y-type fragment ions (y4-y11, data not shown).  Similar to P1, the P2 
y-ion series demonstrated deuterium enrichment onto the N-terminal amino acid residues (Figure 
2.6), suggesting that primary amines do not mediate this unexpected H/D scrambling.  
The histidine residues in P1/P2 constitute another possible source of excess hydrogen 
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atoms.  Thus, a new model peptide, DDDDDDIIEIIE (P3), was designed.  Similar to P1, P3 
relies on substantially different intrinsic exchange rates of isoleucine and aspartic acid to 
concentrate deuterium to the C-terminal residues upon D/H exchange. Following nCID, b- and y-
type fragment ions were observed (Figure 2.7).  H/D scrambling for the y-type fragment ion 
series falls within the theoretical limit (Figure 2.8). This result is in direct contrast to nCID of 
deuterated P1 and suggests that the additional hydrogen atoms participating in the scrambling 
reaction for P1 originate from the histidine residues.  
 
Figure 2.6 Deuteration levels of nCID-derived y-type fragment ions from the peptide P2 
(H*HHHHHIIK*IIK* in which * denotes sites of acetylation). 
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Figure 2.7 nCID MS/MS spectrum of doubly deprotonated P3 (DDDDDDIIEIIE). * indicates 
internal fragments. 
 
Figure 2.8 Deuteration levels observed for y-type ions from nCID of the peptide P3 
(DDDDDDIIEIIE) as well as expected deuteration levels for 0% and 100% scrambling, 
respectively. 
The histidine C-2 hydrogen atom is known to undergo exchange reactions and has been 
utilized to examine local histidine environments [52, 53].  In the gas phase, however, previous 
work in positive-ion mode reported that these hydrogen atoms do not participate in scrambling 
reactions [54].  On the other hand, deprotonation of histidine residues has been shown to 
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promote this process [55] and critical energies for dissociating deprotonated peptides are known 
to be higher than those of protonated peptides [10, 56, 57].  Thus, histidine C-2 hydrogen atoms 
may undergo rearrangement in negative-ion mode.  Accounting for these hydrogen atoms, the 
predicted 100% scrambling curve for P1 y-type ions (Figure 2.9A) is closer to the experimental 
nCID data (Figure 2.9A vs. 2.5D).  However, the experimental curve (Figure 2.9A) is still 
beyond the theoretical deuterium migration limit and the slope differential between experimental 
data and predicted deuteration levels at 100% scrambling still suggests there are unaccounted 
hydrogen atoms participating in the scrambling process.  
 
Figure 2.9 nCID-generated P1 deuteration levels overlaid with 0% and 100% scrambling curves 
with the 100% curve being adjusted to account for hydrogen exchange at histidine C-2 carbon 
atoms (A) and adjusted to account for both histidine C-2 and Cβ hydrogen atom exchange (B).  
nCID-driven y-ion formation in the absence of deprotonated amino acid side chains has 
been proposed to involve hydrogen atom abstraction from -carbon atoms [46].  The energy 
required to abstract C H atoms is in the same range as histidine Cβ-H bonds, which have the 
lowest bond dissociation energies (BDE) for Cβ-H bonds of any residue [58].  Additionally, 
when analyzing phenylalanine—another low Cβ-H BDE residue—containing peptides, Bowie et. 
al. observed nCID derived products that could only be explained via abstraction of Cβ-H atoms 
[58, 59].  Thus, at the energies necessary to induce nCID dissociation, these Cβ-H atoms may 
also need to be considered when calculating the 100% scrambling curve. When both the 
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exchange of histidine C-2 and Cβ hydrogen atoms are considered, the experimental data follows 
the 100% scrambling limit closely (Figure 2.9B).  nCID of P3 does not demonstrate this effect; 
likely because aspartic acid Cβ-H bonds have significantly higher BDEs and the y-type ions from 
this peptide are generated through a lower-energy aspartic acid-driven mechanism, analogous to 
the non-mobile proton positive-ion mode mechanism [48, 60]. The latter mechanism is supported 
by the extensive water loss observed for the b-type ion series (Figure 2.7), a hallmark of the 
aspartic acid-driven mechanism [48]. 
 2.3.2 H/D Scrambling in Radical-Driven Dissociation of Peptide Anions 
As with cations [10-14], the above data demonstrate that collisional activation of anions 
promotes extensive scrambling and is not amenable to improving the structural resolution of 
HDX experiments.  Free radical initiated peptide sequencing (FRIPS) is a radical-driven 
technique that is achieved through derivatization of a peptide with a persistent radical-containing 
precursor [45, 61].  Upon low level collisional activation, this radical precursor undergoes 
homolytic cleavage, generating a radical that propagates throughout the peptide to yield a neutral 
loss, or an a- x-, c-, or z-type ion (Scheme 2.1).  TEMPO-assisted FRIPS was recently applied to 
peptide anions [35, 42] and was shown to allow backbone cleavage without loss of highly labile 
posttranslational modifications, e.g., sulfation [35], suggesting potential applicability towards 
deuterated peptides.  nFRIPS of P1 generated a near complete set of z-type ions (Figure 2.10).  
When deuterated P1 was dissociated with nFRIPS, the generated z-type ions demonstrated near 
complete hydrogen randomization (Figure 2.12A).  However, in contrast to nCID of this peptide, 
no imidazole C-2 hydrogen migration was observed.  We recently calculated that TEMPO-
assisted nFRIPS requires approximately 50 kcal mol
-1 
to
 
promote homolytic cleavage and 
subsequent backbone dissociation [35].  Our current result implies: 1) that heteroatom-hydrogen 
scrambling requires less than 50 kcal mol
-1
 to proceed, and 2) that histidine C-2 and Cβ hydrogen 
migration likely requires more than 50 kcal mol
-1
. 
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Scheme 2.1 FRIPS-driven backbone dissociation. 
 
 
Figure 2.10 nFRIPS MS/MS spectrum of singly deprotonated P1 (HHHHHHIIKIIK).  
Subscripted “r” denotes presence of cleaved TEMPO label [45]. 
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Figure 2.11 EDD MS/MS spectrum of doubly deprotonated P3 (DDDDDDIIEIIE). v3 = third 
harmonic. 
 
Figure 2.12 Deuteration levels of nFRIPS-generated z-type fragment ions (A) and EDD-
generated a-type ions (B) from the peptide P3 as well as predicted 0% and 100% scrambling 
curves.  EDD was performed after both “soft” and “harsh” ion source conditions. 
EDD was the first anion-electron reaction technique reported for peptide MS/MS and 
generates primarily a•- and x-type product ions [40, 41].  The seminal publication [41] 
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demonstrated that EDD is a “soft” dissociation technique, potentially allowing application 
towards deuterated peptides.  When applied to P1, which lacks acidic amino acid residues, EDD 
did not promote backbone fragmentation (data not shown).  Thus, we focused on the acidic 
peptide P3.  Upon electron irradiation, doubly deprotonated P3 underwent fragmentation, 
generating characteristic a•- and x-type fragment ions (Figure 2.11).  In particular, a•6
-
-a•8
-
, a•10
-
, 
and x8
-
-x11
-
 were observed.  However, upon deuterium incorporation, the low EDD fragmentation 
efficiency and resulting low fragment ion abundance, combined with signal dilution across 
broader isotopic envelopes, enabled the calculation of scrambling for only three a•-type product 
ions.  Excitingly, these product ions demonstrated only moderate H/D scrambling (Figure 2.12B).  
The corresponding deuteration levels equate to a scrambling percentage of 51 for a•6
-
, 61 for a•7
-
, 
and 54 for a•8
-
.  
To ensure that this reduction in scrambling (as compared to nCID and nFRIPS) was 
accurate and not due to an unforeseen mechanism, the instrument parameters—particularly the 
ion source—were modified to promote “harsh” conditions (Table 2.3).  The harsher source once 
again promoted extensive hydrogen migration (Figure 2.12B), increasing the scrambling 
percentages to 81, 94, and 95 for a•6
-
, a•7
-
, a•8
-
, respectively.  This result suggests that EDD is 
capable of limiting H/D scrambling for a-type ions.  However, even under gentle ionization 
conditions scrambling levels are too high and the fragmentation efficiency is far too low to be 
feasible for HDX experiments.  EDD utilizes ~20 eV electrons, which are significantly more 
energetic than the <1 eV electrons typically employed in ECD [41, 62]. It has been demonstrated 
that EDD involves both radical-driven fragmentation and vibrational excitation [63, 64]. 
Additionally, previous work demonstrated an uneven deuterium distribution in aspartic acid 
repeats following ETD [65].  This unexpected observation was attributed to the presence of 
nearby lysine residues.  Although lysines are not present in the aspartic acid-rich model peptide 
studied here, it is possible that the observed H/D scrambling can also be attributed to this effect.   
Negative-ion electron capture dissociation (niECD) is a radical-driven dissociation 
technique that is thought to occur through a similar mechanism as its positive-ion mode analogue.  
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In niECD, electron energies are considerably lower (3.5-6.5 eV) than in EDD.  However, niECD 
is most compatible with low charge-state anions [34] and, under conditions suitable for HDX, the 
singly deprotonated P3 ion did not show sufficient abundance for analysis (Figure 2.13A).  To 
increase the abundance of the
 
desired singly deprotonated precursor ion, a truncated version of 
P3 was synthesized.  Following ESI, the singly deprotonated species of the peptide DDDDDIIEII 
(P4) demonstrated significantly higher abundance, rendering it amenable to niECD.  Electron 
irradiation of undeuterated P4 resulted in the formation of primarily c-type ions (Figure 2.13B).  
Similar to EDD, upon deuteration, the niECD efficiency was not widely compatible with the 
broad isotopic distributions observed following HDX and only the c8
2-
, c2, c3, z•7 - CO2, z•8 - CO2, 
and z•9 - CO2 product ions could be analyzed.  Despite the utilization of low energy electrons, the 
z-type ion series demonstrated nearly 100% scrambling; 92, 84, and 100% for the z•7 - CO2, z•8 - 
CO2, and z•9 - CO2 fragment ions respectively.  niECD however, was able to minimize H/D 
scrambling to 32%±8% for the c2 fragment ion and 30%±4% for c3.  
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Figure 2.13 niECD MS/MS spectra of (A) P3 (DDDDDDIIEIIE) and (B) P4 (DDDDDIIEII). v3 
= third harmonic. v5 = fifth harmonic. (A) was collected under the condition of pH = 7.5; (B) was 
collected under the condition of pH = 4.0. 
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 Interestingly, the degree of H/D scrambling (96%±30%) observed for c8
2-
 fragment ion is 
much higher than that of the c2 and c3 ions.  Similar inconsistencies were reported from ECD [15] 
and ETD [29], where the extent of scrambling appears to depend on the size of c-type ions with 
smaller c-ions demonstrating lower degrees of scrambling.  This phenomenon may be related to 
the lifetime difference of the corresponding radical intermediates with their complementary z•-
type fragments [37].  
2.4 Conclusions 
To investigate H/D scrambling in negative-ion mode, several MS/MS techniques were 
applied towards regio-selectively deuterated peptide anions.  We demonstrated that nCID 
mediated extensive H/D scrambling within all peptides examined.  Furthermore, nCID promotes 
aberrant scrambling profiles in histidine-containing peptides.  This unexpected behavior is 
potentially due to the scrambling of histidine C-2 and Cβ-hydrogen atoms.  Radical-driven 
fragmentation methods also promoted H/D scrambling: nFRIPS induced complete randomization 
of the deuterium profile whereas EDD and niECD proceeded with a moderate degree of H/D 
scrambling with niECD slightly outperforming EDD. Interestingly, the scrambling levels 
observed for different fragment ions from the same peptide upon EDD and niECD can be 
different, which may be attributed to the difference in chemical properties of exchangeable 
hydrogen sites and/or the conformation of the precursor peptide ions.  Thus, more detailed 
analysis is needed to elucidate detailed mechanisms of intramolecular H/D migration.  Overall, 
nCID, nFRIPS, EDD, and niECD under current experimental conditions are not amenable to 
HDX MS/MS experiments.  For nCID, nFRIPS, and EDD, this incompatibility is likely due to 
the energetics associated with their mechanisms.  For niECD, however, the energetics of the 
negative-ionization process itself may be too high. In addition, the acidic solution used for 
selective labeling is not ideal for negative-ion ESI due to inferior fragment ion abundance and 
the associated challenge of accurately determining deuterium content. Improving the negative-
ion ESI efficiency under HDX quenching conditions is expected to improve the utility of 
negative-ion MS/MS techniques in HDX MS. Despite limited practical applications, the 
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observed H/D scrambling behavior provided insights into the energetics of these anion 
fragmentation techniques.  
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Chapter 3 
 
 
Supercharging for Improved Electron Capture/Transfer Dissociation (ECD/ETD)-based 
Hydrogen/Deuterium Exchange Mass Spectrometry 
 
 
3.1 Introduction 
Solution-phase hydrogen/deuterium exchange (HDX) coupled with mass spectrometry 
(MS) is widely used to reveal information about protein higher-order structure and dynamics 
[1-3]. Deuterium exchange rates, extracted from uptake curves of deuterium content vs. 
incubation time in D2O (exchange-in experiments) or H2O (exchange-out experiments), reflect 
both protein solvent accessibility and secondary structure stability (hydrogen bonds) [4]. HDX 
can outperform other solution-phase labeling techniques because it targets amide hydrogen atoms 
at every amino acid residue along protein backbones (except proline) and the exchange reaction 
is straightforward to conduct [2]. On the other hand, the reversible nature of H/D exchange 
allows deuterated proteins to undergo back exchange with solvent during the sample analysis 
time, causing undesired deuterium loss [5, 6]. Conventional HDX MS workflows include use of 
an acid protease (typically pepsin) to digest deuterium-labeled proteins prior to liquid 
chromatography (LC) separation and mass analysis. Pepsin digestion allows deuterium uptake to 
be assigned to distinct regions (i.e., peptide segments) of a protein [7, 8]. However; the 
deuterium content resolution is limited by the length of peptic peptides, typically 5-10 amino 
acid residues. When overlapping peptides are generated, e.g., due to the non-specific nature of 
pepsin, the deuterium uptake spatial resolution may increase based on the size of overlapping 
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regions from two peptides [9, 10]. In this situation, however, it is still unlikely to globally assign 
deuterium to individual amino acid amides.  
In contrast to the aforementioned well-established “bottom-up” HDX approach, the 
“top-down” approach bypasses the proteolysis step. Instead, fragmentation of intact proteins take 
place in the gas phase [2]. Improved deuterium spatial resolution can be obtained in top-down 
experiments, down to the single amino acid level, because ladders of complementary fragment 
ion pairs can be generated [11, 12]. It is worth noting, however, that not all tandem mass 
spectrometry (MS/MS) activation techniques are applicable to measuring HDX rates of 
individual amino acid amides. H/D scrambling, which refers to multiple reversible 
proton/deuteron transfers among labile sites in a gaseous peptide or protein ion, is the main issue 
that needs to be addressed in order to utilize gas-phase dissociation to increase spatial resolution 
in HDX MS/MS experiments [13]. Slow heating methods, such as collision-induced dissociation 
(CID), widely used to fragment gaseous peptide and protein ions in commercial mass 
spectrometers, have been shown to generate extensive H/D scrambling and, therefore, 
completely randomize the deuteration pattern embedded in the protein backbone during 
solution-phase HDX [14, 15]. The observation of significant scrambling accompanied with HDX 
CID MS/MS is consistent with the mobile proton model of the CID process [13]. In contrast, 
H/D scrambling is much less pronounced when electron-based MS/MS techniques, e.g., electron 
capture dissociation (ECD) and electron transfer dissociation (ETD), are utilized to fragment 
intact proteins or larger peptides [12, 16-18]. Both ECD and ETD involve prompt fragmentation 
on a picosecond time scale [13, 19-21]. Although the detailed mechanism of peptide backbone 
N-Cα bond cleavage in ECD/ETD is still under debate, it is widely acknowledged that these 
methods are gentle enough to yield peptide backbone fragmentation while retaining labile 
post-translational modifications (PTMs) [19, 22]. Accordingly, negligible H/D scrambling levels 
were observed in both ECD [16] and ETD [17], provided that collisional activation in the ion 
source and during ion transfer was kept at a minimum. Consequently, ECD/ETD are seeing 
increased utilization for generating accurate amide HDX information with close to single amino 
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acid residue resolution [7, 12, 23]. 
In HDX ECD/ETD MS/MS experiments, it is critical to generate highly charged 
protein/peptide ions for maximum fragmentation efficiency [24-26] and accompanying 
deuterium content resolution. ECD/ETD require at least doubly positively charged precursor ions 
[27]; however, our group reported that triply protonated species yield improved peptide sequence 
coverage and higher Mascot scores upon ECD compared to doubly protonated peptides [25]. 
Earlier ETD studies by McLuckey et al. suggested that elevated bath gas temperature can 
increase the overall sequence coverage for doubly protonated tryptic peptides [28]. In addition, 
supplemental collisional activation can efficiently improve ETD outcomes for doubly charged 
peptides, as reported by Coon et al. [29]. Acid is typically added to quench the HDX reaction 
along with decreasing the solution temperature by flash freezing in liquid nitrogen. Acidification 
boosts the charge states of peptide ions formed by positive ion mode electrospray ionization 
(ESI). Williams et al. showed in the early 2000’s [30-32] that further enhanced charging is 
feasible for a variety of analytes by adding m-nitrobenzyl alcohol (m-NBA) to the ESI solvent. A 
number of subsequent studies showed that m-NBA can efficiently supercharge large molecules 
such as intact proteins [33-35] and polymers [31, 32]. Other organic additives, including 
sulfolane [36, 37], dimethyl sulfoxide (DMSO) [38, 39], propylene carbonate (PC) [33, 39, 40], 
and 1,2-butylene carbonate (1,2-BC) [41, 42] have also been reported to effectively supercharge 
proteins. Kjeldsen et al. showed that addition of as little as 0.1% m-NBA to the mobile-phase 
solvent is sufficient to shift the overall charge-state distributions for a variety of tryptic peptides 
in LC ESI ETD MS/MS experiments for improved fragmentation efficiency, sequence coverage, 
and peptide identification accuracy [26]. For example, the calculated average charge state for 
identified bovine serum albumin tryptic peptides was increased from 2.20 to 2.59. Similar 
improvements were reported by Sharp and co-workers for ETD-based quantification of hydroxyl 
radical protein footprinting [43]. Compared with tryptic peptides, peptic peptides can be even 
less compatible with ECD/ETD methods because they are often small and can lack basic residues 
(protonation sites). Rand et al. [23] reported the use of m-NBA in bottom-up HDX LC ETD 
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MS/MS of β2-microglobulin. With the addition of 0.05% m-NBA to the HPLC solvents, the 
deuterium content of 60 out of 93 individual amide groups (65%) of the protein could be 
monitored, compared with only 45% sequence coverage in the absence of supercharging reagent. 
Sterling et al. [44] and Going et al. [45] also utilized chemical/electrothermal supercharging in 
top-down HDX ETD MS/MS for investigating real-time HDX kinetics of proteins from aqueous 
solution. 
In this Chapter, we apply m-NBA to evaluate supercharging of a variety of peptic 
peptides generated from a bottom-up HDX workflow. Because addition of m-NBA to LC 
mobile-phase solvents reduces peptide retention times, we also explore post-column addition of 
m-NBA. Furthermore, we compare the peptic peptide supercharging performance of m-NBA to 
those of propylene carbonate (PC), dimethyl sulfoxide (DMSO), and sulfolane, all of which have 
been reported to effectively supercharge proteins and protein complexes [33-40]. 
3.2 Experimental 
3.2.1 Materials 
Myoglobin from equine heart, cytochrome c from bovine heart, α-casein and β-casein 
from bovine milk, pepsin from porcine gastric mucosa, D2O (99.9 atom % D), m-NBA (≥99.5%), 
PC (99.7%), DMSO (≥99.7%), and sulfolane (≥99.8%) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). All other chemicals were obtained at HPLC or higher grade and used without 
further purification. All solution percent concentrations referred to in this work are 
volume/volume. 
3.2.2 Hydrogen/Deuterium Exchange and Proteolysis 
All protein solutions were prepared from lyophilized solid without additional purification. 
For off-line digestion, a 20 μM stock protein solution in 150 mM ammonium acetate buffer was 
mixed with pepsin in 2% formic acid solution at a substrate/protease molar ratio of 1:1 in an ice 
bath at 0 ºC for 3 min (pH 2.5). The protein digests were then loaded onto a 10 μL loop for 
manual injection LC MS(/MS). HDX experiments were performed by diluting stock protein 
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solutions (5 μL, 400 μM) into 95 μL 150 mM ammonium acetate buffer in D2O for 1, 8, 10, 30, 
and 120 min at 0 ºC before simultaneous quench and pepsin digestion. For the undeuterated 
control, the stock protein solutions were initially diluted into H2O instead of D2O. Each HDX 
reaction was quenched by adding pepsin solution in 2% formic acid at 1:1 (v/v) to decrease the 
final pH to ~2.5. The proteolysis reaction for HDX experiments followed the same steps as 
described above. All HDX runs were performed in triplicate. 
3.2.3 Liquid Chromatography 
An 1100 Agilent HPLC system coupled with two 6-port switching valves (VICI Valco, 
Houston, TX, USA), one for desalting and one for manual injection, was used for all experiments. 
Each protein digest was separated over a short C18 analytical column (Phenomenex Kinetex 5 
μm EVO 50 x 2.1 mm) at a flow rate of 0.2 mL/min. The LC gradient was 7 min long with 5% B 
for 0 to 1 min, 5 -75% B for 1 to 5 min, and 75% B for 5 to 7 min. The eluent within the first 
minute was directed to waste with subsequent eluent introduced into the mass spectrometer. 
Mobile phase A consisted of 5% acetonitrile (ACN) and 0.2% formic acid (FA) in water. Mobile 
phase B consisted of 5% water and 0.2% FA in ACN. 0.1% m-NBA was added to mobile phases 
A and B. m-NBA was dissolved in mobile phase B directly and in mobile phase A with the aid of 
ultrasound. In later experiments, m-NBA was added to the ESI solution via a post-column mixing 
tee with an additional syringe and pump (Fusion 400, Chemyx Inc., Stafford, TX, USA). ACN 
solution with various amounts of m-NBA was placed inside this additional syringe. The resulting 
m-NBA concentration in the ESI solution was altered by altering the infusion flow rate. DMSO, 
sulfolane, and PC were also explored as post column additives with the same device. Control 
runs were conducted with post-column injection of 100% ACN. 
To minimize back exchange in all HDX experiments, LC mobile phases A and B were 
cooled through 0.02’’ i.d., 10-foot-long, coiled PEEK tubings (IDEX Health & Science, Oak 
Harbor, WA, USA) immersed in ice. These tubings were located after the HPLC binary pump. 
An external, cooled, mixing tee (IDEX Health & Science, Oak Harbor, WA, USA) was used to 
combine solvent A and B (Figure 3.1). Both solvent A and B were flowing through the cooling 
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tubings for at least 3.5 min to guarantee sufficient thermal exchange prior to making contact with 
the deuterated samples. The two switching valves were mounted on opposite sidewalls of an 
ice-filled aluminum box (20x20x20 cm, lidless) with their metallic heads pointing inward. This 
ice-filled box housed the HPLC solvent pre-cooling loops, the solvent A & B mixing tee, sample 
injection loop, and the analytical column (Figure 3.1). The syringe for post-column injection was 
pre-cooled in a separate ice bath. 
 
Figure 3.1 Diagram of the HDX LC/MS set-up used in this work. The red arrow and dot 
indicates the point where supercharging reagents were introduced in the case of post-column 
injection. 
3.2.4 Mass Spectrometry 
All experiments were performed in positive ion mode on a 7 T SolariX quadrupole 
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker Daltonics, 
Billerica, MA, USA) equipped with an Apollo II ESI source. The capillary voltage, drying gas 
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flow rate, and drying gas temperature were set to 4,500 V, 3.8 L/min, and 130 ºC respectively. A 
0.25 s external accumulation time and a resolution of 512k were used. For the LC ECD MS/MS 
experiments, data-dependent acquisition with MS/MS boost was used. Accumulation times for 
MS and MS/MS scans were 0.15 and 0.50 s, respectively. Following an MS scan, a total of 3-4 
precursors with charge states ranging from 2 to 5 were isolated (8 m/z window) and transferred 
to the FT-ICR cell for ECD (150 ms irradiation time, - 1.0 V ECD bias voltage, 1 scan for each 
MS/MS spectrum). An indirectly heated hollow dispenser cathode was used to perform ECD 
with a heating current of 1.6 A. Mass spectra were externally calibrated with sodium 
trifluoroacetate to <2 ppm error. 
3.2.5 Data Analysis 
Data analysis was performed manually using Bruker Data Analysis 4.4. Following 
replicate data collection, peptide matches were determined using an in-house Excel macro. 
Peptides were only assigned if the mass error was below 12 ppm. Variable modifications were set 
at 7 missed peptic cleavages, methionine oxidation, serine/threonine/tyrosine phosphorylation 
and N-terminal acetylation. N-terminal methionine loss was set as a fixed modification for 
myoglobin.  
In the proceeding text and figures, the term “average charge state (qavg)” describes the 
effect of m-NBA and other supercharging reagents on the peptide charge-state distribution, as 
determined from Equation 3.1: 
Equation 3.1        
     
 
 
   
 
 
 
where N is the number of peptide charge states, qi is the net charge of the ith charge state, and Wi 
is the ion abundance of the ith charge state. The ion abundance of multiply charged peptides was 
normalized to the net charge due to the nature of “image current” detection in the FT-ICR cell. 
Based on the relatively small molecular size of peptic peptides, only the monoisotopic peak 
abundances were considered.  
ECD efficiency was determined as the ratio of the summed abundances of c- and z-type 
fragment ions with or without neutral losses, not including side chain cleavages, neutral losses, 
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or the charge reduced, undissociated species [M + nH]
(n - 1)+•
, divided by the total ion abundance 
(Equation 3.2). All ion abundances were normalized to charge. 
Equation 3.2                 
                                                
                    
 
For the HDX experiments, the deuterium content of a peptide ion was determined from 
the difference between the weighted average masses of the deuterated and undeuterated peptide. 
Weighted average masses were calculated by dividing the sum of the products of the mass and 
abundance of each isotopic peak by the total abundance of all observed isotopic peaks. 
3.3 Results and Discussion 
3.3.1 Supercharging of peptic peptides 
Protein sequence coverages of myoglobin, cytochrome c, α-casein S1, and β-casein 
obtained from LC/MS experiments following pepsin digestion under the rapid and cold 
conditions required for HDX experiments are shown in Table 3.1 with and without addition of 
0.1% m-NBA to the mobile phase solvents. The myoglobin sequence coverage reached 100% in 
both cases while addition of m-NBA resulted in slight sequence coverage decreases for 
cytochrome c (79% to 75%), α-casein S1 (97% to 93%), and β-casein (91% to 85%). Even 
though addition of m-NBA resulted in detection of fewer peptic peptides, more multiply charged 
peptic peptide ions were generated in the presence of this supercharging reagent. For example, 
the mass spectra shown in Figure 3.2 illustrate the charge-state distribution of the myoglobin 
peptic peptides TALGGILKKKGHHEAEL and FRNDIAAKYKELGFQG, respectively, in the 
absence (a, c) and presence (b, d) of 0.1% m-NBA in the mobile phase. We chose 0.1% m-NBA 
as a starting concentration based on previous literature, which considered the balance between 
efficient supercharging and minimal chemical changes to the mobile phase [26, 46]. As 
demonstrated in Figure 3.2 (a, c), in the absence of m-NBA, doubly protonated species are 
dominant for both of these peptic peptides, showing average charge states of 2.2 and 2.0, 
respectively. With only 0.1% m-NBA (Figure 3.2 (b, d)) the charge-state distributions shift 
significantly towards higher average charge: the peptide TALGGILKKKGHHEAEL showed a 
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distribution of 67% doubly-protonated and 33% triply-protonated species without m-NBA, 
whereas 13% doubly-, 32% triply-, and 56% quadruply-protonated species were observed in the 
presence of m-NBA, corresponding to an average charge state of 3.2; an average increase of a 
whole unit of charge. Supercharging of the peptide FRNDIAAKYKELGFQG was not quite as 
dramatic but, nevertheless, highly effective with the average charge state increasing from 2.0 to 
2.6. However; unfavorably, signal abundance decreased for both peptides upon addition of 
m-NBA.  
Table 3.1 Overall protein sequence coverages of peptically digested myoglobin, cytochrome c, 
α-casein S1, and β-casein following LC/MS experiments with and without 0.1% m-NBA in the 
mobile phase solvents, respectively. These data are based on duplicate measurements. The mass 
error for all assigned peptides was below 12 ppm. 
Overall protein sequence 
coverage 
0% m-NBA 0.1% m-NBA 
myoglobin 100% 100% 
cytochrome c 79% 75% 
α-casein S1 97% 93% 
β-casein 91% 85% 
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Figure 3.2 FT-ICR mass spectra at 4.2(a)/3.9(b) and 4.7(c)/4.3(d) minutes from LC/MS of a 
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myoglobin peptic digest in the absence (a, c) and presence (b, d) of 0.1% m-NBA. The observed 
earlier elution in the presence of m-NBA is due to the corresponding increased solvent strength. 
Average charge states for the peptides TALGGILKKKGHHEAEL (71-87) (a,b) and 
FRNDIAAKYKELGFQG (139-154) (c, d) under the two LC conditions are indicated in the 
upper right of each panel. 
 
Table 3.2 Charge-state distributions and calculated average charge states for myoglobin peptic 
peptides from LC/MS experiments using 0% and 0.1% m-NBA in the mobile phases, 
respectively. 
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Table 3.2 lists all myoglobin peptic peptides observed from LC/MS with and without 
m-NBA. The predominant charge states for these peptides in the absence of m-NBA were 1+ 
(33%) and 2+ (36%) with the remaining 31% having charge states of 3+ and higher. In the 
presence of m-NBA the predominant charge state was 3+ (33%) with 68% of peptides having a 
charge state of 3+ and higher. The calculated overall average charge state for all myoglobin 
peptic peptides observed in the LC/MS experiments increased from 1.74 without m-NBA to 2.75 
with m-NBA. The average charge state increase for these 31 peptides (Table 3.2, rightmost 
column) was 0.95 with a standard deviation of 0.49. As previously discussed for tryptic peptides 
[26], this change in predominant charge state is quite important in data-dependent acquisition as 
3+ and higher charge-state peptide ions are more likely to be selected for ECD/ETD, thus 
improving MS/MS outcome. A similar charge-enhancing effect was observed for α-casein 
(average charge state increasing from 1.74 to 2.26) and β-casein (average charge state increasing 
from 1.88 to 2.34) upon addition of 0.1% m-NBA, although the average charge increase for these 
two proteins was lower than that of myoglobin. This result may be due to α- and β-casein being 
phosphoproteins with a higher fraction of acidic amino acid residues than myoglobin. Acidic 
peptic peptides from these two proteins are less likely to carry multiple positive charges upon 
ESI. Nevertheless, notable shifts in charge state distributions for α- and β-casein peptic peptides 
were observed, as shown in Figure 3.3 for the α-casein peptides FVAPFPEVFGKEKVNEL, 
LRLKKYKVPQL, and YYVPLGTQYTDA. For example, the charge-state distribution of 
FVAPFPEVFGKEKVNEL was shifted from 70% 2+ ions/30% 3+ ions without m-NBA to 22% 
2+ and 78% 3+ ions in the presence of 0.1% m-NBA. The peptide YYVPLGTQYTDA contains 
no basic amino acid residues and yielded almost exclusively singly charged ions (97%) without 
m-NBA; however, addition of supercharging reagent boosted the doubly charged ion abundance 
significantly, to 42%. 
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Figure 3.3 Bar charts showing the shift in charge-state distributions for three α-casein peptic 
peptides; FVAPFPEVFGKEKVNEL (top), LRLKKYKVPQL (middle), and YYVPLGTQYTDA 
(bottom), upon addition of 0.1% m-NBA. 
Figure 3.4 shows the charge state distributions of all peptic peptides from myoglobin, 
cytochrome c, α-casein S1, and β-casein observed under conventional ESI conditions (0% 
m-NBA) and with the addition of 0.1% m-NBA. Similar to myoglobin, cytochrome c peptic 
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peptides showed a high average charge state increase upon addition of m-NBA, from 2.16 to 3.02. 
Both myoglobin and cytochrome c have pI values higher than 7, thus a higher number of 
protonation sites are present compared with the casein proteins. Notably, no peptides were 
predominantly singly charged when electrosprayed with 0.1% m-NBA. This result is significant 
because ECD/ETD are not compatible with singly charged ions.  
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Figure 3.4 Bar charts showing the charge state distributions for peptic peptides from myoglobin, 
cytochrome c, α-casein, and β-casein without (left) and with 0.1% (right) m-NBA in the mobile 
phase solvent. The calculated average charge states for peptic peptides from each protein are 
shown on the upper-right, respectively. 
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3.3.2 Post-column addition of supercharging reagent for improved liquid chromatography 
As previously reported, the presence of m-NBA in mobile phase solvents influences the 
retention time in reversed-phase chromatography [26, 46] with peptide retention inversely related 
to m-NBA concentration. Upon increasing the m-NBA concentration from 0% to 0.5%, the 
retention times of 19 BSA tryptic peptides all dropped linearly, although not to the same extent 
[26]. The same trend was observed here for peptic peptides from all four tested proteins when 0.1% 
m-NBA was added to the LC mobile phase. Base peak chromatograms (BPCs) from LC/MS of 
myoglobin peptide peptides with and without m-NBA are shown in Figure 3.5 (a). These BPCs 
are displayed on the same Y-axis scale, clearly illustrating that addition of 0.1% m-NBA results 
in lower peak abundances and, consequently, reduced sensitivity. In addition, the inset in Figure 
3.5(a) demonstrates the retention time shift of a myoglobin peptic peptide ion, doubly-charged 
IRLFTGHPETL (31-41), upon addition of m-NBA: with 0.1% m-NBA, the peptide eluted at 4.3 
min, while its elution time in the absence of m-NBA was 4.8 min. This observation is in 
agreement with the non-polar nature of m-NBA, resulting in stronger elution. Another possible 
explanation for the shortened peptide retention time is that m-NBA may adsorb to the non-polar 
column material, blocking peptide interactions sites and thus weakening the column retention 
ability. 
To circumvent the problem of retention time shifting, as well as to avoid exposing the 
column to m-NBA, a post-column mixing tee and an additional syringe/pump were added to our 
LC set-up. Miladinovic et al. [47] introduced supercharging reagents directly into the ESI Taylor 
cone via a dual-sprayer ESI microchip and demonstrated average charge state increases for 
peptides and proteins. Their results suggest that the supercharging reaction can be accomplished 
on a short time scale, corresponding to ion formation from a droplet during the ESI process. 
Compared with their set-up, addition of supercharging reagents to the LC eluent through the 
post-column tee allowed much longer time for mixing with the analytes. Considering that 
m-NBA is quite viscous and dissolves poorly in water, m-NBA was dissolved in ACN and then 
transferred to the syringe for infusion. To ensure that the tee infusion flow rate was compatible 
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with the LC flow rate while maintaining ~0.1% m-NBA, the m-NBA concentration in ACN was 
kept low (5%). Figure 3.5(b) shows overlaid BPCs from LC/MS of α-casein (top) and β-casein 
(bottom) peptic peptides with and without 0.1% m-NBA in the ESI solvent, as introduced via the 
post-column tee. The much improved overlap of BPCs generated with and without 0.1% m-NBA 
for each protein suggests that the retention time shifting issue was solved. Extracted ion 
chromatograms (EICs) for one peptide from each protein with and without 0.1% m-NBA (Figure 
3.5(b) insets) confirm that retention times are unaffected when m-NBA is injected through the 
post-column tee. The m-NBA charge-enhancing effect reported in the preceding section was 
unchanged with the post-column addition set-up (data not shown). All remaining data in this 
Chapter were collected in this manner. 
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Figure 3.5 (a) Base peak chromatograms from peptically digested myoglobin and extracted ion 
chromatograms for one peptide (inset) without (top) and with (bottom) 0.1% m-NBA in the 
mobile phase solvents. The shaded yellow areas on the BPCs indicate the retention time of the 
peptide in each case. (b) Base peak chromatograms from peptically digested α-casein (top) and 
β-casein (bottom) and extracted ion chromatogram for one peptide from each protein (insets) 
without and with 0.1% m-NBA added through a post-column mixing tee. The latter set-up 
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eliminated retention time shifts. The shaded yellow areas on the overlaid BPCs indicate the same 
retention time of either peptide with and without 0.1% m-NBA. A simplified diagram of the latter 
set-up is shown in (c).  
3.3.3 Supercharging with varying m-NBA concentrations and with other supercharging 
reagents 
Including 0.1% m-NBA, five different concentrations were evaluated: 0, 0.05, 0.1, 0.2, 
and 0.4%. Figure 3.6(a) shows the average charge states of five myoglobin peptic peptides vs. 
m-NBA concentration, including NVWGKVEADIAGHGQEVL (13-30), IRLFTGHPETL 
(31-41), TALGGILKKKGHHEAEL (71-87), IIHVLHSKHPGDFGADA (112-128), and 
FRNDIAAKYKELGFQG (139-154). With the mixing tee set-up for post-column addition, 
altering of m-NBA concentration was conveniently achieved by changing the flow rate of the 
infused m-NBA ACN solution. Notably, for all these five peptides, the average charge state 
increased steadily with increasing m-NBA concentration although not in the same manner. For 
peptides 13-30, 31-41, and 139-154, the average charge state dropped slightly as the m-NBA 
concentration increased from 0.1% to 0.2% and then stayed relatively unchanged as the m-NBA 
concentration doubled (to 0.4%). The average charge state of peptide 71-87 rose slightly at an 
m-NBA concentration of 0.2% compared with 0.1%; however, further increase to 0.4% did not 
boost the average charges state further. Interestingly, the average charge state of peptide 112-128 
fluctuated more significantly but reached a maximum value at 0.1% m-NBA. One factor possibly 
influencing these results is the notable signal abundance decrease with increasing m-NBA 
concentration. The ESI efficiency may be lowered in the presence of m-NBA due to the 
increased viscosity of the solvent. Because the steepest increase in average charge state was 
observed up to 0.1% m-NBA, and to avoid signal abundance loss, 0.1% m-NBA appeared 
optimal also for post-column addition.  
We also compared the charge-enhancing effect of m-NBA for peptic peptides with three 
other aprotic supercharging reagents; DMSO, PC, and sulfolane (Figure 3.6(b)). The 
concentrations of these reagents were chosen according to the literature [36-39, 46].  For the 
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same five myoglobin peptic peptides, 0.1% m-NBA showed the strongest overall 
charge-enhancing effect, with the exception of the peptide 139-154, which displayed the highest 
charge-state increase when electrosprayed with 150 mM sulfolane. However; 0.1% m-NBA was 
still the second most effective supercharging reagent for this peptide. Both 5% PC and 20% 
DMSO were inferior to 0.1% m-NBA and 150 mM sulfolane for supercharging peptic peptides; 
their presence did not generally alter the charge-state distribution for the examined peptides.  
When further investigating DMSO as a supercharging reagent for peptic peptides, we 
observed that, at our ESI conditions, a minimum concentration of 20% DMSO was necessary to 
induce peptide supercharging. However; the supercharging effect of DMSO was quite varied for 
different peptides, independent of concentration. For example, addition of DMSO did not alter 
the charge-state distribution of myoglobin peptic peptides 13-30 and 31-41 (Figure 3.7(a)). With 
10% DMSO, both charge increase and decrease was observed for a variety of peptides from 
pepsin digests of myoglobin and α-casein S1 (Figure 3.7(b)), similar to previous results from 
Komives et al. [46]. 
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Figure 3.6 Average charge states of five myoglobin peptic peptides (a) as a function of m-NBA 
concentration in the ESI solvent and (b) when no supercharging reagent, 0.1% m-NBA, 5% 
propylene carbonate (PC), 20% DMSO, or 150 mM sulfolane were added to the ESI solvent, 
respectively. 
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Figure 3.7 (a) Average charge states of four myoglobin peptic peptides as a function of DMSO 
concentration in the ESI solvent. (b) Average charge state increase percentages for ten peptic 
peptides (P1-P6 from α-casein, P7-P10 from myoglobin) upon addition of 10% DMSO into the 
ESI solvent. 
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3.3.4 Supercharging in LC ECD MS/MS of peptic peptides 
 
Figure 3.8 ECD MS/MS spectra of the peptic peptide TALGGILKKKGHHEAEL (71-87) from 
myoglobin in precursor ion charge states (a) 2+, (b) 3+, and (c) 4+. The ECD MS/MS spectrum 
for the doubly charged precursor ions was collected without m-NBA in the ESI solution whereas 
the spectra for the triply and quadruply charged precursor ions were collected with 0.1% m-NBA 
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in the ESI solutions. 
Charge enhancement of peptic peptides via supercharging was combined with ECD 
LC/MS/MS to assess effects on ECD fragmentation efficiency and peptide sequence coverage. 
ECD spectra of the doubly, triply, and quadruply charged peptide TALGGILKKKGHHEAEL 
from pepsin digestion of myoglobin are shown in Figure 3.8. For doubly charged precursor ions 
(Fig. 3.8 (a)), the ECD fragmentation efficiency was 12% and the peptide sequence coverage was 
only 6%. Due to the charge reduction occurring upon electron capture/transfer, ECD/ETD of 2+ 
ions only generate one fragment ion for each bond cleavage with the complementary fragment 
being neutral, thus preventing detection of complementary ion pairs. For peptide identification, 
the absence of such complementary fragments decreases peptide identification scores [25]. ECD 
of the triply charged precursor ions (Fig. 3.8 (b)) resulted in greatly improved fragmentation 
efficiency (72%) and peptide sequence coverage (100%) compared with the 2+ precursor ions: a 
total of 16 (out of 16) inter-residue bonds were cleaved, 7 of which yielded complementary c/z 
ion pairs. ECD of quadruply charged precursor ions for this peptide was only feasible upon 
addition of 0.1% m-NBA. The resulting spectrum (Fig. 3.8 (c)) showed extensive (though not the 
most extensive) fragmentation efficiency (63%) and sequence coverage (94%). The lower 
performance for the 4+ charge state may be attributed to its lower abundance (20.0%) compared 
with the 3+ charge state (37.9%) in the presence of 0.1% m-NBA. However; ECD of the 
quadruply charged precursor ions yielded 2 unique c-type ions (c3, c4) and 2 unique z-type ions 
(z3
•
, z7
•
) compared with ECD of the 3+ ions; thus, maximum sequence information is obtained 
by combining these spectra. Additional LC ECD MS/MS results for myoglobin peptic peptides 
are listed in Table 3.3. The precursor ion charge states were automatically selected with the 
AutoMSMS setting in SolariXControl. These pepsin digests were analyzed both with and 
without 0.1% m-NBA. In the absence of m-NBA, doubly charged precursor ions were selected 
for ECD (5 out of 5) and only one out of 5 peptides showed any ion population in a charge state 
higher than 2+ (TALGGILKKKGHHEAEL, 3+ at 47.1%). The ECD fragmentation efficiency 
and peptide sequence coverage for these 2+ precursor ions were below 25% and 50%, 
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respectively. When 0.1% m-NBA was added to the ESI solution, the shift in the charge-state 
distribution resulted in more 3+ precursor ions being selected for ECD. As expected, the shift to 
more triply charged peptide ions, in turn, resulted in more efficient ECD. For example, the 
peptide NVWGKVEADIAGHGQEVL showed a charge-state distribution of 71.2% 2+ and 28.8% 
3+ compared with 80.5% 2+ and 19.5% 3+ in the absence of m-NBA. The total abundance of 3+ 
precursor ions and resulting product ions post dissociation was ~14 times higher than that of 2+ 
precursor ions (1.3x10
8
 vs. 9.6x10
6
) upon addition of m-NBA. The resulting peptide sequence 
coverage was greatly improved from 53% (no m-NBA) to 100% (0.1% m-NBA). The peptide 
FTGHPETL is smaller in size and failed to generate a charge state higher than 2+ even in the 
presence of m-NBA. However, the 2+ ion abundance for this peptide was increased from 15.2% 
to 27.5% upon addition of 0.1% m-NBA, resulting in doubled sequence coverage (86% vs. 43%). 
Similarly, for the peptide FRNDIAAKYKELGFQG, the presence of 0.1% m-NBA increased the 
3+ precursor ion abundance and, consequently, resulted in both improved fragmentation 
efficiency and peptide sequence coverage. Overall, fragmentation of ≥3+ peptide ions resulted in 
greater ECD efficiency and higher peptide sequence coverage. The m-NBA-generated charge 
enhancement increased the probability of ≥3+ peptide ions to be selected for fragmentation. 
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Table 3.3 Example myoglobin peptic peptides observed in LC ECD MS/MS experiments with 
and without 0.1% m-NBA in the ESI solvent. Peptide abundances were normalized to charge. 
“Total analyte abd.” refers to the summed abundance of the precursor ions and ECD product ions 
post dissociation. The shift to more triply- (or higher) charged peptide ions is highly beneficial 
for both ECD fragmentation efficiency and peptide sequence coverage. 
 0% m-NBA 0.1% m-NBA 
Myoglobin 
peptic peptides 
Charge state 
distribution 
Frag 
CS 
Frag 
eff. 
Seq 
cov 
Total 
analyte 
abd. 
Charge state 
distribution 
Frag 
CS 
Frag 
eff. 
Seq 
cov 
Total 
analyte 
abd. 
NVWGKVEADIAGHGQEVL 
2+ (80.5%) 2+ 20% 47% 1.1x108 2+ (71.2%) 2+ 21% 41% 6.3x107 
3+ (19.5%) 3+ 52% 53% 9.6x106 3+ (28.8%) 3+ 59% 100% 1.3x108 
FTGHPETL 
1+ (84.8%)     1+ (72.5%)     
2+ (15.2%) 2+ 21% 43% 3.5x107 2+ (27.5%) 2+ 24% 86% 9.0x107 
TALGGILKKKGHHEAEL 
2+ (40.8%) 2+ 12% 6% 5.9x106 2+ (41.7%)     
3+ (47.1%) 3+ 68% 87% 2.6x107 3+ (37.9%) 3+ 72% 100% 2.6x107 
4+ (12.1%)     4+ (20.0%) 4+ 63% 94% 2.1x107 
     5+ (0.4%)     
FRNDIAA 
1+ (93.6%)     1+ (72.7%)     
2+ (6.4%) 2+ 0% 0% 3.1x106 2+ (27.3%) 2+ 13% 67% 1.4x107 
FRNDIAAKYKELGFQG 
2+ (65.0%) 2+ 17% 47% 1.3x108 2+ (57.8%) 2+ 21% 47% 6.6x107 
3+ (35.0%) 3+ 60% 86% 7.2x107 3+ (37.7%) 3+ 71% 100% 1.8x108 
     4+ (4.5%)     
 
3.3.5 m-NBA supercharging in HDX LC/MS 
When combining ESI supercharging with bottom-up HDX MS, it is of great importance 
to ensure that no significant HDX information is lost due to H/D scrambling or back-exchange. 
m-NBA contains labile hydrogens and functional groups that may allow hydrogen bonding, 
aromatic interaction, and/or ionic interaction with the nitro group. Thus, its effect on overall 
HDX performance needs to be evaluated. 
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Figure 3.9 Differences in deuterium content for ten myoglobin peptic peptides in HDX LC/MS 
experiments with and without 0.1% m-NBA (green bars). The HDX incubation time was 10 min. 
Deuterium content standard deviations from triplicate measurements without and with m-NBA 
(blue and red bars, respectively). The deuterium content difference was smaller than the standard 
deviation for each peptide, except the peptide 139-154 (2+), indicating that the use of m-NBA 
had a minor effect on peptic peptide deuterium uptake levels. 
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Figure 3.10 Deuterium uptake curves for two myoglobin peptic peptides, NVWGKVEA (13-20) 
(left) and KPLAQSHATKHKIPIKY (88-104) (right), at multiple charge states in the absence and 
presence of 0.1% m-NBA in the ESI solvent. Similar HDX behaviors were observed for the same 
peptide with or without m-NBA. 
Myoglobin peptic peptides were analyzed by HDX LC/MS with and without m-NBA 
(0.1%). The averaged deuterium contents and standard deviations were calculated based on 
triplicate measurements. Nine out of ten observed peptide ions (corresponding to 6 different 
peptides) showed deuterium content differences lower than the standard deviation between no 
m-NBA and 0.1% m-NBA, except the doubly charged peptide 139-154 (Figure 3.9). This 
observation indicates that addition of 0.1% m-NBA to the ESI solution did not change peptide 
deuterium levels beyond the experimental error. The deuterium uptake curves for two peptic 
peptides, NVWGKVEA (myoglobin 13-20) and KPLAQSHATKHKIPIKY (myoglobin 88-104), 
with different charge states for HDX incubation times ranging from 0 to 120 min are shown in 
Figure 3.10. Similarly, no significant variation in deuterium incorporation is observed in HDX 
LC/MS with and without 0.1% m-NBA. 
We also explored whether introduction of m-NBA directly into the LC solvents vs. via the 
post-column tee differentially affects deuterium back exchange. Figure 3.11 shows the 
corresponding results for three myoglobin peptic peptides; 2-8, 13-30, and 139-154. A control 
experiment without m-NBA was also conducted in each case. For the peptide 2-8, only singly 
charged ions were observed with unvarying (within error) deuterium contents between the three 
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scenarios (0.1% m-NBA introduced pre- or post-column, and no m-NBA). For the 2+ and 3+ 
ions of the peptide 13-30, the deuterium content with m-NBA in the LC solvent was 3% higher 
than for the other cases.  However, a deuteration level difference below 5% is typically 
insignificant [3, 5, 6]. For the peptide 139-154, nearly identical deuteration levels were observed 
between the three cases. Overall, neither the presence of 0.1% m-NBA, nor the manner of its 
introduction, appears to have a significant effect on peptic peptide deuterium levels. 
It is worth noting, however, that higher charge-state peptide ions showed higher 
deuterium loss compared with their lower charge-state counterparts, e.g., the peptide 13-30, 3+ 
vs. 2+ ions. This effect is probably due to elevated kinetic energy at higher charge and lower 
barriers to proton migration during the desolvation process in the ion source. Similarly, limiting 
peptic peptide charge states to ≤3+ has been previously suggested for LC ECD/ETD experiments 
[23]. 
 
Figure 3.11 Deuterium content for three myoglobin peptic peptides, GLSDGEW (2-8), 
NVWGKVEADIAGHGQEVL (13-30), and FRNDIAAKYKELGFQG (139-154), without 
m-NBA (A), and with 0.1% m-NBA introduced after the analytical column (B), or directly into 
the LC mobile phase (C). Bars in different colors indicate different charge states. 
3.4 Conclusion 
We demonstrate the charge enhancing effect of m-NBA for a variety of peptic peptides 
from myoglobin, cytochrome c, α-casein (S1), and β-casein. With the addition of as low as 0.1% 
m-NBA into the LC mobile-phase solvents, we achieved significant charge-state shifts for peptic 
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peptides in a bottom-up HDX LC/MS workflow, although adverse chromatographic effects were 
observed. Separation in the presence of 0.1% m-NBA generally decreased peptide retention times 
compared with the absence of m-NBA; however, these retention time shifts were circumvented 
by implementing post-column addition of m-NBA through an external mixing tee. With this 
device, the m-NBA concentration in the ESI solution can be changed simply by altering the 
infusion flow rate. 0.1% m-NBA appeared to be an optimal concentration in both 
implementations in terms of compromising between effective supercharging, and acceptable 
signal-to-noise ratios. We found that DMSO and PC were not effective supercharging reagents 
for peptic peptides. Sulfolane was also explored for charge enhancement of peptic peptides and 
was found to be similarly effective as m-NBA. As verified by LC ECD MS/MS experiments, 
m-NBA-based supercharging generates more triply (or higher) charged peptic peptide ions 
compared with the absence of m-NBA, resulting in enhanced ECD efficiency and peptide 
sequence coverage. Finally, we evaluated the effect of 0.1% m-NBA on the detected deuterium 
uptake levels of peptic peptide ions in HDX LC/MS experiments.  The presence of 0.1% 
m-NBA did not skew the results. One advantage of sulfolane-based supercharging, despite the 
required higher concentration compared with m-NBA (150 mM or 1.43%, vs. 0.1%), is that 
addition of this supercharging reagent into the ESI solvent is not expected to alter deuterium 
content of deuterated peptides due to the absence of labile hydrogen in sulfolane. Our results 
suggest that both m-NBA and sulfolane can efficiently improve charging of peptic peptides in a 
bottom-up HDX LC/MS workflow. However; higher charge-state peptide ions were subjected to 
more deuterium loss compared with their lower charge counterparts, thus suggesting that a 
charge state of 3+ for peptic peptides is ideal in HDX ECD/ETD MS/MS. 
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Chapter 4 
 
 
The Presence of b Ions in Electron Capture/Transfer Dissociation (ECD/ETD) of 
Supercharged Peptides 
 
 
4.1 Introduction 
Electron capture dissociation (ECD) is a powerful tandem mass spectrometry (MS/MS) 
technique that involves reactions between multiply charged analyte cations and low-energy (<1 
eV) electrons [1-5]. ECD of multiply protonated polypeptide ions can provide valuable sequence 
information in proteomics, particularly for peptides and proteins containing labile 
post-translational modifications (PTMs) [5-7]. By contrast conventional slow-heating activation 
methods such as the most commonly employed MS/MS approach, collision induced dissociation 
(CID), often fail to locate such PTMs as they are preferentially lost [8-10].  
The primary product ions in ECD of peptides and proteins are c- and z•-type fragment 
ions derived from cleavage of backbone N-Cα bonds [2, 11], complementary to the b- and y-type 
ions that are predominant in CID MS/MS spectra [12, 13]. In addition, a minor ECD 
fragmentation channel yields a
•
- and y-type ions [3, 4]. More unconventional ECD fragments 
have also been reported. For example, Cooper was the first to report the presence of b-type ions 
in some ECD MS/MS spectra [14]. She proposed that the type of charge carrier (arginine vs. 
lysine protonation) is significant in determining the preferred ECD fragmentation channels. The 
position of such basic residues within a peptide sequence may also affect the ECD outcome. 
Specifically, peptides containing lysine charge carrier(s) yielded more b ions upon ECD than 
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those containing arginine. However; b ions were not detected for peptides with N-terminal Lys or 
Arg, possibly due to gas-phase structural differences. Haselmann and Schmidt reported 
examination of a series of custom peptides as probes for b ion formation in ECD [15]. For these 
peptides, ECD spectra containing b ions also showed abundant losses of hydrogen radicals from 
the charge reduced precursor ions. Less abundant b ions were observed in ECD of the peptide 
H-Lys-Ala4-Lys-Ala4-NH2 compared with its N-terminally acetylated form. This result was 
explained through the “mobile proton” framework in which b ion formation upon collisional 
activation proceeds through backbone amide protonation. Upon N-terminal acetylation, one basic 
site (primary amine) is removed, increasing the probability of one proton being located at the 
peptide backbone. Lee et al. showed that, for peptide cations containing a lysine homologue, b 
ion formation was more prevalent with decreasing length and proton affinity of the primary 
amine side chain, both resulting in increased probability of backbone protonation [16]. Thus, the 
formation of b ions can be explained in the framework of the mobile proton model [17, 18]. Ab 
initio direct dynamics calculations by Uggerud et al. also revealed that b-type ions can be 
generated from electron capture at a protonated backbone amide nitrogen [19]. Our group 
examined ECD of doubly protonated peptides with one or no basic amino acid residues and 
observed the presence of abundant b ions [20]. Li et al. also reported abundant b ions in ECD of 
the doubly protonated peptide GSNKGAIIGLM containing only one basic amino acid residue, 
including high abundance b8 and b10 ions [21], in agreement with our observations [20]. 
However, they also reported low abundance b ions from electron transfer dissociation (ETD) of 
doubly and triply protonated peptides [21], but these may have resulted from vibrational 
excitation due to supplemental CID activation [22, 23]. We proposed that protonation of 
backbone amide nitrogens (due to the lack of basic side chains) is a prerequisite for b ion 
formation in ECD [20]. 
Supercharging [24-28] is an increasingly employed strategy in electron capture/transfer 
dissociation (ECD/ETD) experiments because at least doubly charged precursor ions are required 
but a precursor ion charge ≥3+ yields much improved fragmentation efficiencies [22, 29-33]. 
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Kjeldsen et al. reported that the average charge states of tryptic peptides, particularly 
phosphopeptides, were significantly increased by adding 0.1% m-nitrobenzyl alcohol (m-NBA) 
to liquid chromatography (LC)/MS solvents [34]. The charge-enhancing ability of m-NBA 
benefited both peptide sequencing and PTM characterization in LC ETD MS/MS experiments 
due to improved ETD efficiency. A similar strategy was used by Rand et al. in bottom-up ETD 
hydrogen/deuterium exchange (HDX) MS/MS experiments [35] to enhance peptide sequence 
coverage and HDX spatial resolution. However, supercharged peptides and proteins result in 
more complex ECD/ETD spectra [34, 36]. We hypothesize that additional fragment ions detected 
in ECD/ETD of supercharged peptides may correspond to b ions, because, when the number of 
protons increases, backbone protonation becomes more likely. A mixture of a-, b-, c-, x-, y-, and 
z- ions was observed from ECD of extremely supercharged protein ions formed by electrospray 
ionization (ESI) [36]. However, to our knowledge, unconventional fragments from ECD or ETD 
of supercharged peptides have not been previously reported. 
Here, we apply ECD towards a variety of peptides, with or without basic amino acid 
residues, and with and without supercharging to particularly investigate b ion formation under 
such conditions. In addition, we examine ETD of the same peptides. ETD generally results in 
highly analogous fragmentation to ECD and involves a similar fragmentation mechanism [5, 37]. 
However, to our knowledge, the presence of b ions in ETD spectra has not previously been noted 
in the absence of supplemental activation. 
4.2 Experimental 
4.2.1 Reagents and Sample Preparation 
Unless otherwise specified, all chemicals, peptides, and proteins were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) and used without further purification. Three groups of 
peptides were examined; first peptides containing few or no basic amino acid residues, including 
cholecystokinin fragment 26-33 (CCK = H-DYMGWMDF-NH2), desulfated caerulein (DC = 
pEQDYTGWMDF-NH2), avian luteinizing hormone releasing hormone (Q
8
-LHRH = 
pEHWSYGLQPG-NH2), (pGlu
5
, D-Trp
7,9,10
)-substance P fragment 5-11 (TrpSP = 
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pEQWFWWM-NH2), and oxytocin (OT = H-CYFQNCPLG-NH2, 1-5 disulfide bond). 
Desulfated caerulein was purchased from Bachem (Torrance, CA, USA) and Q
8
-LHRH was 
obtained from Abcam (Cambridge, MA, USA). Melittin 
(H-GIGAVLKVLTTGLPALISWIKRKRQQ-NH2) is the only peptide in the second group. The 
third group contained peptides derived from proteolytic digestion of equine heart myoglobin and 
α-casein from bovine milk. Both porcine pepsin and porcine trypsin (mass spectrometry grade, 
Promega, Madison, WI, USA) were used for digestion.  
Pepsin digestion was performed by mixing protein and pepsin 1:1 in water with 0.3% 
formic acid (0 ˚C, pH~2.5) followed by 2 min incubation prior to LC/MS analysis. Trypsin 
digestion was performed by mixing trypsin with protein at a 1:100 molar ratio in 50 mM 
ammonium bicarbonate buffer (pH adjusted to ~7.8 with ammonium hydroxide and formic acid) 
and incubating overnight at 37 ˚C followed by heating at 100 ˚C for 5 min to denature the 
protease. The digests were then diluted to 5-10 μM and directly infused via ESI in 1:1 
H2O/methanol, 0.2% formic acid, with or without 0.1% m-NBA. 
4.2.2 Liquid Chromatography 
An Agilent 1100 HPLC system coupled with a 6-port switching valve (VICI Valco, 
Houston, TX, USA) was used for LC ECD MS/MS experiments of peptic mixtures from 
myoglobin or α-casein. The protein digests were separated over a C18 reversed-phase analytical 
column (Phenomenex Kinetex 5 μm EVO 50 x 2.1 mm) at a flow rate of 0.2 mL/min. Mobile 
phase A was 95/5 water/acetonitrile with 0.2% formic acid and mobile phase B was 5/95 
water/acetonitrile with 0.2% formic acid. 0.1% m-NBA was added to the LC eluate via a 
post-column mixing tee with a syringe and pump when necessary. The 7-min-long LC gradient 
started at 5% B, held for 1 min, then linearly increased to 75% B for 4 min, and kept at 75% B 
for another 2 min. Eluate within the first minute was directed to waste. The injection volume was 
6-8 μL. 
4.2.3 Mass Spectrometry 
All mass spectra were acquired in positive ion mode on a 7-T SolariX quadrupole Fourier 
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transform ion cyclotron resonance (Q-FT-ICR) mass spectrometer (Bruker Daltonics, Billerica, 
MA) equipped with an Apollo II ESI source. Duplicate measurements were performed for all 
experiments. ECD was performed in the ICR cell using an indirectly heated hollow dispenser 
cathode (1.6 A) at a bias voltage at - 1.0 V and an irradiation time of 100-200 ms. ETD was 
performed in the hexapole collision cell where both analyte ions and radical anionic fluoranthene 
reagent (m/z 202) were accumulated. Reagent accumulation time was set to 160-180 ms and the 
reaction time was kept at 0. Following electron transfer events in the collision cell, product ions 
were transferred to the ICR cell and detected as an image current. For both ECD and ETD, 
precursor ions were mass-selectively filtered by the quadrupole using a 4-6 m/z isolation window, 
then accumulated in the collision cell for 0.2-0.3 s prior to MS/MS. The collision voltage was 
kept at a low level (- 0.1 to + 0.1 V) to minimize supplemental collisional activation. ECD and 
ETD MS/MS spectra were acquired with 512k or 1M data points averaged over 16 or 32 scans in 
an m/z range from 200 to 1,800. Peptide standards and proteolytic mixtures were electrosprayed 
at a flow rate of 100 μL/h. The nebulizer gas pressure, drying gas flow rate, and drying gas 
temperature for ESI were kept at 1.0 bar, 4.0 L/min, and 150 ˚C, respectively. For LC/MS, the 
capillary voltage, drying gas flow rate, and drying gas temperature were set to 4,500 V, 3.8 L/min, 
and 130 ˚C, respectively. Data dependent acquisition with MS/MS boost were used for auto ECD 
with an ion accumulation time of 0.15 s for MS scans and 0.50 s for MS/MS scans. For each MS 
scan, the four most abundant species with charge states ranging from 2 to 5 were selected for 
ECD (8 m/z isolation width, 150 ms irradiation time, -1.0 V bias voltage, 1 scan for each ECD 
spectrum). A series of CID experiments were also performed with stepwise increased collision 
voltage in an increment of 0.5 V to determine the onset voltage for CID-based generation of b 
ions. Mass spectra were externally calibrated with sodium trifluoroacetate to <2 ppm error. 
4.2.4 Data Analysis 
All data analysis was performed manually using Bruker Data Analysis 4.4. Reference 
masses of all precursor and fragment ions were determined by the MS Product function 
(http://prospector.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msproduct) in Protein 
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Prospector. Only peak assignments with a mass accuracy better than 20 ppm and observed in 
duplicate measurements were accepted. Ion abundance was determined based on the 
monoisotopic peak with charge-state normalization. b ion relative abundance was defined as the 
ratio of the b ion abundance versus the precursor ion abundance upon isolation in the quadrupole 
(prior to dissociation). b ion partitioning was determined as the percentage of the b ion 
abundance among all product ions, including backbone fragments, neutral losses, and internal 
fragments, but not including the charge reduced species [M + nH]
(n-1)+•
.  
4.3 Results and Discussion 
4.3.1 ECD and ETD of peptides with few or no basic amino acid residues 
Several peptides with few or no basic amino acid residues were examined to perform a 
side-by-side comparison between ECD and ETD. Our previous work with a different FT-ICR 
mass spectrometer (Apex-Q) showed that the peptides CCK, DC, Q
8
-LHRH, TrpSP, and OT all 
yielded abundant b ions upon ECD of their doubly protonated forms [20]. Figure 4.1(a) shows 
the ECD spectrum of doubly protonated CCK from our newer SolariX instrument. b-type ions 
(highlighted in blue) are abundant, including b ions with water loss (labeled with asterisks). By 
contrast no b ions were generated in ETD of the same peptide (Figure 4.1(b)). Interestingly, the 
c- and z•-type product ions typical of ExD are prevalent in ETD but significantly less abundant 
than b-type ions in ECD. b5 and b6 ions, corresponding to the most abundant sequence ions upon 
ECD of [CCK + 2H]
2+
, are present in the ETD spectrum at lower abundance (labeled with 
circles). However; control experiments performed with the same sample and ion source/transfer 
settings, including precursor ion quadrupole isolation, but without introducing ETD reagent 
showed that these b ions were already present at the same abundance prior to ETD, presumably 
due to the labile nature of this peptide. By contrast, their abundance increased significantly upon 
ECD and, thus, they are a result of electron irradiation in the latter case. The typical charge 
reduced species, [CCK + 2H]
+•
, was mostly absent in the ECD spectrum (Figure 4.1(a) inset). 
Instead the [CCK + H]
+
 species from hydrogen radical loss was prevalent, similar to the reports 
by Haselmann and Schmidt for ECD spectra with a significant b ion population [15]. A peak that 
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could correspond to hydrogen atom loss from the charge-reduced [CCK + 2H]
+•
 species was also 
observed in the ETD spectrum (Figure 4.1(b) inset), but to a much lower degree compared with 
ECD.  However, this peak can also be explained from proton transfer to the fluoranthene anion 
during the ETD reaction. Figures 4.1 (c)(d) show ECD (c) and ETD (d) spectra of doubly 
protonated Q
8
-LHRH. ECD generated a mixture of different types of sequence ions, including c-, 
z-, b-, y-, and a-type ions (Figure 4.1(c)). Abundant hydrogen loss from the charge reduced 
[Q
8
-LHRH + 2H]
+•
 species was noted although a mixture of [Q
8
-LHRH + H]
+ 
and [Q
8
-LHRH + 
2H]
+• 
is apparent for this peptide (Figure 4.1(c) inset). ETD, on the other hand, generated a less 
complex spectrum with mostly c- and z•-type ions (Figure 4.1 (d)). A low abundance b8 ion was 
present prior to ETD (labeled with a circle). Hydrogen radical loss (or proton transfer) from the 
charge-reduced radical species was virtually absent for this peptide (Figure 4.1(d) inset). Three 
other peptides with few or no basic amino acid residues were subjected to ECD and ETD in their 
doubly protonated forms, as shown in Table 4.1. A number of b ions were exclusively observed 
from ECD of these peptides, as well as abundant hydrogen loss from the charge-reduced species. 
Neither outcome was apparent in ETD. Thus, as noted in previous ECD experiments, the 
occurrence of abundant b ions is related to preferred hydrogen loss from the charge-reduced 
radical [14-16, 20].  
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Figure 4.1 (a) ECD and (b) ETD MS/MS spectra of doubly protonated CCK; (c) ECD and (d) 
ETD MS/MS spectra of doubly protonated Q
8
-LHRH. b-type fragment ions are highlighted in 
blue. b/y product ions present prior to electron irradiation (ECD) or ion-ion reaction (ETD) as a 
result of peptide vibrational excitation are labeled with circles (
○
); * = water loss; 
Δ 
= ammonia 
loss. Insets show expanded views of the charge reduced precursor ions. 
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Table 4.1 Comparison of backbone fragmentation in ECD vs. ETD for three doubly protonated 
peptides lacking basic amino acid residues. b-type fragment ions are highlighted in red.  
 
4.3.2 ECD and ETD of the 4+, 5+, and 6+ charge states of melittin 
To further investigate the b ion formation in ExD, melittin carrying four and five protons 
was fragmented with ECD and ETD, respectively. For quadruply protonated melittin, only one 
minor b ion (b23
2+
) was observed upon ECD (Figure 4.2 (a)). However; a large number of b ions 
were detected in ECD of the 5+ charge state (Figure 4.2 (c)). By contrast, ETD of the 4+ charge 
state did not result in any b ions (Figure 4.2 (b)) while the 5+ charge states yielded two minor b 
ions (b23
2+
, b25
3+
) from ETD (Figure 4.2 (d)). The striking difference between ECD and ETD 
spectra of the 5+ charge state of melittin in terms of the presence of b ions again clearly showed 
significant differences between these two activation methods. Our previous work [20] proposed 
that b ions should be expected for higher charge states when the number of protons is higher than 
the number of basic sites. This hypothesis is supported by the high number of b ions formed in 
ECD of quintuply protonated melittin but not in that of the quadruply protonated form. Melittin 
has six basic sites: the N-terminus and five basic amino acid residues (K
7
, KRKR
21-24
). Due to 
the consecutive order of the four basic residues KRKR
21-24
 protonation of each one is 
thermodynamically unfavorable. Thus, it is quite likely that one proton in the 5+ charge state is 
located on a backbone amide nitrogen, consistent with the prevalent b ions. 
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By adding 0.1% m-NBA to the ESI solvent, the 6+ charge state of melittin could be 
isolated and subjected to ECD and ETD, respectively. Both spectra were rather complex (data 
not shown) with an even larger number of b ions generated in ECD of the 6+ charge state 
compared to the 5+ ion (Table 4.2). Interestingly, the ETD spectrum of the 6+ charge state of 
melittin showed several additional b ions not observed for the 5+ precursor ion (Table 4.2). The 
increased number of b ions in both ECD and ETD of the 6+ charge state of melittin is likely due 
to the even higher probability of backbone protonation compared with the 5+ charge state. 
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Figure 4.2 (a)(c) ECD and (b)(d) ETD MS/MS spectra of the (a)(b) 4+ and (c)(d) 5+ charge 
states of melittin. Only the precursor ions, charge reduced species, and b ions are labeled. 
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Table 4.2 Comparison of backbone fragmentation in ECD vs. ETD for the 4+, 5+, and 6+ charge 
states of melittin. Basic amino acids are highlighted in blue. Only b-type fragment ions are 
included in this table. * indicates that the ECD/ETD experiment was performed following 
addition of 0.1% m-NBA into the ESI solvent. 
 
4.3.3 b ions observed in ECD and ETD of tryptic and peptic peptides with varying charge 
states 
Table 4.3 shows b ions detected in ECD and ETD of myoglobin and α-casein tryptic 
(a)/peptic (b) peptides. Doubly charged tryptic peptides are unlikely to be protonated at backbone 
amides. Accordingly, b ions were not detected in ECD of such species (Table 4.3(a)). The triply 
charged form of VEADIAGHGQEVLIR generated one b ion in ECD but no b ions in ETD. The 
tryptic peptide LFTGHPETLEKFDKFK with two missed cleavage sites did not show any b ions 
upon ECD of the triply protonated form but the 4+ and 5+ charge states (generated via 
supercharging with m-NBA) yielded 2 and 11 b-type ions, respectively.  However, no b ions 
were observed from ETD, even for the 5+ ions. This charge state may still preclude backbone 
protonation as there are five basic sites in this peptide (the N-terminus, histidine, and 3 lysines).  
Peptic peptides do not, like tryptic peptides, contain basic amino acid residues at the 
C-terminus. Also, due to the less selective nature of pepsin, peptic peptides are often shorter than 
tryptic peptides. For these reasons, at higher charges states, peptic peptides may be more likely to 
include backbone protonation. Accordingly, b ions were observed from two doubly protonated 
peptic peptides upon ECD (Table 4.3(b)). One of these two peptides, FRQFYQL, also generated 
one b ion upon ETD. It is feasible that backbone protonation occurs in this peptide as there is an 
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arginine residue close to the N-terminus. Triply and quadruply protonated peptic peptides were 
generated with the aid of m-NBA-based supercharging. All such triply charged peptides, except 
LRLKKYKVPQL, generated b ions from ECD. The latter peptide, which contains five basic sites, 
was also present in a 4+ charge state, which did yield b ions from ECD.  None of these peptides 
generated b ions upon ETD, again highlighting differences between these two activation 
methods. 
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Table 4.3 b ions generated from ECD vs. ETD of (a) tryptic peptides and (b) peptic peptides 
from myoglobin and α-casein in different charge states. The basic amino acid residues in each 
peptide are highlighted in blue. * indicates that the ECD/ETD experiment was performed with 
addition of 0.1% m-NBA into the ESI solvent. 
(a) 
 
(b)
 
4.3.4 Possible mechanisms for the formation of b ions from supercharged peptides upon 
ECD and ETD 
ECD and ETD are thought to share similar, if not identical, fragmentation mechanisms. 
Nevertheless, we observe a clear difference in the charge density threshold when b ions are 
formed from these activation methods. We propose that this difference is due to different initial 
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internal energy of the charge reduced radical intermediates upon electron capture/transfer [23] 
prior to dissociation. There are both fundamental and experimental differences that could account 
for this energy difference. First, the source of electrons in the two techniques is not the same; the 
recombination energy upon electron transfer (close to the electron affinity of the radical reagent 
anions [38]) is significantly lower compared to the recombination energy upon capture of free 
thermal electrons [1, 39-41]. Second, ETD is typically performed in an ion trapping device, e.g., 
the collision cell on the SolariX FT-ICR mass spectrometer, at a pressure ~10
-3
 mbar, allowing 
for collisionally cooled precursor ions, whereas ECD takes place under ultra-high vacuum (UHV, 
~10
-10
 mbar) in the absence of collision gas. In addition, the electron-emitting cathode used for 
ECD is heated to a high temperature, thus resulting in blackbody radiation within the ICR cell, a 
potential source of precursor ion vibrational excitation. 
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Figure 4.3 (a) Relative abundance of b5 through b9 ions from doubly protonated desulfated 
caerulein upon ECD when the ECD lens voltage was set to 10 V (to promote electron injection, 
blue bars) and - 20 V (to preclude electron injection, red bars) respectively. (b)(c) b ion 
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abundance partitioning for doubly protonated desulfated caerulein upon ECD with varying (b) 
ECD pulse length and (c) ECD bias voltage. 
To examine whether the increased ICR cell temperature at ECD conditions is directly 
responsible for the enhanced formation of b ions in ECD vs. ETD, a negative voltage (- 20 V) 
was applied to the ECD lens, located between the cathode and the ICR cell, to prevent electrons 
from entering the cell, while the cathode remained hot. The relative abundances of b5-b9 ions 
detected from doubly protonated desulfated caerulein under ECD conditions at these two lens 
voltages are shown in Figure 4.3 (a). All b ions were significantly reduced or absent at the lens 
voltage preventing electrons from entering the ICR cell, with only the b7 ion present at rather low 
abundance (1.5% relative to the precursor ion abundance) in the absence of electron irradiation 
This result indicates that the formation of b ions in ECD is a radical-initiated process consistent 
with previous work [14]. We also found that the presence of b ions and their relative abundance 
among all ECD product ions are not affected by the ECD pulse length or ECD bias voltage 
(Figure 4.3 (b)(c)). 
It has been reported that inelastic collisions with electrons can induce vibrational and/or 
electronic excitation, resulting in analyte fragmentation; a process termed electron impact 
excitation of ions from organics (EIEIO) [42, 43]. However; EIEIO typically employs 
significantly higher electron energy (70 eV) than typical ECD conditions. In hot ECD (HECD) 
experiments [44] at ~10 eV electron energy, b/y-type ions are observed but this energy is still 
much higher than what is employed here. Cooper performed double resonance experiments to 
exclude that b ions result from secondary fragmentation of c ions [14]. The observation that 
abundant b ions are accompanied by abundant hydrogen radical loss from the charge reduced 
species suggests that such loss is favorable and results in peptide vibrational excitation. To 
further compare the ECD-generated b ions to those typically observed in CID, a series of CID 
experiments was performed on doubly protonated Q
8
-LHRH and desulfated caerulein, both of 
which generated abundant b ions upon ECD. These experiments gradually increased the collision 
energy to determine the onset voltage for formation of each b ion. As shown in Figure 4.4, an 
obvious inverse relationship between the b ion onset voltage determined by CID and the b ion 
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abundance in ECD was seen. For example, b7 and b8 ions from doubly protonated Q
8
-LHRH 
were highly abundant upon ECD with an onset voltage close to 0, indicative of weak peptide 
bonds at LQ
78
 and QP
89
. 
 
(Figure 4.4 continued on the next page) 
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Figure 4.4 b ion relative abundance (%, blue bars) of doubly protonated Q
8
-LHRH (top) and 
desulfated caerulein (bottom) upon ECD co-plotted with the b ion onset voltage (V, red line) 
obtained by CID. 
In sum, a proposed pathway describing b ion formation in ExD involves electron 
capture/transfer by/to a peptide with at least one proton located at a backbone amide to form a 
hydrogen atom (H•). The associated recombination energy results in preferred loss of this 
hydrogen radical, leaving a vibrationally excited peptide ion that undergoes dissociation, forming 
b-type ions. The initial ion temperature upon electron capture/transfer appears to influence the 
probability of hydrogen atom ejection. This ejection probability is higher in ECD compared with 
ETD based on the local environment of each experiment (temperature and pressure). It is also 
enhanced for higher charge states, particularly those generated via supercharging strategies.  
4.4 Conclusions 
In this work, the number and abundance of b ions generated in ECD are examined as a 
function of precursor ion charge state. As previously demonstrated, b ions are more prominent in 
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ECD spectra when the number of protons outnumber the basic sites. Interestingly, ETD, 
commonly believed to be analogous to ECD, generates much fewer b ions at the same charge 
state. Nevertheless, at high charge states, including those generated via supercharging, b ions are 
also seen in ETD spectra but at significantly lower levels than in ECD. This difference is related 
to the energetics and local environment of these two MS/MS experiments. We propose that, 
similar to the observations by Haselmann and Schmidt [15], b ions are formed following 
hydrogen atom ejection from charge-reduced precursor ions. 
Supercharging is a useful strategy to enhance ECD/ETD-type peptide/protein sequencing; 
however, the occurrence of unconventional fragments, such as b ions, complicates spectral 
interpretation, may underestimate fragmentation efficiency, and may lead to lower peptide scores. 
Thus, b ions should be included in ExD database searches for higher charge states. In specialized 
tandem mass spectrometry experiments that require minimal vibrational activation, such as HDX 
MS/MS, ETD appears more appropriate than ECD.  
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Chapter 5 
 
 
Off-line HILIC Sample Preparation for Improved Detection of Host Cell Proteins in Drug 
Substances 
 
 
5.1 Introduction 
Host cell proteins (HCPs) are native proteins from the host organism used to express a 
biotherapeutic antibodies. HCPs may be co-purified with the drug substance protein [1]. The 
presence of these impurities in biotherapeutics may potentially elicit immune responses in patients, 
affect drug efficacy, and cause product instability [2, 3]. Therefore, effective removal of these 
impurities needs to be achieved in the downstream purification process during manufacturing, and 
HCPs present must be monitored and characterized to understand potential risks [4, 5]. 
Enzyme-linked immunosorbent assay (ELISA) remains the most common technique used 
for HCP characterization in industry because of its high sensitivity, high throughput, and 
capability for quantification [1]. Generally, generic HCP ELISAs are developed using polyclonal 
antibodies raised against antigen proteins produced in culture from a process-representative null 
host cell line. However, achieving antibody coverage of all HCP species present within a certain 
manufacturing process is still a challenge, and even the best process-specific HCP ELISA cannot 
detect 100% of the HCPs for a given host cell line [5]. 
In addition to ELISA, protein separation and visualization methods, such as 1D and 2D 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [6], 2D-differential 
in-gel electrophoresis (2D-DIGE), western blotting (WB) [7], and capillary zone electrophoresis 
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(CZE), are valuable tools for HCP characterization. While protein-specific antibodies can be used 
effectively with ELISA and WB techniques, separation techniques alone do not enable protein 
identification, nor is it practical to raise specific antibodies for all HCPs.  
LC/MS-based “shotgun” proteomics is a powerful method for HCP characterization to 
support downstream purification process development [8, 9] and is increasingly common 
throughout industry. In contrast to ELISA and 1D/2D gel electrophoresis methods, HCPs can be 
identified upon database searches against the entire proteome of the host organism. Approximate 
quantification of individual HCP species can also be achieved by spiking in known amounts of 
internal standard proteins in 2D-LC/MS
E
 and by utilizing the “Hi-3” [4, 10] quantitative strategy, 
or more accurately quantified using specific peptide or protein standards. However, because 
HCPs contained within a biopharmaceutical product are typically at less than 100 ppm 
concentration (ng of HCP per mg biotherapeutic protein), a dynamic range of up to 6 orders of 
magnitude is required in order to detect these low abundance species within the overwhelming 
background of the drug substance, a challenge for even state-of-the-art mass spectrometers.  
Strategies to circumvent this problem include chromatographically resolving HCP 
peptides from drug substance peptides by using long LC gradients, using multiple columns, and 
adding multiple separation dimensions such as 2D-LC [10, 11] and/or ion mobility [11]. The 
drawback of enhanced separation is that throughput can be greatly sacrificed, limiting the types of 
studies which can be supported. Other approaches include enriching residual HCPs by removing 
the monoclonal antibody (mAb) with affinity purification [9], precipitating the mAb after minimal 
digestion under native conditions [12]; and applying novel data acquisition methods allowing 
more peptide species to be fragmented by tandem mass spectrometry (for example, 
data-independent acquisition and MS
E
) [10, 11]. 
The native digestion/mAb-precipitation sample preparation method, first described in a 
recent publication by Huang et al. [12], mitigates this dynamic range issue by depletion of the 
mAb. The method relies on the hypothesis that the mAb will maintain its folded three-dimensional 
structure under native conditions (neutral pH, non-denaturing buffer) and resist protease digestion 
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when incubated with trypsin, while less-rigid HCPs will be digested into peptides. After 
incubation, undigested protein (presumably the therapeutic mAb) is precipitated and removed, 
while HCP peptides in the supernatant are recovered and analyzed by LC/MS. There are a few 
concerns associated with this method, including risks that heat-labile HCP peptides may be lost, 
HCPs may co-precipitate with the mAb, and the method is designed to work optimally for 
digestion-resistant drug substances such as mAbs, thus it may not perform as well for other 
molecules such as fusion proteins [13, 14], which are known to be structurally flexible. 
A novel hydrophilic interaction chromatography (HILIC) method based on a large pore 
size stationary phase has shown potential for characterization of product-related low molecular 
weight (LMW) impurities in mAb products, such as mAb fragments and subunits [15]. Upon 
HILIC separation, the elution order was observed to be mostly determined by the molecular 
weight, with LMW species eluting earlier [15]. 
Here, we demonstrate a new approach involving offline HILIC sample preparation to 
separate HCPs from therapeutic protein in order to improve LC/MS sensitivity for low-level HCPs. 
Our results indicate that most HCP species can be well-resolved from the therapeutic protein 
utilizing HILIC separation, collected in fractions and concentrated, then subjected to trypsin 
digestion and LC/MS analysis. The HILIC-enriched HCP method shows improved sensitivity to 
several HCPs in the NISTmAb (RM 8671) that were not reported or observed using other 
LC/MS strategies, and can serve as a complementary technique for HCP detection to previously 
published analytical strategies. This method is also demonstrated successfully for HCP analysis of 
non-mAb drug substances, in particular for a fusion protein. 
5.2 Experimental 
5.2.1 Materials 
A recombinant IgG1 mAb (BMS mAb 1), a fusion protein (BMS fusion protein 1), and 
Chinese hamster ovary (CHO) null strain material (containing HCPs without drug substance) 
produced by Bristol-Myers Squibb (Hopewell, NJ) were used in this work. Humanized IgG1κ 
monoclonal antibody standard RM 8671 was purchased from the National Institute of Standards 
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and Technology (NIST, Gaithersberg, MD). All chemicals were reagent grade or better. 
Ammonium formate, ammonium hydroxide solution (~1 M in water), DL-dithiothreitol (DTT), 
dimethyl sulfoxide (DMSO), and Trizma pre-set crystals (pH 8.0) were purchased from 
Sigma-Aldrich Co. (St. Louis, MO). Water and acetonitrile (LC-MS grade), formic acid (FA), and 
trifluoroacetic acid (TFA) were obtained from Thermo Fisher Scientific (Rockford, IL). Urea 
(crystalline) was purchased from Alfa Aesar (Tewksbury, MA). Sequencing grade modified 
trypsin was obtained from Promega (Madison, WI). Pre-mixed chromatographic solvents (water 
containing 0.1% TFA, and acetonitrile containing 0.1% TFA), were from J. T. Baker Chemical Co. 
(Phillipsburg, NJ).  
5.2.2 Offline HILIC Sample Preparation 
For initial method development, BMS mAb 1 material was diluted in water to a 
concentration of 2.50 mg/mL, with or without spiked HCP standard at a concentration of 2.35 
mg/mL. A 4 µL injection volume was utilized for aqueous samples. To increase mass loading on 
column, concentrated BMS mAb 1 drug substance (74.7 mg/mL in buffer) was mixed with CHO 
null strain material to produce 10,000 (10k) or 1,000 (1k) ppm spiked HCP in 37.5 mg/mL 
therapeutic protein.  
For higher mass loading with lower concentration samples, organic solvents were added. 
NISTmAb (10 mg/mL) or BMS fusion protein 1 (25 mg/mL) were mixed with acetonitrile, 
DMSO, and TFA to a final ratio of 28/66/5/1 for therapeutic protein 
solution/acetonitrile/DMSO/TFA (v/v). The resulting concentration was 2.8 mg/mL for 
NISTmAb and 7.0 mg/mL for BMS fusion protein 1. For BMS mAb 1, 150 µg was loaded onto 
the HILIC column per injection; for NISTmAb and BMS fusion protein 1, 700 µg was loaded 
onto the HILIC column per injection. Samples were analyzed in duplicate. 
5.2.3 HILIC Separation Parameters and Fraction Collection 
A Waters ACQUITY UPLC I-Class system was used for all HILIC separations with an 
ACQUITY UPLC BEH Glycoprotein Amide column (300 Å, 1.7 μm, 2.1 x 150 mm, Waters, 
Milford, MA). The column was set at 60 °C and the LC solvents were 0.1% TFA in water as A 
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and 0.1% TFA in acetonitrile as B. For completely aqueous samples, the separation was 
performed with a 24-min gradient starting at 15% A for the first 0.5 min at 0.2 mL/min, ramping 
up to 28% A in another 0.5 min, and then linearly increasing from 28% to 42% A over the next 
23 min. The gradient was then ramped to 99% A in 2 min with an increase of flow rate to 0.25 
mL/min and held for 3 min before decreasing to 15% A in 3 min and then maintained at the 
initial condition for another 8 min to equilibrate the column. UV chromatograms were acquired 
at 215 and 280 nm.  
For samples diluted in organic solvents, or for non-mAb samples, the gradient was 
modified slightly. For NISTmAb, the same gradient as above but with an initial condition of 28% 
A instead of 15% A was used. For BMS fusion protein 1, the 24 min LC gradient also 
commenced at 28% A but was held constant for 0.5 min before linearly increasing to 38% A in 
12.5 min, then ramping to 58% A over another 11 min. 
Based on the main UV peak location, indicating the therapeutic protein elution time, the 
HILIC eluate was collected in three separate fractions: pre-peak (Fraction #1); main peak 
(Fraction #2); and post-peak (Fraction #3). The main peak generally eluted between ~12 min and 
15-19 min after injection. Fractions from two HILIC runs were combined for the BMS mAb 1 
spiked samples. For NISTmAb and BMS fusion protein 1, a single injection of 700 μg was 
performed and the fractions were collected from only one HILIC run. 
Ammonium hydroxide solution (1 M) was added to each fraction to adjust pH to 6-7 (~18 
μL per mL) before each fraction was concentrated down to < 30 μL using a centrifugal vacuum 
concentrator set to 40°C coupled with a refrigerated vapor trap (Savant SPD111V and RVT5105, 
Thermo Scientific, Waltham, MA). Concentrated/dried samples were reconstituted with 100 μL 
of digestion buffer containing 2 M urea and 50 mM tris-HCl (pH 8.0). Each sample was 
vigorously mixed by a vortex mixer, then combined with 50 mg/mL DTT solution. For BMS 
mAb 1 spiked samples, 2 µL of the DTT solution was added to each fraction. For NISTmAb and 
BMS fusion protein 1, 3 μL, 6 μL, and 2 μL of DTT solution was added to Fractions #1, 2 and 3, 
respectively. Fractions were then incubated for 20 min at 60 °C. 
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5.2.4 Trypsin Digestion 
After cooling to room temperature, each fraction was treated with 0.5 mg/mL trypsin and 
incubated at 37 °C overnight (>15 h). For BMS mAb 1 spiked samples, the volume of the trypsin 
solution added was 2 μL, 3 μL and 1 μL to Fractions #1, 2 and 3, respectively. For NISTmAb 
and BMS fusion protein 1, the volume of the trypsin solution added was 5 μL, 10 μL and 3 μL to 
Fractions #1, 2 and 3, respectively. Digests were centrifuged at 13,000 x g for 2 min. The 
supernatant was transferred to an HPLC vial and 5 µL of 10% FA in water was added and mixed 
before LC MS/MS analysis. As control experiments, the aforementioned therapeutic protein 
samples were also prepared using the mAb-precipitation digestion method as described elsewhere 
[12]. 
5.2.5 UPLC-MS/MS Analysis of Tryptically Digested HILIC Fractions 
The total volume of the digest for each HILIC fraction (100-120 μL) was injected for 
UPLC-MS/MS analysis unless otherwise specified. Tryptic digests were separated using a Waters 
ACQUITY UPLC CSH C18 column (1.7 μm, 2.1 x 100 mm) on a Waters ACQUITY UPLC 
system (Milford, MA). The mobile-phase solvent A was water with 0.1% FA and the solvent B 
was acetonitrile with 0.1% FA. Separation was performed at a column temperature of 60 °C with a 
mobile-phase gradient reported elsewhere [12]. On-line mass spectrometric analysis was 
conducted using an Orbitrap Fusion Lumos Tribrid Mass Spectrometer (Thermo Scientific, 
Waltham, MA) in positive ion mode utilizing orbitrap (OT) and ion trap (IT) detection for MS1 
scans and MS2 scans, respectively. The MS1 full scan was conducted in a mass range of 230-1,500 
m/z (resolution 120,000, AGC target 4.0e5, and maximum injection time 50 ms) followed by 
data-dependent HCD fragmentation (collision energy 32%, AGC target 1.0e4, and maximum 
injection time 300 ms) in a 3-s cycle time. Dynamic exclusion was applied after 1 scan for a 
duration of 60 s. The ion source (H-ESI) settings were as follows: ESI voltage 3,500 V, sheath gas 
flow rate 30, aux gas flow rate 7, sweep gas flow rate 1, ion transfer tube temperature 300 °C, and 
vaporizer temperature 150 °C. Precursor ions were selected in the quadrupole using a 1.4 m/z 
window.  
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5.2.6 Database Search Parameters 
MS/MS data were searched for HCP identification using Byonic 3.1.0 (ProteinMetrics, 
San Carlos, CA) against a customized protein database including the therapeutic protein sequence 
and the CHO or mouse proteome, as appropriate, downloaded from UniProt.org. Search 
parameters were set as follows: mass tolerance as 10 ppm for precursors and 0.4 Da for fragments, 
fully specific peptide termini with ≤ 3 missed cleavages, and protein FDR cutoff at 1%. N-terminal 
glutamine formation of pyroglutamate was considered a common variable modification and 
oxidized methionine a rare variable modification (maximum 1 common and 1 rare modification). 
Protein hits with |Log Prob| score lower than 4.0, decoys, and common protein contaminants were 
excluded. Protein hits with only 1 or 2 unique peptides were manually verified to remove false 
positives. 
5.3 Results and Discussion 
Our HILIC-enriched HCP method was developed to address the dynamic range limitation 
of current LC/MS instrumentation when applied towards the detection of residual HCPs in 
biotherapeutic proteins. The separation capability of HILIC to dissociate and enrich HCP species 
from therapeutic proteins was explored to develop a protocol for collecting and reconstituting 
HCP fractions, followed by trypsin digestion and analysis by LC-MS/MS (Figure 5.1). This 
strategy takes advantage of the high loading capacity of the HILIC column to provide a 
semi-preparatory scale separation within 24 min. A large drying chamber helped fast 
concentration of HILIC fractions and a 2-h mobile-phase gradient was used for the 
UPLC-MS/MS analysis of trypsin digests of these fractions, enabling a comparable throughput 
for HCP detection to other LC/MS HCP methods [12] (particularly if only Fraction #1 is 
analyzed). 
The HILIC chromatographic step can be advantageous for separation of HCPs from 
therapeutic proteins as compared with other strategies. The developed method allows up to 700 µg 
per injection, with greater column loads possible. The denaturing conditions (high organic mobile 
phase) used are believed to facilitate disruption of protein-protein interactions between HCPs and 
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the drug substance, enabling separations that may not be achieved with other columns. The utilized 
amide column features wide pores and small particle size (300 Å and 1.7 μm, respectively) to 
achieve high resolution HILIC separation for intact proteins as compared with other types of 
HILIC columns. We selected the largest commercially available column diameter and length (2.1 
x 150 mm) to maximize loading capacity. 
Though protein precipitation may be problematic for high organic solvent concentrations, 
our HILIC method was optimized to maintain solubility. For example, 0.1% TFA not only 
improves separation resolution via ion pairing, but significantly increases solubility of therapeutic 
proteins in high acetonitrile mobile phases, and prevented column clogging observed with other 
additives such as formic acid (data not shown). Acetonitrile also facilitates concentration of 
fractions due to its higher vapor pressure than aqueous solvents.  
Following fraction collection, the pH value of each fraction was adjusted to ~7 to prevent a 
decrease in pH from concentration of TFA during drying. Upon completion of the concentration 
step, white precipitation could be observed at the bottom of the microcentrifuge vial in a small 
amount of liquid for Fraction #2 samples and some Fraction #1 samples, but no precipitation was 
observed in the concentrated Fraction #3 samples. A chaotropic salt (urea) was added to the 
digestion buffer in order to improve reconstitution of the precipitated proteins. Subsequent heated 
reduction and overnight incubation with trypsin ensured thorough digestion of all present protein 
species into peptides. 
 
Figure 5.1 Proposed protocol for our HILIC-enriched HCP LC/MS method. 
HILIC & Fraction 
collection 
Fraction 
concentration & 
Trypsin digestion 
LC MS/MS peptide 
mapping 
Database 
searching 
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5.3.1 Separation Profiles of HCPs and Therapeutic mAb using HILIC 
As shown in the UV chromatogram in Figure 5.2, spiked HCPs (blue line) are well 
resolved from BMS mAb 1 (black line). This result agrees with the previously reported finding 
that LMW impurities (such as many HCPs [14]) in therapeutic mAbs can be characterized based 
on a size-related elution order when a similar HILIC strategy was used [15]. 
 
Figure 5.2 280 nm UV chromatograms from HILIC separation of 10.0 μg BMS mAb 1 drug 
substance with (red line) and without (black line) addition of 9.4 μg HCP standard from CHO null 
cell line. Blank (water, brown line) and null cell HCP material only (blue line) chromatograms are 
also shown for reference. A Waters UPLC BEH Glycoprotein Amide column (300 Å, 1.7 μm, 2.1 
x 150 mm) was used.  
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Figure 5.3 280 nm UV chromatograms from HILIC separation of 5.0 μg BMS mAb 1 drug 
substance with (red line) and without (blue line) addition of 4.7 μg HCP standard from CHO null 
cell line. Blank (water, black line) and null cell HCP material only (green line) chromatograms are 
also shown for reference. A Waters XBridge HILIC column (5 μm, 4.6 x 150 mm) was used at an 
operating temperature of 45 °C. Mobile phase solvent A was 20 mM ammonium formate in water 
containing 0.1% formic acid and mobile phase solvent B was 20 mM ammonium formate in 90/10 
acetonitrile/water containing 0.1% formic acid.  
 
Table 5.1 LC mobile phase gradient and flow rate used with the Waters XBridge HILIC column 
(data in Figure 5.3). 
Time (min) Flow rate 
(mL/min) 
A% B% 
0 0.4 50.0 50.0 
25 0.4 99.0 1.0 
30 0.4 99.0 1.0 
31 0.4 50.0 50.0 
34 0.6 50.0 50.0 
36 0.6 99.5 0.5 
39 0.6 99.5 0.5 
41 0.6 50.0 50.0 
61 0.4 50.0 50.0 
62 0.4 50.0 50.0 
We also evaluated two other commercially available HPLC HILIC columns – a Waters 
XBridge HILIC column (150 Å, 5 μm, 4.6 x 150 mm) and a Phenomenex Luna HILIC column 
(200 Å, 5 μm, 4.6 x 150 mm). We observed that separation between the HCP standard and mAbs 
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could be achieved using the XBridge column with different mobile phase solvents and gradient 
(Table 5.1) compared with the Glycoprotein Amide column used in Figure 5.2; however, the 
loading capacity for the former column was limited, with the UV chromatogram showing 
significant tailing upon loading of just 5.0 μg mAb and 4.7 μg HCP standard (Figure 5.3). The 
Luna column did not show capability of separating intact proteins (data not shown). Because the 
Waters Glycoprotein Amide column provided the highest separation performance, it was used 
for all subsequent experiments. 
5.3.2 HCP Detection with Spiked Samples 
Highly purified drug substance BMS mAb 1 was spiked with HCP standard to evaluate the 
performance of the HILIC-enriched HCP method. Figure 5.4 shows the chromatographic profile 
from HILIC separation of 150 μg drug material spiked with 10k ppm HCPs. The main peak area 
(Fraction #2) appeared at a retention time of 11.7–15.5 min, indicating that the therapeutic 
protein was well-retained on the column (retention factor ~5). The spiked HCP species were 
barely visible on the UV chromatogram, probably due to the sensitivity limits of UV detection. 
However, based on the separation profile in Figure 5.2, it is probable that the majority of HCP 
species eluted into Fraction #1. 
Respective fractions from two consecutive HILIC chromatograms were pooled for 
reconstitution, digestion, and LC/MS analysis. As indicated in Table 5.2, when 1k ppm HCP 
standards were spiked into BMS mAb 1, a total of 89 HCPs were identified from Fractions #1, 
#2, and #3, with 92% (82 out of 89) of HCPs observed from Fraction #1. In addition, there were 
5 HCPs co-eluting with the mAb (Fraction #2). However, the mAb-precipitation method was 
only able to detect 41 HCPs. Of the 82 HCPs present in Fraction #1, 62 were not detected with 
the mAb-precipitation method. These results indicate that the HILIC-enriched HCP method 
showed improved sensitivity for many HCPs and provided complementary information for HCP 
detection compared with the mAb-precipitation method.  
Interestingly, a different trend was observed with the 10k ppm HCP-spiked sample. 
While the mAb-precipitation method was able to detect 225 HCPs, a total of 193 HCPs were 
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observed from the three HILIC-enriched fractions. Even though the total number of HCPs 
identified by our method was lower than the mAb-precipitation method, the two methods showed 
sensitivity for different HCPs, thus providing complementary information and expanding the total 
number of HCPs identified to 294, as shown in Table 5.2. For example, 56 out of 162 (35%) 
identified HCPs from Fraction #1 were not observed using the mAb-precipitation method. Four 
out of 13 (31%) from Fraction #2 and 12 out of 35 (34%) from Fraction #3 were newly identified 
as well.  
While the difference in selectivity of the two sample preparation strategies is evident from 
our study, the cause of these differences is not obvious. Potential sensitivity limitations of the 
mAb-precipitation method include risk of high background from over-digestion of the mAb, 
under-digestion of certain HCPs under non-denaturing conditions, co-precipitation of HCP 
peptides with the mAb, or degradation of thermally labile peptides during the precipitation step. 
Potential limitations of our HILIC enrichment method include risk of strong adsorption or 
precipitation of certain HCPs in the mobile phase, preventing elution; however our solvents were 
optimized to minimize this risk, and no column clogging or increase in back pressure was 
observed. Additionally, precipitate was observed in Fractions #1 and #2 after drying. Though 
pellets appeared to fully dissolve in the 2 M urea buffer utilized for digestion, it is possible that not 
all HCPs were fully reconstituted prior to digestion. Lastly, some HCPs may, by virtue of their size, 
hydrophobicity, or strong protein interactions (not disrupted by acetonitrile), co-elute with the 
therapeutic. As shown in Table 5.2, some HCPs were observed only in Fraction #2, which 
supports this hypothesis. The presence of high levels of therapeutic in Fraction #2 may limit 
sensitivity for low-level HCPs in that fraction. 
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Figure 5.4 The 280 nm UV chromatogram following HILIC separation of 150 μg BMS mAb 1 
drug substance spiked with 10k ppm HCPs. The LC eluate was collected as Fraction #1, #2, and #3 
separately, as indicated by the different retention time ranges: 1.0–11.7 min for Fraction #1, 
11.7–15.5 min for Fraction #2, and 15.5–24.0 min for Fraction #3. 
 
Table 5.2 The numbers of HCPs identified in the three HILIC-enriched fractions compared with 
those identified by the mAb-precipitation method for BMS mAb 1 spiked with 1k and 10k ppm 
HCP standards, NISTmAb, and BMS fusion protein 1. The numbers in parentheses indicate how 
many HCPs were uniquely identified by the HILIC-enriched HCP method but not by the 
mAb-precipitation method for each sample. 
Method 
BMS mAb 1 + 
1k ppm HCP 
BMS mAb 1 + 
10k ppm HCP 
NISTmAb 
BMS fusion 
protein 1 
HILIC-enriched HCP method 89 (66) 193 (69) 71 (21) 22 (7) 
Fraction #1 only 81 (62) 150 (54) 68 (21) 18 (6) 
Both Fractions #1 and #2 1 (0) 2 (0) 0 (0) 0 (0) 
Fraction #2 only 3 (2) 6 (3) 0 (0) 0 (0) 
Both Fractions #2 and #3 1 (1) 1 (1) 0 (0) 0 (0) 
Fraction #3 only 3 (1) 24 (9) 1 (0) 2 (1) 
Both Fractions #1 and #3 0 (0) 6 (2) 1 (0) 0 (0) 
Fractions #1, #2, and #3 0 (0) 4 (0) 1 (0) 2 (0) 
mAb-precipitation method 41 225 91 17 
Two methods combined 107 294 112 24 
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5.3.3 HCP detection with NISTmAb 
NISTmAb standard (RM 8671) is commonly used to evaluate LC/MS method performance, 
and is particularly informative for HCP characterization given its relatively low purity compared 
with most therapeutic mAbs [11, 12]. To analyze this standard by our method, a large injection 
volume was required to ensure a high loading amount of NISTmAb on the HILIC column, because 
its concentration was relatively low (10 mg/mL) compared with the BMS drug substances (74.7 
mg/mL for BMS mAb 1 and 25.0 mg/mL for BMS fusion protein 1). A dilution strategy for 
NISTmAb (and other therapeutic proteins) was therefore developed, to overcome solubility risks 
with the HILIC mobile phase.  
To prevent precipitation, DMSO and TFA were added to NISTmAb, enabling solubility 
in up to 72% acetonitrile. We also adjusted the HILIC mobile phase starting conditions to be 
aligned with the sample solvent strength, maintaining protein solubility. Figure 5.5 shows the UV 
chromatogram of the HILIC separation when 700 μg NISTmAb material was loaded in one 
injection. While some increase in peak tailing was observed at high loading, the front of the mAb 
peak remained at about the same retention time as previous smaller injections (~12 min) and the 
peak returned to baseline at ~17 min. No change in peak shape or back pressure was observed after 
~50 injections, supporting that high mass loading is not impacting the column adversely. As 
described above, most HCPs present in the sample are believed to elute earlier than the mAb, 
possibly within the solvent front as indicated by the small peak around 2 min, thus the peak tailing 
is not expected to impact separation of HCPs from NISTmAb. 
The numbers of HCPs that could be identified from each fraction from NISTmAb are 
shown in Table 5.2, and are compared with the mAb-precipitation method. 71 and 91 HCPs were 
detected in total by our method and the mAb-precipitation method, respectively, for NISTmAb. 
99% (70/71) of HCPs detected with the HILIC-enriched HCP method came from Fraction #1. A 
total of 21 new HCPs (Table 5.3) were identified by this method compared with the 
mAb-precipitation method, increasing the total identified HCPs to 112. These 21 new HCPs were 
detected in duplicate measurements.  
 151 
A list of all 71 HCPs identified from the three HILIC fractions is shown in Table 5.4. To 
ensure that no protein identifications were the result of HCP carry-over, the HILIC column was 
washed with two water injections prior to NISTmAb injection. Additionally, a blank sample was 
analyzed with no sample protein but including the digestion protocol to assess false positive HCPs. 
As further precaution, the MS/MS spectra of the identified peptides from the 21 novel HCPs 
(Table 5.3) were all manually verified. Two of these MS/MS spectra (peptides from ubiquitin-60S 
ribosomal protein L40 and ATPase inhibitor, mitochondrial) are shown in Figure 5.6. To our 
knowledge, these 21 HCP species have not been previously reported within NISTmAb [11, 12]. In 
addition, the concentrations of the 50 HCPs commonly identified by our method and previous 
work are reported to range from less than 1 to over 200 ppm in NISTmAb [11, 12], 
demonstrating the great sensitivity of our method for HCP characterization in biotherapeutic 
protein drugs.  
 
Figure 5.5 280 nm UV chromatograms following HILIC separation of 700 μg NISTmAb. Two 
control injections are indicated with a red line (water) and blue line (solvent blank, 
H2O/ACN/DMSO/TFA 28/66/5/1 (v/v)). The LC eluate was collected in Fractions #1, #2, and #3 
separately, as indicated by the different retention time ranges: 1.0–11.9 min for Fraction #1, 
11.9–17.3 min for Fraction #2, and 17.3–24.0 min for Fraction #3. 
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Table 5.3 NISTmAb HCPs uniquely identified with our HILIC-enriched HCP LC/MS method. 
These HCPs were not observed with the mAb-precipitation method and, to our knowledge, have 
not been reported previously.  
No. Accession # HCP Name 
1 Q8K019 Bcl-2-associated transcription factor 1 
2 P62984 Ubiquitin-60S ribosomal protein L40 
3 O35143 ATPase inhibitor, mitochondrial 
4 Q9CXW3 Calcyclin-binding protein 
5 P70333 Heterogeneous nuclear ribonucleoprotein H2 
6 Q9CQE1 Protein NipSnap homolog 3B 
7 O35166 Golgi SNAP receptor complex member 2 
8 P23116 Eukaryotic translation initiation factor 3 subunit A 
9 Q61035 Histidine--tRNA ligase, cytoplasmic 
10 P62897 Cytochrome c, somatic 
11 Q62504 Msx2-interacting protein 
12 Q99K48 Non-POU domain-containing octamer-binding protein 
13 P62843 40S ribosomal protein S15 
14 Q8CI11 Guanine nucleotide-binding protein-like 3 
15 P54227 Stathmin 
16 O08784 Treacle protein 
17 D3Z0M9 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23 
18 Q3U0P5 Ectonucleoside triphosphate diphosphohydrolase 6 
19 P51954 Serine/threonine-protein kinase Nek1 
20 A2AFI3 RNA binding motif protein, X chromosome, isoform CRA_b 
21 Q9DBG7 Signal recognition particle receptor subunit alpha 
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Table 5.4 A full list of identified HCPs in NISTmAb (RM 8671) using our HILIC-enriched HCP 
LC/MS method. For each identified HCP, the number of unique peptides observed, protein 
sequence coverage (%), and HILIC fraction are also listed. 
No. 
Accession 
# 
HCP name 
# of 
unique 
peptides 
Coverage % 
HILIC 
fraction 
1 P05064 Fructose-bisphosphate aldolase A 32 63.46 1,2,3 
2 P05063 Fructose-bisphosphate aldolase C 26 52.62 1 
3 P06745 Glucose-6-phosphate isomerase 31 49.10 1 
4 Q9CZ44 NSFL1 cofactor p47 14 37.84 1 
5 Q922R8 Protein disulfide-isomerase A6 11 15.00 1 
6 O88569 Heterogeneous nuclear ribonucleoproteins A2/B1 10 25.50 1 
7 Q5SUH7 Clathrin interactor 1 7 12.52 1 
8 Q9WTP6 Adenylate kinase 2, mitochondrial 11 43.51 1 
9 Q9ER00 Syntaxin-12 OS=Mus musculus 6 24.45 1 
10 Q68FL6 Methionine--tRNA ligase, cytoplasmic 3 4.66 1 
11 P56812 Programmed cell death protein 5 4 38.89 1 
12 Q923D2 Flavin reductase (NADPH) 5 33.98 1 
13 Q8K4Z5 Splicing factor 3A subunit 1 6 8.22 1 
14 Q8K019 Bcl-2-associated transcription factor 1 7 5.44 1 
15 F6ZDS4 Nucleoprotein TPR 5 2.30 1 
16 Q91YR9 Prostaglandin reductase 1 5 13.98 1 
17 P49312 Heterogeneous nuclear ribonucleoprotein A1  4 15.94 1 
18 P40142 Transketolase  4 10.43 1 
19 P62984 Ubiquitin-60S ribosomal protein L40  4 34.37 1 
20 Q9DBP5 UMP-CMP kinase  4 23.47 1 
21 P45878 Peptidyl-prolyl cis-trans isomerase FKBP2  4 32.86 1 
22 Q8BGD9 Eukaryotic translation initiation factor 4B  3 6.87 1 
23 Q99PL5 Ribosome-binding protein 1  2 1.87 1 
24 P21460 Cystatin-C  4 22.86 1 
25 Q8BL97 Serine/arginine-rich splicing factor 7  6 24.72 1 
26 Q68FF6 ARF GTPase-activating protein GIT1  6 6.62 1 
27 Q9Z0X1 Apoptosis-inducing factor 1, mitochondrial  4 10.29 1 
28 O08583 THO complex subunit 4  2 14.12 1 
29 Q8K4F5 Protein ABHD11  5 18.24 1 
30 O35143 ATPase inhibitor, mitochondrial  6 27.36 1 
31 Q9D8B3 Charged multivesicular body protein 4b  4 16.96 1 
32 Q9CXW3 Calcyclin-binding protein  3 9.61 1 
33 Q60864 Stress-induced-phosphoprotein 1  4 6.81 1 
34 Q03173 Protein enabled homolog  6 9.35 1 
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No. 
Accession 
# 
HCP name 
# of 
unique 
peptides 
Coverage % 
HILIC 
fraction 
35 P55302 
Alpha-2-macroglobulin receptor-associated 
protein 
4 11.67 1 
36 P01887 Beta-2-microglobulin  7 26.05 1 
37 Q8CGC7 Bifunctional glutamate/proline--tRNA ligase  2 2.31 1 
38 P70372 ELAV-like protein 1  2 11.04 1 
39 P70333 Heterogeneous nuclear ribonucleoprotein H2  2 4.90 1 
40 Q99020 Heterogeneous nuclear ribonucleoprotein A/B  3 12.63 1 
41 Q9CQE1 Protein NipSnap homolog 3B  4 17.41 1 
42 Q9D2M8 Ubiquitin-conjugating enzyme E2 variant 2  5 32.41 1 
43 Q61335 B-cell receptor-associated protein 31  4 11.43 1 
44 P97855 Ras GTPase-activating protein-binding protein 1  5 12.26 1 
45 Q3TLH4 Protein PRRC2C  2 1.05 1 
46 Q9DB15 39S ribosomal protein L12, mitochondrial  3 15.92 1 
47 P08249 Malate dehydrogenase, mitochondrial  3 10.65 1 
48 P99029 Peroxiredoxin-5, mitochondrial  2 8.57 1 
49 P10126 Elongation factor 1-alpha 1  2 4.33 1 
50 O35166 Golgi SNAP receptor complex member 2  2 10.85 1 
51 Q922I7 MCG13402, isoform CRA_c  4 5.77 1 
52 P23116 
Eukaryotic translation initiation factor 3 subunit 
A  
4 2.23 1 
53 Q61035 Histidine--tRNA ligase, cytoplasmic  2 3.93 1 
54 P62897 Cytochrome c, somatic  1 10.48 1 
55 Q62504 Msx2-interacting protein  3 0.96 1 
56 Q792Z1 MCG140784  2 8.13 1,3 
57 P40124 Adenylyl cyclase-associated protein 1  3 5.49 1 
58 Q99K48 
Non-POU domain-containing octamer-binding 
protein  
3 5.92 1 
59 P62843 40S ribosomal protein S15  1 8.97 1 
60 Q62418 Drebrin-like protein  2 4.59 1 
61 Q8CI11 Guanine nucleotide-binding protein-like 3  3 4.46 1 
62 P54227 Stathmin  3 14.77 1 
63 O08784 Treacle protein  1 1.06 1 
64 D3Z0M9 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23  3 3.42 1 
65 Q9CQF3 
Cleavage and polyadenylation specificity factor 
subunit 5 
1 5.29 1 
66 Q3U0P5 
Ectonucleoside triphosphate diphosphohydrolase 
6  
1 2.20 1 
67 P51954 Serine/threonine-protein kinase Nek1  3 1.50 1 
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No. 
Accession 
# 
HCP name 
# of 
unique 
peptides 
Coverage % 
HILIC 
fraction 
68 Q9JIX8 
Apoptotic chromatin condensation inducer in the 
nucleus  
4 5.16 1 
69 A2AFI3 
RNA binding motif protein, X chromosome, 
isoform CRA_b  
1 4.32 1 
70 Q9DBG7 Signal recognition particle receptor subunit alpha  1 1.89 1 
71 Q62179 Semaphorin-4B  1 1.22 3 
 
 
 
(Figure 5.6 continued on the next page) 
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Figure 5.6 MS/MS spectra for two identified peptides from two novel HCPs detected in 
NISTmAb, (A) ubiquitin-60S ribosomal protein L40 (P62984) and (B) ATPase inhibitor, 
mitochondrial (O35143). 
5.3.4 HCP detection with fusion protein 
BMS fusion protein 1 was analyzed using our HILIC-enriched HCP method. 700 μg of the 
fusion protein drug product was loaded onto the HILIC column for HCP enrichment (UV 
chromatogram in Figure 5.7). For comparison, the mAb-precipitation method was also used in 
parallel. As indicated in Table 5.2, 22 HCPs were identified by the HILIC-enriched HCP method, 
showing a 30% increase compared with the precipitation method. Notably, 7 out of these 22 
HCPs were unique to our method. For example, the HILIC method identified endoplasmic 
reticulum resident protein 29 (accession #: G3H284) with high confidence (28% sequence 
coverage), while it was undetected using the precipitation approach.  
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Figure 5.7 280 nm UV chromatogram from HILIC separation of 700 μg BMS fusion protein 1. 
The LC eluate was collected in Fraction #1, #2, and #3 separately, as indicated by the different 
retention time ranges: 1.0–12.0 min for Fraction #1, 12.0–19.0 min for Fraction #2, and 19.0–24.0 
min for Fraction #3. 
The higher number of HCPs detected for BMS fusion protein 1 with the HILIC method 
may relate to the enrichment mechanism for the “mAb-precipitation” strategy. That approach 
relies on the resistance of antibodies to digestion, attributed to their stable higher-order structure 
under native conditions [12]. HCP enrichment is therefore achieved during sample preparation by 
removing the minimally digested therapeutic via precipitation. However, this method may not be 
effective for other kinds of therapeutic proteins that are less rigid in structure and, therefore, less 
resistant to trypsin digestion, e.g., fusion proteins. The “mAb-precipitation” and HILIC sample 
preparation methods again proved complementary, together detecting 24 HCPs, more than either 
technique alone. 
5.4 Conclusions 
The offline HILIC sample preparation method developed in this work can enrich HCPs and 
deplete high abundance therapeutic proteins and, therefore, improve the sensitivity for HCP 
detection in drug substances. This strategy takes advantage of high organic solvent concentration 
in the LC mobile phase to disrupt protein-protein interactions and consequently provide effective 
separation between HCPs and antibodies. The method enables characterization of HCPs in both 
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mAb and non-mAb drug substances with similar performance, which may be advantageous 
compared to other strategies. 
Further benefits will be explored for improving HCP detection sensitivity with increased 
throughput. For future work, semi-preparatory scale HILIC columns (i.e., 4.6 mm i.d.) may 
provide higher sensitivity at similar throughput by allowing greater column loading. Further 
optimization in the drying and reconstitution steps may further improve recovery of HCPs. Lastly, 
a similar “mAb-precipitation” method to the published accounts may be performed on Fraction #2 
to provide enrichment of any HCPs co-eluting with the mAb. This strategy should detect any 
HCPs currently observed with the “mAb-precipitation” technique but not with our approach. 
Quantification strategies can also be developed based on the current protocol by spiking in internal 
standards before or after the HILIC enrichment, or following digestion. This HILIC approach also 
provides another strategy for size or hydrophobicity-based separation of process and sample HCPs, 
and as future studies improve our understanding of the HILIC separation mechanism for intact 
proteins, a more detailed correlation with the physical properties of HCPs eluting before, with, and 
after the biotherapeutic protein will be achieved. 
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Chapter 6 
 
 
Conclusions and Future Directions 
 
 
6.1 Dissertation Summary 
Chapters 2 through 4 in this dissertation explore alternative gas-phase fragmentation 
techniques and improve existing MS/MS methods for HDX MS experiments with the goal of 
elucidating protein higher-order structures. ECD and ETD have been demonstrated to proceed, 
under carefully tuned conditions, with minimal intramolecular H/D migration and are 
increasingly utilized in bottom-up and top-down HDX MS workflows to improve spatial 
resolution, i.e., to localize deuteriums down to the single amino acid residue level.  
In Chapter 2, the feasibility of a series of negative ion mode MS/MS techniques for HDX 
MS/MS was examined. We focused on several regio-selectively deuterated peptide anions as 
probes to determine the extent of H/D scrambling associated with nCID, nFRIPS, EDD, and 
niECD. It was concluded that nCID induces extensive H/D scrambling within all peptides 
examined. In addition, unusual scrambling behavior was observed with histidine-containing 
peptides, presumably due to the involvement of histidine C-2 and Cβ-hydrogen atoms in H/D 
scrambling. nFRIPS, EDD, and niECD were also found to promote scrambling but to various 
extents. Complete randomization of the deuteration profile was observed upon nFRIPS, whereas 
EDD and niECD proceeded with moderate scrambling levels. niECD showed slightly lower H/D 
scrambling levels that EDD. In general, neither examined negative ion mode MS/MS technique 
is practical for improving spatial resolution in HDX MS/MS experiments, due to the energetics 
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of the fragmentation process itself and/or the negative ionization process. Nevertheless, my 
results provided new insights into the mechanisms of these anion fragmentation techniques.  
In Chapter 3, we incorporated supercharging strategies into conventional ECD/ETD HDX 
MS workflows to enhance the extent of charging (≥3+) for pepsin-derived peptides, with the goal 
of improving ECD/ETD fragmentation efficiency, sequence coverage, and, consequently 
improve spatial resolution in HDX MS experiments. By adding as little as 0.1% m-NBA to the 
LC mobile-phase solvents, a significant increase in average charge state was observed for all 
peptic peptides in a typical bottom-up HDX LC/MS workflow, although poorer chromatographic 
separation and increased chemical noise were also noted from the TICs. The presence of 0.1% 
m-NBA in the mobile phase shortened peptide retention times; however, these shifts could be 
avoided by injecting m-NBA through an external mixing tee located after the analytical column. 
Upon increasing the m-NBA concentration in the ESI solvent, the extent of charge enhancement 
further increased for myoglobin peptic peptides, but 0.1% appeared to be an optimal 
concentration for achieving a compromise between effective supercharging and acceptable S/N 
ratios. Sulfolane was found to be as effective as m-NBA for supercharging peptic peptides, while 
DMSO and propylene carbonate were not effective. As verified by LC ECD auto MS/MS on a 
SolariX FT-ICR instrument, the abundance of peptide peptides with ≥ 3+ charge states increased 
upon addition of m-NBA, which improved ECD fragmentation efficiency and peptide sequence 
coverage. We also verified that 0.1% m-NBA, either added to the LC mobile phase or injected 
post column, did not skew the deuterium contents of peptic peptide ions in HDX LC/MS 
experiments, suggesting that m-NBA can be used as an effective supercharging additive in 
ECD/ETD-based bottom-up HDX LC/MS workflows for improving HDX spatial resolution.  
In Chapter 4, we specifically explored the occurrence of b ions, an unconventional type 
of fragment ion in ECD/ETD, of supercharged peptides. This work was inspired by the 
supercharging work in Chapter 3, as more fragments and associated more complex spectra were 
frequently observed upon ECD of highly charged peptide ions. To our knowledge, b ions have 
been reported to occur in ECD, but not in ETD, consistent with our findings that, for peptides 
162 
 
with few or no basic amino acid residues that yield abundant b ions upon ECD, ETD did not 
generate any b ions. Upon ECD of melittin and proteolytic peptides containing one or multiple 
basic sites, the number and abundance of b ions increased with the precursor ion charge state, 
suggesting that b ions are prominent in ECD spectra when the number of protons is higher than 
the number of basic sites in a peptide, e.g., following supercharging. Significantly less abundant 
b ions were observed in ETD spectra of supercharged peptides compared with ECD spectra. 
Nevertheless, these experiments are the first report of b ions from ECD/ETD as a function of 
precursor ion charge state. Our results provided insight into the different energy deposition and 
initial peptide temperature in ECD and ETD. We propose that, for supercharged peptide ions, a 
proton is likely located at a backbone amide, where electron attachment generates a hydrogen 
radical, which is preferentially ejected. The elevated internal energy of the remaining peptide is 
sufficient to generate b-type ions in ECD. Hydrogen radical ejection is less pronounced in ETD, 
thus b ion formation is much rarer in ETD. We suggest that b ions should be considered in ExD 
database searches for high peptide and protein charge states. Our data suggest that, for 
supercharging-assisted HDX MS/MS experiments, ETD is more suitable than ECD for 
minimizing deuterium loss and H/D scrambling.  
Chapter 5 describes an offline HILIC sample preparation method that we developed for 
improving detection of residual-level host cell proteins in biotherapeutic proteins, as a work 
report for a six-month co-op program that I undertook at Bristol-Myers Squibb. This method 
utilizes the separation ability of HILIC to enrich HCPs while depleting highly abundant 
therapeutic proteins. The denaturing conditions used in the HILIC-based sample treatment 
facilitated disruption of protein-protein interactions between HCPs and therapeutic proteins to 
achieve efficient separation. This HILIC-enriched HCP LC/MS method enabled detection of 
HCPs in drug substances that had not previously been observed with other conventional flow rate 
LC/MS strategies, and is applicable to both mAb and non-mAb drug substances with similar 
performance.  
Overall, the analytical strategies explored and developed in this dissertation contribute to 
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improving LC and MS tools for protein interaction analysis.  
6.2 Future Directions 
6.2.1 Hydrogen scrambling mechanisms in negative ion mode MS/MS 
Following our study regarding H/D scrambling behavior in negative ion mode gas-phase 
fragmentation techniques presented in Chapter 2, there are several interesting questions worth 
further investigation. We have shown that radical-driven fragmentation methods can promote 
H/D scrambling, although to a smaller extent than collision-based fragmentation. However, the 
scrambling levels measured for different fragment ions from the same peptide upon EDD and 
niECD were different, indicating that intramolecular H/D scrambling might occur locally instead 
of evenly across the whole peptide anion. For example, the c8 ion exhibited a much higher 
hydrogen scrambling level than the c2 and c3 ions in niECD of peptide P4. Similar regio-selective 
H/D scrambling has been reported upon ETD for a smaller peptide, RPYIL [1]. It is implied that 
different chemical properties and steric effects of exchangeable sites within a fragment ion, as 
well as the gaseous conformation of the precursor ion may lead to different scrambling rates. 
Work by Rand et al. [2] shows another example: uneven distribution of deuteriums was observed 
in the Asp repeat of a selectively labeled peptide, K2D6IIKIIK, upon ETD, which was not 
expected based on the known effect of primary structure on backbone amide hydrogen exchange 
[3]. Thus, to fully understand the mechanisms behind H/D scrambling, examination of multiple 
peptide models are needed for each type of MS/MS method. 
A practical challenge for conducting hydrogen scrambling studies on selectively 
deuterated peptide anions is the reduced ionization efficiency and backbone fragmentation 
efficiency associated with radical-driven negative ion mode MS/MS, from which abundant 
neutral losses, such as water and ammonia, are frequently observed. It has been reported that the 
abundant NH3 loss upon ETD of peptide ions can indicate the extent of hydrogen scrambling 
during HDX ETD experiments [4], based on the several orders of magnitude higher 
solution-phase HDX rates of the N-terminal amine, the C-terminal carboxyl group, and the 
peptide side chains compared with backbone amide hydrogens [3]. Similarly, we may be able to 
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utilize ions originating from ammonia or water loss from the charge-reduced (or increased) 
peptide ion as a reporter of the extent of H/D scrambling upon negative ion mode MS/MS. This 
approach would provide higher confidence in determining the deuterium content of the reporter 
ion, particularly when inadequate numbers/abundance of backbone fragment ions are generated. 
6.2.2 Supercharging combined with ECD HDX MS/MS for elucidation of structural 
changes of a modular polyketide synthase during its catalytic cycle 
We observed higher deuterium loss (increased back-exchange) with increasing peptide 
ion charge state, e.g. upon supercharging, compared with lower charge states. This observation is 
probably due to the in-source elevated kinetic energy at higher charge states, resulting in 
facilitated D/H exchange with residual gas molecules along the ion path, such as water, formic 
acid, and m-NBA. This result suggests that future experiments need to be carefully planned: even 
though highly charged ions often yield superior ECD/ETD spectra, extremely supercharged 
peptide ions should probably not be used for HDX measurements [5]. 
Although supercharging strategies have been previously reported in both bottom-up [6] 
and top-down [7, 8] HDX MS, Chapter 3 in this dissertation presents a detailed comparison 
between different supercharging reagents and various m-NBA concentrations. In addition, a 
post-column injection method for introducing supercharging reagent is described. One future 
application of this strategy is to facilitate ECD fragmentation in HDX LC MS/MS experiments to 
elucidate the structural rearrangements of a modular polyketide synthase, PikAIII, during its 
catalytic cycle [9, 10]. This prospective project is based on a collaboration with Life Sciences 
Institute researchers at Michigan. HDX coupled to ExD MS/MS holds potential for pinpointing 
conformational changes in PikAIII down to the level of individual residues. The newly-installed 
Agilent 6560 Ion Mobility Q-TOF LC/MS system equipped with a LEAP HDX PAL platform 
and an e-MSion ExD cell has the unique capability to perform this type of experiment. Given the 
size of the PikAIII polypeptide (over 1,500 amino acid residues), a middle-down method may be 
necessary. m-NBA, and other supercharging agents such as propylene carbonate and 1,2-butylene 
carbonate, can effectively supercharge small-to-medium size protein ions to promote top-down 
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ECD/ETD [11, 12] (one example is shown in Figures 6.1 and 6.2); therefore, they may also be 
ideal for larger peptides generated from a middle-down protocol. 
 
Figure 6.1 Charge-state distributions of apo-myoglobin with (bottom) and without (top) addition 
of 0.1% m-NBA into the ESI solvent (50/50/0.2 water/methanol/formic acid). The mass spectra 
were collected on a SolariX FT-ICR mass spectrometer.  
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Figure 6.2 Backbone cleavages in apo-myoglobin upon ECD of the 17+ charge state (top) versus 
the 22+ charge state (bottom). a
•
/x, b/y, and c/z• fragment ions are color-coded as shown in the 
legend. The addition of 0.1% m-NBA into the ESI solvent promoted the generation of more 
highly-charged protein ions, improving sequence coverage from 59% (17+) to 72% (22+). 
6.2.3 Investigation of the occurrence of b-type ions in ECD/ETD of supercharged peptides 
ECD is generally believed to be a “non-ergodic” process [13], but debates regarding its 
mechanisms have been ongoing since its invention in 1998. We believe that the work presented 
in Chapter 4 sheds light on a typically minor fragmentation pathway in ECD, but further 
investigation into the cause of b ions in ECD of supercharged peptides is warranted as it appears 
to be a major fragmentation pathway in such cases. One important question to answer is whether 
b ions occur from vibrational excitation upon H-desorption in ECD. Figure 6.3 presents an idea 
to support/reject this hypothesis. In Chapter 2, we showed that the extent of H/D scrambling in a 
selectively deuterated model peptide fragmented by ECD can be tuned by altering the “softness” 
of the ion source and the ion transport conditions, and that ECD can proceed with minimal 
hydrogen scrambling provided that the ion is not excessively heated. Similarly, we can use this 
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experimental method to measure the hydrogen scrambling levels of c-, z•-, and b-ions, 
respectively, upon ECD of a supercharged model peptide. Under “harsh” conditions, both 
c-/z•-ions and b-ions are expected to show high scrambling levels (~100%); whereas under “soft” 
conditions, minimal hydrogen scrambling (<10%) can be achieved for c-/z•-ions. If b ions are 
generated from vibrational excitation in ECD, they should show extensive H/D scrambling 
despite the “soft” source conditions, and vice versa. 
 
Figure 6.3 Diagram of proposed H/D scrambling behaviors of c-, z•-, and b-ions generated from 
ECD of a supercharged, selectively-deuterated peptide ion under “soft” and “harsh” conditions, 
respectively. 
In addition, we can use other criteria to determine if b ions are formed via CID-like 
vibrational activation in ECD. Loss of labile modifications is frequently observed to a 
significantly greater extent in CID than in ECD/ETD spectra, e.g., for phosphorylation (due to 
the gas-phase lability of phosphoester bonds) [14]. We can perform ECD/ETD of high charge 
state phosphopeptides and examine how the extent of b ion formation correlates with 
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phosphate/phosphoric acid loss. Figure 6.4 shows example ECD/ETD spectra of a supercharged 
phosphopeptide ion, FQpSEEQQQTEDELQDK. The ECD spectrum of the 4+ charge state 
shows a plenitude of b ions, some with H3PO4 neutral loss. However, no H3PO4 loss is seen for c 
and z ions, or for the charge-reduced species generated upon ECD. On the contrary, ETD of the 
same peptide ion does not yield b ions or PTM losses. Phosphoric acid loss from b ions appears 
to occur only in ECD of supercharged phosphopeptides. Fundamental studies of this kind are 
valuable references for the design of MS experiments for which minimum vibrational activation 
is desirable, e.g., HDX ExD MS/MS. 
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Figure 6.4 ECD (top) and ETD (bottom) MS/MS spectra of a quadruply protonated 
monophosphorylated peptide from trypsin digestion of β-casein. This charge state is only 
observed following supercharging with m-NBA. In the ECD spectrum, only b ions and b ions 
with neutral loss are labeled (red). 
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6.2.4 Further characterization and optimization of the offline HILIC method and the 
potential of utilizing HDX MS to investigate interactions between HCPs and biotherapeutic 
proteins 
When using the offline HILIC sample preparation method developed for HCP detection 
in biotherapeutics, samples are loaded onto an HILIC column and collected from eluates, 
followed by concentration, trypsin digestion, and LC/MS analysis. Potential HCP loss may be 
attributed to their adsorption on the HILIC column during chromatographic separation. This 
problem becomes more significant for HCPs present in the drug substance at very low ppm 
levels. For future work, the HCP recovery percentage of the current method needs to be 
evaluated by running more HCP-spiked drug substance samples. So far, only 10k and 1k ppm 
HCP spiked mAb samples have been characterized using our method. For future work, 100 and 
10 ppm HCP spiked samples need to be analyzed to test the viability of our method for lower 
ppm level HCPs. Optimization of the current digestion protocol may also be necessary to further 
improve the sensitivity for low ppm level HCPs. 
In addition, further benefits will be realized in the future if throughput can be increased. 
Currently, the first-step chromatography is conducted on a Waters HILIC column with the largest 
commercially available size, 2.1 x 150 mm. A semi-preparatory scale (i.e., 4.6 mm i.d.) custom 
column with the same packing material has been ordered and manufactured from Waters. This 
larger column may provide improved sensitivity at similar throughput by allowing greater 
column loading. Quantification strategies can also be developed based on the current protocol by 
spiking in internal standards before or after the HILIC enrichment, or after digestion. To improve 
our understanding of the principles of HILIC separation for intact proteins, we can examine the 
common/different physical properties of the HCPs eluting before, with, and after the therapeutic 
protein.  
Also, characterizing interactions between HCPs and therapeutic proteins via HDX MS 
would be useful to elucidate the effects of coexisting HCP impurities toward the higher-order 
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structure of the therapeutic protein. One HCP candidate to study is phospholipase B-like 2 
(PLBL2), a Chinese Hamster Ovary (CHO)-derived HCP that is challenging to remove in the 
purification processes for multiple antibody therapeutics [15]. It is of particular concern for being 
implicated in the literature as being potentially immunogenic [16, 17]. We have also identified 
PLBL2 in our HCP standard pool produced from CHO null cell line. The ultimate goal is to 
determine how these HCPs influence the stability and/or efficacy of the drug product and to 
develop powerful purification methods to achieve robust removal of these impurities.  
 
With an increase in the number of protein therapeutics being pursued in the 
biopharmaceutical industry, there is an increasing demand for bioanalytical science to understand 
the characteristics of biotherapeutic proteins. Higher-order structural elucidation is a key aspect 
where HDX MS tools are valuable. Understanding the relationship between protein structure and 
function enables rational protein engineering to enhance therapeutic properties, improve safety 
and consistency of manufacturing, and reduce undesired interactions between impurities and 
biotherapeutic drug products. In the future, our ability to characterize the higher-order structure 
and interactions of large biomolecules on a routine level will be truly critical.  
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